10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

ANNUAL REPORT PURSUANT

TO SECTIONS 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

(Mark One)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2006

OR

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File No. 001-16537

ORASURE TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	36-4370966
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
220 East First Street Bethlehem, Pennsylvania	18015
(Address of Principal Executive Offices)	(Zip Code)

(610) 882-1820

(Registrant’s Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Name of Each Exchange on Which Registered
Common Stock $0.000001 par value per share	The NASDAQ Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨    No x

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ¨    No x

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. x

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨ Accelerated filer x Non-accelerated filer ¨

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨    No x

State the aggregate market value of the voting and non-voting common equity held by nonaffiliates, computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the Registrant’s most recently completed second fiscal quarter (June 30, 2006): $434,917,582

Indicate the number of shares outstanding of each of the Registrant’s classes of common stock, as of March 12, 2007: 46,127,212 shares.

Documents Incorporated by Reference:

Portions of the Registrant’s Definitive Proxy Statement for the 2007 Annual Meeting of Stockholders are incorporated by reference into Part III of this Report.

Table of Contents

		Page
PART I
ITEM 1.	Business	1
ITEM 1A.	Risk Factors	19
ITEM 1B.	Unresolved Staff Comments	33
ITEM 2.	Properties	33
ITEM 3.	Legal Proceedings	33
ITEM 4.	Submission of Matters to a Vote of Security Holders	34
PART II
ITEM 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	35
ITEM 6.	Selected Financial Data	37
ITEM 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	38
ITEM 7A.	Quantitative and Qualitative Disclosures About Market Risk	55
ITEM 8.	Financial Statements and Supplementary Data	55
ITEM 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	56
ITEM 9A.	Controls and Procedures	56
ITEM 9B.	Other Information	57
PART III
ITEM 10.	Directors, Executive Officers and Corporate Governance	58
ITEM 11.	Executive Compensation	58
ITEM 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	58
ITEM 13.	Certain Relationships and Related Transactions, and Director Independence	58
ITEM 14.	Principal Accountant Fees and Services	58
PART IV
ITEM 15.	Exhibits and Financial Statement Schedules	59

This Report contains certain “forward-looking statements,” within the meaning of the Federal securities laws. These may include statements about our expected revenues, earnings, expenses or other financial performance, future product performance or development, expected regulatory filings and approvals, planned business transactions, views of future industry, competitive or market conditions, and other factors that could affect our future operations, results of operations or financial position. These statements often include words, such as “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions.

Forward-looking statements are not guarantees of future performance or results. Known and unknown factors could cause actual performance or results to be materially different from those expressed or implied in these statements. Factors that could affect our results are discussed more fully under Item 1A., entitled “Risk Factors,” and elsewhere in this Annual Report. Although forward-looking statements help to provide complete information about us, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this Report and we undertake no duty to update these statements.

PART I

ITEM 1.    Business.

Our business principally involves the development, manufacture, marketing and sale of oral fluid specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types, and other medical devices. Our diagnostic products include tests which are processed in a laboratory and tests which are performed on a rapid basis at the point of care. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. One of our products is also sold in the over-the-counter (“OTC”) or consumer retail market in the United States, Canada, Europe, Australia and certain other foreign countries.

In vitro diagnostic testing is the process of analyzing oral fluid, blood, urine and other bodily fluids or tissue for the presence of specific substances or markers for infectious diseases, drugs of abuse or other conditions. In vitro diagnostic tests are performed outside the body, in contrast to in vivo tests, which are performed directly on or within the body. The substance or marker that a diagnostic test is intended to detect is generally referred to as an analyte.

Immunodiagnostic testing is the leading method of in vitro testing for antigens and antibodies. When an infectious disease is caused by pathogens, such as bacteria, viruses and fungi, or other substances are present, the body responds by producing an antibody. Substances that stimulate production of antibodies are generally referred to as antigens. An antibody binds specifically with an antigen in a lock-and-key fashion that initiates a biochemical reaction to attempt to neutralize and, ultimately, eliminate the antigen. The ability of an antibody to bind with a specific antigen provides the basis for immunodiagnostic testing.

Our Company was formed in May 2000 under Delaware law solely for the purposes of combining two companies, STC Technologies, Inc. (“STC” or “STC Technologies”) and Epitope, Inc. (“Epitope”), and changing the state of incorporation of Epitope from Oregon to Delaware. STC Technologies and Epitope were merged into our Company on September 29, 2000. Our principal offices are located at 220 East First Street, Bethlehem, Pennsylvania 18015, and our telephone number is (610) 882-1820.

Additional information about us can be found on our website. Our website address is www.orasure.com. We make available free of charge through a link provided at such website our Annual Reports on Form 10-K, our

1

Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, as well as any amendments to those Reports. These Reports are made available as soon as reasonably practicable after they are filed or furnished to the Securities and Exchange Commission. Our Internet website and the information contained in or connected to that website are not intended to be incorporated by reference into this Annual Report.

Products

The following is a summary of our principal products and their regulatory and commercial status:

Product	Description	Regulatory Status	Commercial Status
OraQuick ADVANCE® HIV-1/2	A rapid, point-of-care test for antibodies to the Human Immunodeficiency Virus Type 1 (“HIV-1”) and Type 2 (“HIV-2” and together with HIV-1, “HIV-1/2”) that can be visually read at the point of care in approximately 20 minutes.	Premarket approval (“PMA”) approved by the U.S. Food and Drug Administration (“FDA”) (March 2004—June 2004) for use with oral fluid, finger-stick and venous whole blood, and plasma. CLIA (Clinical Laboratory Improvement Amendments of 1988) waived for use with oral fluid, finger-stick and venous whole blood (June 2004).	Marketed
		CE mark application filed.	Pending
		Registered in Mexico.	Marketed
OraQuick ADVANCE® OTC		In development.
OraQuick® HCV	A rapid, point-of-care test for antibodies to the hepatitis C virus (“HCV”)	In development.
OraSure®	Oral fluid collection device for the detection of antibodies to HIV-1 in an oral fluid sample in a laboratory setting.	PMA approved by FDA in December 1994.	Marketed
		Also FDA 510(k) cleared for use in detecting cocaine and cotinine (an indicator of nicotine) in oral fluid.	Marketed
		CE marked and registered in the United Kingdom. Also registered in Mexico, Canada, Columbia, South Africa, Afghanistan, Argentina, Brazil and Trinidad.	Marketed
Intercept®	Oral fluid collection device, along with nine related immunoassays, for oral fluid drugs of abuse (“DOA”) testing in a laboratory setting.	Collection device—FDA 510(k) cleared in 2000.	Marketed
MICRO-PLATE DOA Assays	Used to detect the following drugs in an oral fluid sample: marijuana, cocaine, opiates, amphetamines, methamphetamines, PCP, benzodiazepines, barbiturates and methadone.	Nine drug assays—FDA 510(k) cleared during 2000-2001.	Marketed
		Intercept® device CE marked and registered in the United Kingdom. Various assays are CE marked and registered in the United Kingdom, Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Mexico, Netherlands, Portugal, Spain, Sweden, Korea, Canada, Afghanistan and Brazil.	Marketed

2

Product	Description	Regulatory Status	Commercial Status
Homogeneous DOA Assays	Homogeneous fully-automated oral fluid DOA assays.	In development.
Cryosurgical Systems—Professional	Cryosurgical system for the removal of warts and other benign skin lesions, marketed under the Histofreezer® tradename primarily to the physicians’ office market.	Nine indications—FDA 510(k) cleared during 1991—1999.	Marketed
		CE marked and registered in Europe, Venezuela, Thailand, New Zealand, Hong Kong, Brazil, Mexico, Canada and Afghanistan.	Marketed
Cryosurgical Systems—OTC	Cryosurgical (freezing) system for the removal of common and plantar warts, sold in the OTC markets in the United States and Canada under the Compound W Freeze Off® tradename by Prestige Brands Holdings, Inc., in Europe, Australia and New Zealand under the Scholl and Dr. Scholl Freeze Spray tradenames by SSL International plc. and in Mexico under the POINTTS tradename by Genomma Labs.	FDA 510(k) cleared for two Freeze Off® indications in February 2003. Freeze Off® registered in Canada. Scholl Freeze Spray CE marked and registered in several European countries. POINTTS registered in Mexico.	Marketed Marketed Marketed Marketed
Cryosurgical Systems—OTC Product Line Extensions	Cryosurgical system for an indication other than common warts or plantar warts.	In development.
	Cryosurgical system combined with salicylic acid.	In development.

In addition to the above products, we also sell certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test approved by the FDA for confirming positive HIV-1 test results obtained from the use of our OraSure^® collection device; and the FDA 510(k) cleared Q.E.D.^® point-of-care saliva alcohol test.

OraQuick^® Rapid Test Platform

OraQuick^® is our rapid test platform designed to test oral fluid, whole blood (i.e., both finger-stick and venous) and plasma samples for the presence of various antibodies or analytes. The device uses a porous flat pad to collect an oral fluid specimen. After collection, the pad is inserted into a vial containing a pre-measured amount of developer solution and allowed to develop. When whole blood or plasma is to be tested, a loop collection device is used to collect a drop of blood or plasma and mix it in the developer solution, after which the collection pad is inserted into the solution and allowed to develop. In all cases, the specimen and developer solution then flow through the testing device where test results are observable in approximately 20 minutes. The OraQuick^® device is a screening test and requires a confirmation test where an initial positive result is obtained.

We have commercialized this technology in the form of our OraQuick ADVANCE^® rapid HIV-1/2 antibody test. This is a rapid, point-of-care test which has received FDA approval for the detection of antibodies to both HIV-1 and HIV-2 in oral fluid, finger-stick and venous whole blood and plasma. This test is available for use by the nearly 40,000 locations in the United States certified under the Clinical Laboratory Improvements Amendment of 1988 (“CLIA”) to perform moderately complex tests. We have also received a CLIA waiver for use of the OraQuick ADVANCE^® test with oral fluid and finger-stick and venous whole blood. As a result, the test can be used by approximately 140,000 additional sites in the United States not certified under CLIA to perform moderately complex tests, such as outreach clinics, community-based organizations and physicians’ offices.

3

On the international front, we are in the process of obtaining a CE mark for our OraQuick ADVANCE^® test so that we will be able to sell this product in Europe. We have a distributor in place for the United Kingdom and are pursuing distribution arrangements in several additional European countries. We are selling OraQuick^® in Mexico and Africa and are completing registrations of our OraQuick^® test in several countries in Latin America, Asia, the Middle East and Russia. We are aggressively seeking to expand our distribution network for this product throughout the world.

We believe that the OraQuick ADVANCE^® device, because it is approved for detecting antibodies to both HIV-1 and HIV-2 in finger-stick and venous whole blood, oral fluid and plasma samples, provides a significant competitive advantage in the market for rapid HIV testing in the United States and elsewhere around the world. Demand for OraQuick ADVANCE^® has quickly grown since the launch of that product in late 2004.

OraSure^®/Intercept^® Collection Devices

Our OraSure^® oral fluid collection device is used in conjunction with screening and confirmatory tests for HIV-1 antibodies and other analytes. This device consists of a small, treated cotton-fiber pad on a handle that is placed in a person’s mouth for two to five minutes. The device collects oral mucosal transudate (“OMT”), a serum-derived fluid that contains higher concentrations of certain antibodies and analytes than saliva. As a result, OMT testing is a highly accurate method for detecting HIV-1 infection and other analytes.

We believe that oral fluid testing has several significant advantages over blood or urine-based systems for infectious disease testing, for both health care professionals and the individuals being tested. These advantages include eliminating the risk of needle-stick accidents, providing a non-invasive collection technique, requiring minimal training to administer, providing rapid and efficient collection in almost any setting, and reducing the cost of administration by a trained health care professional.

We have received premarket approval from the FDA to sell the OraSure^® collection device for use with a laboratory-based enzyme immunoassay (“EIA”) screening test for HIV-1 antibody detection. This EIA screening test has been approved by the FDA for use with our OraSure^® device and is manufactured and sold by bioMerieux, Inc. (“BMX”).

HIV-1 antibody detection using the OraSure^® collection device involves three steps:

• Collection of an oral fluid specimen using the OraSure^® device;

• Screening of the specimen for HIV-1 antibodies at a laboratory with an EIA screening test approved by the FDA for use with the OraSure^® device; and

• Laboratory confirmation of any positive screening test results with our oral fluid Western blot HIV-1 confirmatory test (described below).

A trained health care professional then conveys test results and provides appropriate counseling to the individual who was tested. We have also received FDA 510(k) clearance for use of the OraSure^® collection device with EIAs to test for cocaine and cotinine (a metabolite of nicotine) in oral fluid specimens primarily for insurance risk assessment purposes.

In late 2006, BMX announced that it will discontinue manufacturing the HIV-1 EIA screening test during 2007 and that, due to quality problems, it may have difficulty supplying this screening test prior to the time it ceases manufacturing. As a result, we are working with BMX, the FDA and Centers for Disease Control and Prevention (“CDC”), our major laboratory customers and other potential suppliers to find or develop an alternative HIV-1 EIA screening test that can be used with oral fluid samples collected with our OraSure^® device.

A collection device that is substantially similar to the OraSure^® device is sold under the name Intercept^®, and is used to collect OMT for oral fluid drug testing. We have received FDA 510(k) clearance to use the

4

Intercept^® collection device with laboratory-based EIAs to test for drugs of abuse commonly identified by the National Institute for Drug Abuse (“NIDA”) as the NIDA-5 (i.e., cannabinoids (marijuana), cocaine, opiates, amphetamines/methamphetamines and phencyclidine (“PCP”)), and for barbiturates, methadone and benzodiazepines. Each of these EIAs is also FDA 510(k) cleared for use with the Intercept^® device.

We have received a CE mark for the Intercept^® and OraSure^® devices and both are distributed in Canada, the United Kingdom and Mexico. The OraSure^® device and our oral fluid drugs of abuse assays are also sold in several other foreign countries.

We believe that the Intercept^® device has several advantages over competing urine and other drugs-of-abuse testing products, including its lower total testing cost, its non-invasive nature, mobility and accuracy, the ease of maintaining a chain-of-custody, the treatment of test subjects with greater dignity, no requirement for specially-prepared collection facilities and difficulty of sample adulteration. The availability of an oral fluid test is intended to allow our customers to test for drug impairment, eliminate scheduling costs and inconvenience, and thereby streamline the testing process.

Cryosurgical Systems (Skin Lesion Removal Products)

The Histofreezer^® cryosurgical removal system is a low-cost alternative to liquid nitrogen and other methods for removal of warts and other benign skin lesions by physicians. The Histofreezer^® product mixes two environmentally friendly cryogenic gases in a small aerosol canister. When released, these gases are delivered to a specially designed foam bud, cooling the bud to a maximum of –50°C to –55°C. The frozen bud is then applied to the wart or lesion for 15 to 40 seconds (depending on the type of lesion) creating localized destruction of the target area by freezing. We have received 510(k) clearance for use of the Histofreezer^® product to remove common warts and eight other types of benign skin lesions, and this product has been CE marked and registered for distribution throughout Europe.

We have also received FDA 510(k) clearance to market and sell a cryosurgical product similar to the Histofreezer^® product in the OTC or retail market for the removal of common and plantar warts only. This product is being distributed in the United States and Canadian OTC markets under the name Freeze Off^® by Prestige Brands Holdings, Inc. (“Prestige”), the owner of the Compound W^® line of wart removal products. Prestige is the owner of both the Freeze Off^® and Compound W^® tradenames. In September 2006, Prestige announced that it had acquired the Wartner^® cryosurgical wart removal product line, which competes with the Freeze Off^® product in the U.S. and Canadian OTC markets. Because we believe that the Wartner acquisition constitutes a breach of our agreement with Prestige, we have initiated an arbitration proceeding against Prestige. As a result, it is uncertain whether Prestige will continue to distribute the Freeze Off^® product after 2007. For a more detailed description of our dispute with Prestige, see Item 3, “Legal Proceedings,” in this Annual Report.

Internationally, we distribute a similar CE marked cryosurgical wart removal product into the OTC footcare market in Europe, Australia and New Zealand through our distributor, SSL International plc (“SSL”), under the Scholl and Dr. Scholl trademarks. SSL is the owner of the Scholl and Dr. Scholl trademarks in countries outside North and South America. We have also launched an OTC cryosurgical product in Mexico through our distributor Genomma Labs, under the POINTTS tradename.

Immunoassay Tests and Reagents

We develop and sell immunoassay tests in two formats, known as MICRO-PLATE and AUTO-LYTE^®, to meet the specific needs of our customers.

In a MICRO-PLATE kit, the sample to be tested is placed into a small plastic receptacle, called a microwell, along with the reagents. The result of the test is determined by the color of the microwell upon completion of the reaction. Controlling the reaction involves the use of a variety of reagents by laboratory personnel. Test results

5

are analyzed by any of a variety of commercially available laboratory instruments, which we may also provide to our laboratory customers. MICRO-PLATE tests can be performed on commonly used instruments and can detect drugs in urine, serum and sweat specimens. MICRO-PLATE tests are also used as part of the Intercept^® product line to detect drugs of abuse in oral fluid specimens.

AUTO-LYTE^® tests are sold in the form of bottles of liquid reagents. These reagents are run on commercially available laboratory-based automated analytical instruments, which are manufactured by a variety of third parties. AUTO-LYTE^® is typically used in high volume, automated, commercial reference insurance laboratories to detect certain drugs or chemicals in urine. Test results are produced quickly, allowing for high throughput. In recent years, sales of our AUTO-LYTE^® tests have been substantially reduced largely because of competition from cheaper “home-brew” tests used by our laboratory customers. As a result, we eventually expect to stop selling our AUTO-LYTE^® tests.

Western blot HIV-1 Confirmatory Test

We sell an oral fluid Western blot HIV-1 confirmatory test that received premarket approval from the FDA in 1996. This test uses the original specimen collected with the OraSure^® oral fluid collection device to confirm positive results of initial oral fluid HIV-1 EIA screening tests. The oral fluid Western blot HIV-1 confirmatory test is currently marketed under an exclusive arrangement with BMX.

In March 2007, BMX notified us that it will not renew the agreement under which it supplies the HIV-1 antigen used to manufacture our oral fluid Western blot HIV-1 confirmatory test or the agreement under which it distributes that product on an exclusive, world-wide basis. As a result, these agreements will terminate on December 31, 2007. Pursuant to the terms of the antigen supply agreement, we have the right to purchase an additional two-year supply of the antigen following termination so that we can continue to manufacture and sell our oral fluid Western blot test. When this additional two-year supply is combined with our existing inventory of the HIV-1 antigen, we believe we will have a sufficient supply of HIV-1 antigen to meet the demand for our Western blot test for three to four years after the agreement terminates. We also intend to pursue a long-term supply agreement directly with the vendor (a former affiliate of BMX) used by BMX to manufacture the HIV-1 antigen. During 2006, sales of our oral fluid Western blot HIV-1 confirmatory test totaled approximately $330,000.

Q.E.D.^® Saliva Alcohol Test

Our Q.E.D.^® saliva alcohol test is a point-of-care test device that is a cost-effective alternative to breath or blood alcohol testing. The test is a quantitative, saliva-based method for the detection of ethanol, has been cleared for sale by the FDA and has received a CLIA waiver. The U.S. Department of Transportation (“DOT”) has also approved the test for purchase.

Each Q.E.D.^® test kit contains a collection stick that is used to collect a sample of saliva and a disposable detection device that displays results in a format similar to a thermometer. The Q.E.D.^® device is easy to operate and instrumentation is not required to read the result. The product has a testing range of 0 to 0.145% blood alcohol and produces results in approximately two minutes.

Products Under Development

OraQuick^® Platform

We believe that OraQuick^® has significant potential as a point-of-care testing platform for clinics and other public health entities, hospitals, physicians’ offices and other markets. Because the OraQuick^® platform is simple to use and can operate in a non-invasive manner with oral fluid, we believe it will be suitable for use by consumers without the assistance of a doctor or other medical professional. We also believe that OraQuick^® provides a platform technology that can be modified for detection of a variety of infectious diseases in addition to HIV, such as viral hepatitis and certain sexually transmitted diseases.

6

We are currently devoting significant resources to obtaining FDA approval to sell our OraQuick ADVANCE^® HIV-1/2 test in the United States OTC market. We have completed several laboratory-based operational studies and have initiated and will continue to perform additional clinical studies, including label comprehension studies, in support of our application for FDA approval. We are also developing a counseling and referral system and product packaging and labeling suitable for the OTC market, all of which will be key components of our clinical studies. We expect this clinical work to continue during 2007 and early 2008, after which we intend to submit an application for FDA approval.

During 2005, we obtained a license from Ortho-Clinical Diagnostics and Chiron Corporation to patents relating to the Hepatitis C virus, or HCV, and we have made substantial progress in developing a rapid HCV test using the OraQuick^® platform. In addition, in late 2006 we entered into an agreement with Schering-Plough Corporation (“Schering-Plough”) to collaborate on the development and promotion of our OraQuick^® HCV test for use with oral fluid. Under the terms of our agreement, we will be reimbursed by Schering-Plough for a portion of our costs to develop the test, and Schering-Plough will provide detailing and other promotional support for the test in the U.S. physicians’ office market, once the test is approved by the FDA. We are also in negotiations to obtain rights to a rapid HCV test manufactured by a third party that we intend to distribute into international markets.

OraSure^®/Intercept^® Applications

Oral mucosal transudate, or OMT, contains many constituents found in blood and serum, although in lower concentrations. We believe the OraSure^® and Intercept^® devices are a platform technology with a wide variety of potential applications, where laboratory testing is available. For example, the OraSure^® device may be useful for the collection of a variety of antibodies or markers for infectious diseases or conditions in addition to HIV-1, such as antibodies to viral hepatitis.

In 2004, the Substance Abuse and Mental Health Services Administration (“SAMHSA”) issued proposed regulations for oral fluid drug testing for federal workers. When issued in final form, these regulations may require certain modifications to our Intercept^® product in order to permit its use by federal workers. As a result, we are developing modifications to the Intercept^® collection device that we anticipate will be required by these regulations or are otherwise likely to be desired by our customers.

We are also currently developing additional drugs of abuse assays for use with our Intercept^® collection device. In October 2006, we signed a letter of intent with Roche Diagnostics to negotiate a joint development and commercialization agreement for homogeneous fully-automated oral fluid drugs of abuse assays that can be run on random access chemistry analyzers. The oral fluid assays will be developed for use with our Intercept^® collection device and Roche’s KIMS (kinetic information of microparticles in solution) technology. The assays will be designed to run on various automated analyzers and to allow oral fluid samples to be processed with the same efficiency currently achieved with urine-based drug tests. The parties are in the process of negotiating a definitive joint development and commercialization agreement.

In light of BMX’s announced decision to cease production of the HIV-1 EIA screening assay used with our OraSure^® device, we are working with BMX, the FDA and CDC, our major laboratory customers and other potential suppliers to find or develop an alternative HIV-1 EIA screening test that can be used with our OraSure^® device.

OTC Cryosurgical Systems Products

We currently sell our Histofreezer^® cryosurgical systems product in the physicians’ office or professional market. This product has been approved by the FDA for the treatment of a total of nine different types of benign skin lesions. Our OTC cryosurgical product has been approved by the FDA for two types of skin lesions—common warts and plantar warts.

7

We believe that one or more of the seven remaining Histofreezer^® indications may be attractive to the OTC market. We are developing an OTC cryosurgical product for one of these indications, and we intend to seek FDA 510(k) clearance of that product during 2007. In addition, we are developing an extension of our existing OTC cryosurgical wart removal product in order to sell that product in combination with salicylic acid for the treatment of common and plantar warts. We also intend to seek FDA clearance of this product extension in 2007.

Business Strategy

We have adopted a multi-part growth strategy, pursuant to which we intend to leverage our extensive diagnostic experience in order to maximize the available opportunities from our existing products and technologies, and supplement our existing product pipeline by accessing other technologies and products. We intend to follow a disciplined approach to maximize the value of our business for the benefit of our stockholders.

Our overall vision is to become a recognized global leader focused on providing innovative diagnostic solutions that add substantial value to existing and emerging healthcare needs. In order to achieve this vision, our business strategy includes the following key elements:

• Extension of Base Businesses.    We intend to maximize the sales potential of our existing product lines and technologies in the markets where they are currently sold, with a focus on expanding, where possible, the number of our oral fluid product offerings. Under this part of the strategy, we intend to fully capitalize on the potential market reach of our OraQuick^®, OraSure^®, Intercept^®, Histofreezer^® and Freeze Off^® products by investing in our sales and marketing efforts where appropriate, making product improvements and enhancements, and optimizing our distribution channels. We also intend to expand the reach of our existing products and technology platforms into new markets and will focus specifically on expanding into international markets.

• Infectious Disease Testing.    We will pursue new products and technology platforms in the infectious disease, point-of-care testing business to supplement our existing product pipeline. This may include either the development of new infectious disease products or the acquisition of new technologies or products. One new product we are pursuing is the development of a rapid HCV test on our OraQuick^® platform.

• OTC Opportunities.    We intend to identify or develop products that can be sold in the OTC or retail marketplace. A significant opportunity that we are pursuing under this part of our strategy is to seek FDA approval to sell our OraQuick ADVANCE^® rapid HIV-1/2 antibody test in the United States OTC market. We are also working to expand the distribution of our OTC cryosurgical product internationally beyond Europe, Australia, New Zealand and Mexico where the product is currently distributed.

• Operational Improvements.    We intend to remain focused on the continuous improvement of our operations. These improvements will include, but not be limited to, expanding the use of automated manufacturing for our product lines as demand increases, expanding the global sourcing of components and assemblies to achieve efficiencies and cost improvements, making infrastructure and information technology investments as needed to improve effectiveness and productivity, and modifying our processes in order to continuously improve quality and the effectiveness of our operations.

Research and Development

In 2006, our research and development activities focused primarily on the development of a rapid HCV test using our OraQuick^® technology platform, clinical and regulatory activities related to obtaining a CE mark for the OraQuick ADVANCE^® test, preliminary work to obtain FDA approval for use of OraQuick ADVANCE^® in the United States OTC market, and development of certain improvements to existing products in both the Intercept^® and cryosurgical wart removal product lines.

From time to time, we supplement our own research and development activities by funding external research at universities and certain other entities. We may continue to fund external research.

8

Research and development expenses totaled $8.6 million in 2006, $5.3 million in 2005 and $6.1 million in 2004. These expenses include the costs associated with research and development, regulatory affairs, clinical trials and product support.

Sales and Marketing

We attempt to reach our major target markets through a combination of direct sales, strategic partnerships, and independent distributors. Our marketing strategy is to raise awareness through a full array of marketing activities, which include trade shows, print advertising, special programs and distributor promotions, to support sales in each target market.

We market our products in the United States and internationally. Revenues attributable to customers in the United States were $56.8 million, $59.9 million and $47.8 million in 2006, 2005 and 2004, respectively. Revenues attributable to international customers amounted to $11.4 million, $9.5 million and $6.2 million, or 17%, 14% and 11% of our total revenues, in 2006, 2005 and 2004, respectively.

Infectious Disease Testing

We market the OraQuick ADVANCE^® rapid HIV-1/2 antibody test directly to customers in the public health market for HIV testing. This market consists of a broad range of clinics and laboratories and includes states, counties, the CDC, SAMHSA and other governmental agencies, family planning clinics, colleges and universities, correctional facilities and the military. There are also a number of organizations in the public health market, such as AIDS service organizations and various community-based organizations set up primarily for the purpose of encouraging and enabling HIV testing.

Abbott Laboratories (“Abbott”) was appointed as our exclusive distributor in the U.S. hospital market and as a non-exclusive distributor in the U.S. physicians’ office marketplace. As our exclusive distributor to hospitals, Abbott sells OraQuick ADVANCE^® to federal hospitals under the terms of our Federal Supply Schedule on file with the General Services Administration. Under our agreement with Abbott, we have retained exclusive rights for all other markets, including sales to the public health and criminal justice markets, the military, the CDC, SAMHSA and other governmental agencies. We have a small sales force that supports Abbott in order to maximize the penetration of OraQuick ADVANCE^® in the hospital market.

Abbott recently announced that it will sell part of its diagnostics business, including its rights to distribute OraQuick ADVANCE^®, to General Electric (“GE”). This transaction is expected to close during the first half of 2007. We intend to meet with executives from GE to discuss their plans for the OraQuick ADVANCE^® product.

We currently distribute our OraQuick^® test in several foreign countries. We expect the number of countries to increase as we find new distributors, complete registrations in additional countries and obtain a CE mark for this product.

We also market the OraSure^® oral fluid collection device for HIV-1 testing, separately and as a kit in combination with laboratory testing services. To better serve our public health customers, we have entered into agreements with two commercial laboratories to provide prepackaged OraSure^® test kits, with prepaid laboratory testing and specimen shipping costs included. We also sell the OraSure^® device in the international public health market.

Substance Abuse Testing

Our substance abuse testing products are marketed to laboratories serving the workplace testing, forensic toxicology, criminal justice and drug rehabilitation markets.

We have entered into agreements for the distribution of Intercept^® collection devices and associated MICRO-PLATE assays for drugs-of-abuse testing in the workplace testing market in the United States and

9

Canada through several laboratory distributors, including Quest Diagnostics (“Quest”) and Clinical Reference Laboratory, and internationally for workplace, criminal justice and forensic toxicology testing through Bio-Rad Laboratories, Concateno (which recently acquired Altrix HealthCare, plc) and other distributors. In some cases, we assist our laboratory customers in customizing their testing services by selling them equipment required to test oral fluid specimens collected with the Intercept^® device.

The forensic toxicology market in the United States for our substance abuse testing products consists of 250—300 laboratories including federal, state and county crime laboratories, medical examiner laboratories and reference laboratories. The criminal justice market consists of a wide variety of entities in the criminal justice system that require drug screening, such as pre-trial services, parole and probation officials, police forces, drug courts, prisons, drug treatment programs and community/family service programs.

We also distribute our Q.E.D.^® saliva alcohol test primarily through various distributors in the United States and internationally. The markets for alcohol testing are relatively small and fragmented with a broad range of legal and procedural barriers to entry. Markets range from law enforcement testing to workplace testing of employees in safety sensitive occupations. Typical usage situations include pre-employment, random, post-accident, reasonable-cause and return-to-duty testing.

Cryosurgical Systems

Most of our Histofreezer^® sales occur in the United States to distributors that, in turn, resell the product to primary care physicians and podiatrists in the United States. Major U.S. distributors include Cardinal Healthcare, McKesson HBOC, Physicians Sales & Service, AmerisourceBergen Corporation, and Henry Schein. Internationally, we established a sales office in Reeuwijk, The Netherlands, and we are selling the Histofreezer^® product through a network of distributors in more than 20 countries worldwide.

We sell Freeze Off^®, a product similar to Histofreezer^®, in the OTC market in the U.S. and Canada pursuant to a distribution agreement with Prestige Brands, the owner of the Compound W^® line of wart removal products. Additionally, we distribute cryosurgical wart removal products in the OTC footcare market in Europe, Australia and New Zealand through our distributor, SSL, under its Scholl and Dr. Scholl tradenames, and in the OTC market in Mexico under the POINTTS tradename through our distributor, Genomma Labs. For a description of our pending dispute with Prestige Brands, see Item 3, “Legal Proceedings,” in this Annual Report.

Insurance Risk Assessment

We currently market the OraSure^® oral fluid collection device for use in screening life insurance applicants in the United States and internationally to test for three of the most important underwriting risk factors: HIV-1, cocaine and cotinine (a metabolite of nicotine). Devices are sold to insurance testing laboratories, including Quest Diagnostics, Heritage Labs and Clinical Reference Laboratory. These laboratories in turn provide the devices to insurance companies, usually in combination with testing services.

We also maintain a direct sales force that promotes use of the OraSure^® device directly to insurance companies for life insurance risk assessment. Insurance companies then make their own decision regarding which laboratory to use to supply their collection devices and testing services. Our OraSure^® Western blot confirmatory test is distributed through BMX to laboratories and is used to confirm oral fluid specimens collected with our OraSure^® device that initially test positive for HIV-1. For a description of BMX’s recent election not to renew the Western blot agreements after December 31, 2007, see the Section entitled, “Western blot HIV-1 Confirmatory Test,” in this Annual Report.

Because insurance companies are in various stages of their adoption of the OraSure^® device, there exists a wide range of policy limits where the product is being applied. Some insurance companies have chosen to extend their testing to lower policy limits where they did not test at all before, while others have used OraSure^® to

10

replace some of their blood and urine-based testing. In general, most of our insurance company customers use the OraSure^® device in connection with life insurance policies having face amounts of up to $250,000, with some customers using the device for policies of up to $500,000 in amount.

In recent years, we have experienced a decline in sales of OraSure^® and related assays for insurance testing, primarily due to a reduction in the number of applications for life insurance policies and changes in underwriting requirements, as well as some consolidation in the industry leading to a reevaluation of testing methods. However, our sales force continues to encourage additional insurance companies to use OraSure^® and to extend the use of the product by existing customers. We believe there are several factors which could help expand the use of our device, including increasing acceptance of the reliability of oral fluid testing, the high quality of test results, the low cost of oral fluid testing relative to blood tests and the ease of use of the OraSure^® device.

We also sell our AUTO-LYTE^® assays and reagents in the insurance testing market directly to laboratories, including Heritage Labs and Clinical Reference Laboratory.

International Markets

We sell most of our products into international markets primarily through distributors with knowledge of their local markets. Principal markets include physicians’ offices, insurance risk assessment, substance abuse, public health and laboratory testing.

We assist our international distributors in registering the products and obtaining required regulatory approvals in each country, and we provide training and support materials. Our international marketing program includes direct assistance to distributors in arranging for laboratory services, cooperation from screening test manufacturers and performance of Western blot confirmatory tests when necessary.

Significant Products and Customers

Several different products have contributed significantly to our financial performance, accounting for 10% or more of total revenues during the past three years. The OraSure^® and Intercept^® oral fluid collection devices, cryosurgical systems products, and OraQuick^® rapid HIV test accounted for total revenues of $15.1 million, $17.3 million and $25.6 million in 2006, $15.9 million, $22.7 million and $21.6 million in 2005, and $14.6 million, $20.2 million and $10.2 million in 2004, respectively. As new products are developed and commercialized, we expect to receive a greater portion of our revenues from these new products.

We currently have two customers, Quest and Abbott, which accounted for 14% and 10% of our total revenues, respectively, during 2006. The loss of Quest or Abbott, or a significant decrease in the volume of products purchased by either customer, could have a material adverse effect on our results.

Supply and Manufacturing

We manufacture our OraQuick ADVANCE^® test in our Bethlehem, Pennsylvania facility. In addition, we have entered into a supply agreement for the assembly of the OraQuick^® device in Thailand, in order to supply certain international markets. This supply agreement had an initial term of one year, and automatically renews for additional annual periods unless either party provides a timely notice of termination prior to the end of an annual period. We believe that other firms would be able to manufacture the OraQuick^® test on terms no less favorable than those set forth in the agreement if the Thailand contractor would be unable or unwilling to continue manufacturing this product.

We can purchase the HIV antigen and the nitrocellulose required for the OraQuick^® test only from a limited number of sources. The antigen is currently purchased from a single contract supplier under a long-term agreement with an initial term ending in January 2010 and one-year automatic renewal terms thereafter. The

11

nitrocellulose used in the test is also provided by a single contract supplier, under a supply agreement with a five-year term ending in 2009. If for any reason these suppliers are unwilling or no longer able to supply our antigen or nitrocellulose needs, we believe that alternative supplies could be obtained at a competitive cost. However, a change in the antigen or nitrocellulose would require FDA approval and some additional development work. This in turn would require significant time to complete and could disrupt our ability to manufacture and sell the OraQuick^® device.

We manufacture both the OraSure^® and Intercept^® collection devices in our Bethlehem, Pennsylvania facility, and we expect to continue to do so for the foreseeable future.

The oral fluid Western blot HIV-1 confirmatory test is currently manufactured in our Bethlehem, Pennsylvania facility. The HIV antigen needed to manufacture the Western blot test is currently available from only a limited number of sources. For many years, we have purchased the antigen for this product from BMX on an exclusive basis. BMX is also the exclusive distributor of the Western blot test kits. Our agreements with BMX provide for the supply by BMX of the HIV-1 antigen and distribution of the oral fluid Western blot product by BMX on an exclusive worldwide basis. In March 2007, BMX notified us that it will not renew the agreements under which it supplies the HIV-1 antigen and distributes that product on an exclusive, world-wide basis, beyond December 31, 2007. For a further description of BMX’s election not to renew the Western blot agreements, see the Section entitled, “Western blot HIV-1 Confirmatory Test,” in this Annual Report.

Histofreezer^® is assembled in The Netherlands by Koninklijke, Utermöhlen, N.V. (“Utermöhlen”), the company from which we acquired the product in 1998. We purchase the product pursuant to an exclusive production agreement. Utermöhlen also supplies Freeze Off^®, the OTC cryosurgical product for the U.S. and Canadian markets. Assuming minimum purchase requirements are met, our agreement with Utermöhlen will terminate at the end of 2008 with respect to the Histofreezer^® product. The Utermöhlen agreement was scheduled to terminate at the end of 2006 with respect to the Freeze Off^® product, subject to a minimum purchase requirement. However, we did not meet that requirement by the end of 2006 due to unexpectedly low purchases of the product by our distributor, Prestige. As a result, we expect to continue to purchase product for the U.S. OTC market from Utermöhlen for the foreseeable future. The cryosurgical wart removal products distributed in international OTC markets are supplied by vendors located in the United States.

We believe that additional suppliers of all of our cryosurgical products are available on terms no less favorable than the terms of our existing supply agreements in the event that our current suppliers would be unable or unwilling to continue manufacturing these products.

Our AUTO-LYTE^® and MICRO-PLATE assays are manufactured in our Bethlehem, Pennsylvania facility. These tests require the production of highly specific and sensitive antibodies corresponding to the antigen of interest. Substantially all our antibody requirements are provided by contract suppliers. We believe that we have adequate reserves of antibody supplies and that we have access to sufficient raw materials for these products.

The Q.E.D.^® saliva alcohol test is manufactured and packaged for shipment in our Bethlehem, Pennsylvania facility.

Employees

As of December 31, 2006, we had 250 full-time employees, including 66 in sales, marketing and client services; 26 in research and development; 105 in operations, manufacturing, quality control, information systems, purchasing and shipping; 19 in regulatory affairs and quality assurance, and 34 in administration and finance. This compares to 233 employees as of December 31, 2005. Our employees are not currently represented by a collective bargaining agreement.

12

Competition

The diagnostic industry is a multi-billion dollar international industry and is intensely competitive. Many of our competitors are substantially larger than we are, and they have greater financial, research, manufacturing and marketing resources.

Important competitive factors for our products include product quality, price, ease of use, customer service and reputation. Industry competition is based on the following:

• Scientific and technological capability;

• Proprietary know-how;

• The ability to develop and market products and processes;

• The ability to obtain FDA or other regulatory approvals;

• The ability to manufacture products that meet applicable FDA requirements (i.e., good manufacturing practices);

• Access to adequate capital;

• The ability to attract and retain qualified personnel; and

• The availability of patent protection.

A few large corporations produce a wide variety of diagnostic tests and other medical devices and equipment. A larger number of mid-size companies generally compete only in the diagnostic industry and a significant number of small companies produce only a few diagnostic products. As a result, the diagnostic test industry is highly fragmented and segmented.

The future market for diagnostic tests is expected to be characterized by consolidation, greater cost consciousness and tighter reimbursement policies. The purchasers of diagnostic products are expected to place increased emphasis on lowering costs, reducing inventory levels, automation, service and volume discounts. The increased complexity of the market is expected to force many competitors to enter into joint ventures or license certain products or technologies.

We expect competition to intensify as technological advances are made and become more widely known, and as new products reach the market. Furthermore, new testing methodologies could be developed in the future that render our products impractical, uneconomical or obsolete. There can be no assurance that our competitors will not succeed in developing or marketing technologies and products that are more effective than those we develop or that would render our technologies and products obsolete or otherwise commercially unattractive. In addition, there can be no assurance that our competitors will not succeed in obtaining regulatory approval for these products, or introduce or commercialize them before we can do so. These developments could have a material adverse effect on our business, financial condition and results of operations.

Several companies market or have announced plans to market oral specimen collection devices and tests both within and outside the United States. We expect the number of devices competing with our Intercept^®, OraQuick^® and OraSure^® devices to increase as the benefits of oral specimen-based testing become more widely accepted.

Competition in the market for HIV testing is intense and is expected to increase. We believe that the principal competition will come from existing laboratory-based blood tests, point-of-care rapid blood tests, laboratory-based urine assays, or other oral fluid-based tests that may be developed. Our competitors include specialized biotechnology firms, as well as pharmaceutical companies with biotechnology divisions and medical diagnostic companies.

13

Significant competitors for our OraQuick ADVANCE^® rapid test, such as the Ortho Diagnostics division of Johnson & Johnson, Bio-Rad Laboratories, Abbott and BMX, sell laboratory-based HIV-1/2 EIAs, and Maxim Biomedical (formerly Calypte, Inc.) sells an HIV-1 screening test for urine, in the United States. MedMira and Trinity Biotech each sell competing rapid HIV-1 blood tests, and Bio-Rad Laboratories and Chembio sell competing rapid HIV-1/2 blood tests in the United States. These tests compete with our OraQuick ADVANCE^® test in hospitals or other laboratory settings. In addition, Trinity Biotech and Chembio have received CLIA waivers for their rapid HIV tests, and these tests compete with our OraQuick ADVANCE^® test in the markets outside of the traditional hospital and laboratory settings. These companies, or others, may continue to expand the bodily fluids with which a rapid HIV test may be performed, or develop and commercialize new rapid HIV tests, which would provide further competition for our OraQuick ADVANCE^® test. We believe other companies may also seek FDA approval to sell competing rapid HIV tests in the future.

Internationally, our OraQuick ADVANCE^® test competes against rapid HIV tests sold by a number of other entities, and often these competing tests are sold at prices substantially below the prices we charge for our OraQuick ADVANCE^® test. Calypte has developed a rapid oral fluid HIV test which is now being sold in certain foreign countries.

The Intercept^® drug testing system competes with laboratory-based drug testing products and services using testing matrices such as urine, hair, sweat and oral fluid. Major competitors include Ansys Technologies, Inc., Dade Behring, Psychemedics and Immunalysis.

Our MICRO-PLATE oral fluid drug assays, which are sold for use with the Intercept^® and OraSure^® collection devices, are expected to come under increasing competitive pressure from “home-brew” assays developed internally by our laboratory customers. Our oral fluid MICRO-PLATE assays also compete with urine-based homogeneous assays that are run on fully-automated, random access analyzers. These tests provide strong competitive pressure because they provide the benefits of automation, including lower costs and short turn-around times. In addition, we believe our competitors are developing oral fluid tests suitable for use on these fully automated homogeneous assay systems and these assays, if and when they are developed and commercialized, will represent a significant competitive threat to our oral fluid MICRO-PLATE business. In order to meet this competition, we executed a letter of intent with Roche Diagnostics in October 2006 to enter into an agreement for the joint development and commercialization of fully-automated homogeneous oral fluid drugs of abuse assays for use with our Intercept^® device. We expect final agreements with Roche to be executed during the first half of 2007.

Our MICRO-PLATE drugs-of-abuse reagents sold in the forensic toxicology market are targeted to forensic testing laboratories where sensitivity, automation and “system solutions” are important. In the past, these laboratories have typically had to rely on radioimmunoassay test methods to provide an adequate level of sensitivity. Radioimmunoassays require radioactive materials, which have a short shelf-life and disposal problems. Our MICRO-PLATE tests meet the laboratories’ sensitivity needs, run on automated equipment, are not radioimmunoassays, and are offered to the laboratory as a complete system solution of reagents, instrumentation and software to meet the specific needs of each customer. We compete with both homogeneous and heterogeneous tests manufactured by many companies. Significant competitors in the market for these assays include Microgenics, Inc., Roche Diagnostics and Immunalysis.

Sales of our AUTO-LYTE^® urine assays have declined substantially during the past several years, primarily due to competition from assays developed internally by our laboratory customers (i.e., “home brews”), which can be produced at a cost lower than the price typically paid for our products. Many of our customers no longer purchase our AUTO-LYTE^® assays, and we eventually expect to stop selling this product line.

The Histofreezer^® product’s delivery system and operating temperature, which is warmer than liquid nitrogen, provide us with the opportunity to target sales to primary care physicians, such as family practitioners, pediatricians and podiatrists. We do not generally target sales to dermatologists because they have the volume of

14

patients required to support the capital costs associated with a liquid nitrogen delivery system, which is also used to remove warts and other benign skin lesions. There is limited competition for convenient cryosurgical products for wart removal in the primary care physician market. Major competitors for the Histofreezer^® product include Cryosurgery, Inc. in the United States and Wartner in Europe. Wartner may also eventually compete with Histofreezer^® in the physician market in the United States.

The Freeze Off^® product, sold by Prestige under its Compound W^® tradename, competes with other OTC wart removal products in the United States. Schering-Plough sells a competing cryosurgical wart removal product under its Dr. Scholl’s brand and another competing cryosurgical wart removal product is sold in the OTC market under the Wartner^® name. Wartner also sells a product that competes with our cryosurgical product in the European OTC footcare market. During 2006, Prestige acquired the Wartner^® product sold in the United States and Canada, and we believe this action constitutes a material breach of our agreement with Prestige. For a further discussion of our dispute with Prestige regarding this matter, see Item 3, “Legal Proceedings,” in this Annual Report.

Q.E.D.^® has two direct competitors, Ansys Technologies, Inc. and Chematics. These companies offer semi-quantitative saliva-based alcohol tests and have received DOT approval. Indirect competitors who offer breath testing equipment include Intoximeters, Dräger and CMI. Although there are lower priced tests on the market that use oral fluid or breath as a test medium, these tests are qualitative tests that are believed to be substantially lower in quality and provide fewer benefits than our Q.E.D.^® test.

Patents and Proprietary Information

We seek patent and other intellectual property rights to protect and preserve our proprietary technology and our right to capitalize on the results of our research and development activities. We also rely on trade secrets, know-how, continuing technological innovations and licensing opportunities to provide competitive advantages for our products in our markets and to accelerate new product introductions. We regularly search for third-party patents in fields related to our business to shape our own patent and product commercialization strategies as effectively as possible and to identify licensing opportunities. United States patents generally have a maximum term of 20 years from the date an application is filed.

We have 16 United States patents and numerous foreign patents for the OraSure^® and Intercept^® collection devices and technology relating to oral fluid collection, containers for oral fluids, methods to test oral fluid, formulations for the manufacture of synthetic oral fluid, and methods to control the volume of oral fluid collected and dispersed. We have also applied for additional patents, in both the United States and certain foreign countries, on such products and technology.

We have one issued patent for our OraQuick ADVANCE^® rapid HIV-1/2 antibody test in the United States, and we received notice that the claims of a related patent have been allowed. We also have several related patent applications pending for this product in the United States and internationally. We have obtained licenses to certain lateral flow patents and to certain HIV-1 and HIV-2 patents held by other parties. We also have obtained a license to certain HCV patents which we intend to use to manufacture and sell a rapid HCV test on the OraQuick^® or other technology platform. We obtained these licenses through the payment of certain upfront fees and an agreement to pay ongoing royalties. We believe these fees and royalties are comparable to those generally paid by other companies under similar arrangements.

We may need to obtain licenses or other rights under, or enter into distribution or other business arrangements in connection with, certain other intellectual property patents in order to manufacture and sell the OraQuick ADVANCE^® test or other tests that use the same or similar technology platform. See Section 1A, entitled “Risk Factors,” for a further discussion of these issues.

We have five United States patents and numerous foreign patents issued for apparatuses and methods for the topical removal of skin lesions relating to our cryosurgical wart removal products, and we have a pending patent

15

application related to these products. We have also licensed another patent relating to apparatuses and methods for the topical removal of skin lesions relating to our cryosurgical wart removal products.

We have four United States patents and numerous foreign patents and patent applications for the technology used in the Q.E.D.^® test. These patents are related to the analog-to-digital technology color control systems and methods, systems and devices for the test, and detection of biochemical molecules.

We have one United States patent relating to the method for detecting blood in urine specimens using our AUTO-LYTE^® products.

We require our employees, consultants, outside collaborators and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed by or made known to the individual during the course of the individual’s relationship with us, is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual during his or her tenure with us will be our exclusive property.

We own rights to trademarks and service marks that we believe are necessary to conduct our business as currently operated. In the United States, we own the OraSure^®, Intercept^®, OraQuick^®, OraQuick ADVANCE^®, Histofreezer^®, Q.E.D.^® and AUTO-LYTE^® trademarks. We also own many of these marks and others in several foreign countries. The Compound W^® and Freeze Off^® trademarks are owned by Prestige, or its affiliates, in the United States and Canada, the Scholl and Dr. Scholl tradenames are owned by SSL in Europe, Australia, New Zealand and other countries outside North and South America, and the POINTTS tradename is owned by Genomma Labs in Mexico.

Although important, the issuance of a patent or existence of trademark or trade secret protection does not in itself ensure the success of our business. Competitors may be able to produce products competing with our patented products without infringing our patent rights. Issuance of a patent in one country generally does not prevent manufacture or sale of the patented product in other countries. The issuance of a patent is not conclusive as to validity or as to the enforceable scope of the patent. The validity or enforceability of a patent can be challenged by litigation after its issuance. If the outcome of such litigation is adverse to the owner of the patent, the owner’s rights could be diminished or withdrawn. Trade secret protection does not prevent independent discovery and exploitation of the secret product or technique.

Government Regulation

General

Most of our products are regulated by the FDA, certain state and local agencies and comparable regulatory bodies in other countries. This regulated environment governs almost all aspects of development, production, and marketing, including product testing, authorizations to market, labeling, promotion, manufacturing and recordkeeping.

All of our FDA-regulated products require some form of action by the FDA before they can be marketed in the United States. After approval or clearance by the FDA, we must continue to comply with other FDA requirements applicable to marketed products. Both before and after approval or clearance, failure to comply with the FDA’s requirements can lead to significant penalties or could disrupt our ability to sell these products. In addition, the FDA could refuse permission to obtain certificates needed to export our products if the agency determines that we are not in compliance.

Domestic Regulation

Most of our products are regulated in the United States as medical devices.

16

There are two mechanisms by which regulated medical devices can be placed on the market in the United States. Some products may qualify for clearance under Section 510(k) of the Federal Food, Drug and Cosmetic Act. To obtain this clearance from the FDA, the manufacturer must provide a premarket notification that it intends to begin marketing the product, and show that the product is substantially equivalent to another legally marketed product (i.e., that it has the same intended use and is as safe and effective as a legally marketed device and does not raise different questions of safety and effectiveness). In some cases, the submission must include data from human clinical studies. Marketing may commence when the FDA issues a clearance letter finding substantial equivalence. An applicant must submit a 510(k) application at least 90 days before marketing of the affected product commences. Although FDA clearance may be granted within that 90-day period, in some cases as much as a year or more may be required before clearance is obtained, if at all.

If the medical device does not qualify for the 510(k) procedure (either because it is not substantially equivalent to a legally marketed device or because it is required by statute and the FDA’s regulations to have an approved premarket application), the FDA must approve a premarket application, or PMA, before marketing can begin. PMAs must demonstrate, among other matters, that the medical device provides a reasonable assurance of safety and effectiveness. A PMA is typically a complex submission, including the results of preclinical and clinical studies. Preparing a PMA is a detailed and time-consuming process. Once a PMA has been submitted, the FDA is required to review the submission within 180 days. However, the FDA’s review may, and often is, much longer, often requiring one year or more, and may include requests for additional data and facility inspections before approval is granted, if at all.

Some of our products are used for non-medical purposes and many of our drugs-of-abuse products sold to state crime labs are for forensic use. The FDA does not currently regulate products used for these purposes.

Every company that manufactures medical devices distributed in the United States must comply with the FDA’s Quality System Regulations (“QSRs”). These regulations govern the manufacturing process, including design, manufacture, testing, release, packaging, distribution, documentation and purchasing. In complying with QSRs, manufacturers must continue to expend time, money and effort in the area of production and quality assurance to ensure full technical compliance. Companies are also subject to other post-market and general requirements, including restrictions imposed on marketed products, promotional standards and requirements for recordkeeping and reporting of certain adverse reactions. If there are any modifications made to our marketed devices, a premarket notification or PMA may be required to be submitted to, and cleared or approved by, the FDA, before the modified device may be marketed. The FDA regularly inspects companies to determine compliance with QSRs and other post-market requirements. Failure to comply with statutory requirements and the FDA’s regulations can result in warning letters, monetary penalties, suspension or withdrawal of regulatory approvals, operating restrictions, total or partial suspension of production, injunctions, product recalls, seizure of products and criminal prosecution.

The Clinical Laboratory Improvements Amendments of 1988, or CLIA, prohibit laboratories from performing tests for the purpose of providing information for the diagnosis, prevention or treatment of any disease or impairment of, or the assessment of, the health of human beings, unless there is in effect for such laboratories a certificate issued by the U.S. Department of Health and Human Services applicable to the category of examination or procedure performed. We consider the applicability of the requirements of CLIA in the design and development of our products. We have obtained a waiver of the CLIA requirements for both our OraQuick ADVANCE^® rapid HIV-1/2 antibody test and our Q.E.D.^® alcohol saliva test and may seek similar waivers for certain other products. A CLIA waiver allows certain customers to use the waived products that may not have been able to use them without complying with certain quality control and other requirements.

Certain of our products may also be affected by state regulations in the United States. For example, there are several states that restrict or do not currently permit oral fluid drug testing in the workplace or other markets. In addition, several states prohibit or limit the use of rapid, point-of-care HIV testing. We are presently working with legislators or regulators in certain of these states in an effort to modify or remove any restrictions affecting our ability to sell products.

17

International

We are also subject to regulations in foreign countries governing products, human clinical trials and marketing, and may need to obtain approval from international public health agencies, such as the World Health Organization, in order to sell products in certain countries. Approval processes vary from country to country, and the length of time required for approval or to obtain other clearances may in some cases be longer than that required for U.S. governmental approvals. We generally pursue approval only in those countries that we believe have a significant market opportunity.

The International Organization for Standardization (“ISO”) is a worldwide federation of national standards bodies from some 130 countries, established in 1947. The mission of the ISO is to promote the development of standardization and related activities in the world with a view to facilitating the international exchange of goods and services. ISO certification is a pre-requisite to use of the CE mark and indicates that our quality system complies with standards applicable to activities ranging from initial product design and development through production and distribution. The CE mark is a European Union (“EU”) requirement to sell products that fall under the scope of the Medical Devices Directive (“MDD”) and the In Vitro Diagnostic Directive (“IVDD”). The CE mark is evidence that the manufacturer and the product meet the requirements of all applicable directives, including the MDD and IVDD.

We received authorization to use the CE mark for the OraSure^® and Intercept^® collection devices and our Histofreezer^® product line, and SSL International has obtained authorization to use the CE mark for our cryosurgical wart removal product in the OTC European footcare market. In addition, we are currently in the process of obtaining authorization to affix a CE mark to our OraQuick ADVANCE^® HIV-1/2 test.

We must also comply with certain registration requirements as dictated by Health Canada, prior to commencing sales in Canada. We have completed this process for several of our current products and may do so with respect to other products in the future. In addition, Canadian law requires manufacturers of medical devices to have a quality management system that meets various ISO requirements in order to obtain a license to sell their devices in Canada.

Anti-Kickback Laws

The Federal Anti-Kickback Statute prohibits the knowing and willful offer, payment, solicitation, or receipt of any form of remuneration in return for, or to induce:

• The referral of a person;

• The furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs; or

• The purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable under Medicare, Medicaid, or other governmental programs.

Our products are or may be purchased by customers that will seek or receive reimbursement under Medicare, Medicaid or other governmental programs. Noncompliance with the federal anti-kickback legislation can result in exclusion from Medicare, Medicaid, or other governmental programs, restrictions on our ability to operate in certain jurisdictions, as well as civil and criminal penalties, any of which could have an adverse effect on our business and results of operations.

The Federal Civil Monetary Penalties Law prohibits the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s selection of a particular supplier of Medicare or Medicaid payable items or services. Noncompliance can result in civil money penalties of up to $10,000 for each wrongful act, assessment of three times the amount claimed for each item or service and exclusion from the Federal healthcare programs.

18

Many states have also adopted some form of anti-kickback laws. A determination of liability under such laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions.

We believe that we are operating in compliance with these laws.

Foreign Corrupt Practices Act

The U.S. Foreign Corrupt Practices Act (“FCPA”) prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Our present and future business has and will continue to be subject to the FCPA and various other laws, rules and/or regulations applicable to us as a result of our international sales.

Environmental Regulation

Because of the nature of our current and proposed research, development, and manufacturing processes, we are subject to stringent federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge and handling and disposal of materials and wastes. We believe that we have complied with these laws and regulations in all material respects.

The foregoing discussion of our business should be read in conjunction with the Financial Statements and accompanying notes included in Item 15 of this Annual Report.

ITEM 1A.    Risk Factors

The following is a discussion of certain significant risk factors that could potentially negatively impact our financial condition, performance and prospects.

Regulatory Risks

The Need to Obtain Regulatory Approvals and Respond to Changes in Regulatory Requirements Could Adversely Affect Our Business.

Many of our proposed and existing products are subject to regulation by the FDA and other governmental or public health agencies. In particular, we are subject to strict governmental controls on the development, manufacture, labeling, distribution and marketing of our products. In addition, we are often required to obtain approval or registration with foreign governments or regulatory bodies before we can import and sell our products in foreign countries.

The process of obtaining required approvals or clearances from governmental or public health agencies can involve lengthy and detailed laboratory testing, human clinical trials, sampling activities and other costly, time- consuming procedures. These approvals can require the submission of a large amount of clinical data which may require significant time to obtain. It is also possible that a product will not perform at a level needed to generate the clinical data required to obtain an approval or clearance. The submission of an application to the FDA or other regulatory authority does not guarantee that an approval or clearance to market the product will be received. Each authority may impose its own requirements and delay or refuse to grant approval or clearance, even though a product has been approved in another country or by another agency.

Moreover, the approval or clearance process for a new product can be complex and lengthy. This time span increases our costs to develop new products as well as the risk that we will not succeed in introducing or selling them in the United States or other countries.

19

We are in the process of conducting clinical studies to support an application for FDA approval of our OraQuick ADVANCE^® HIV-1/2 test for sale in the United States OTC market. We also expect to conduct clinical trials in support of our application for FDA approval of our OraQuick^® HCV test for professional use. There can be no assurance that these clinical trials will generate sufficient data to support FDA approval of either product or that FDA approval will be obtained. Failure to obtain or any delay in obtaining FDA approval for either product could significantly reduce future revenues and could adversely affect our financial performance.

Newly promulgated or changed regulations could also require us to undergo additional trials or procedures, or could make it impractical or impossible for us to market our products for certain uses, in certain markets, or at all. For example, during 2004 SAMHSA, which is part of the U.S. Department of Health and Human Services, issued proposed regulations for the use of oral fluid drug testing for federal workers. Although the SAMHSA regulations have been withdrawn, if and when they are issued in final form, they could permit us to market and sell our oral fluid drug tests for use with federal workers only if certain modifications are made to our products. If we are unable to make these modifications, or if the modifications require significant time to develop, our ability to sell our oral fluid drug testing products in that market could be limited. In addition, the extent to which the final SAMHSA regulations permit the sale of our oral fluid drug tests for use with federal workers may influence whether customers in the workplace, criminal justice or other unregulated markets use our products.

The regulations in some states may restrict our ability to sell products in those states. For example, certain states restrict or do not allow the testing of oral fluid for drugs of abuse or the rapid, point-of-care testing for HIV. While we intend to work with state legislators and regulators to remove or modify any applicable restrictions, there is no guarantee we will be successful in these efforts.

In addition, all in vitro diagnostic products that are to be sold in the EU must bear the CE mark indicating conformance with the essential requirements of the IVDD. We are not permitted to sell our products in the EU without a CE mark, which could lead to the termination of strategic alliances and agreements for sales of those products in the EU. We have obtained the CE mark for several of our existing products and we intend to CE mark our OraQuick ADVANCE^® test and certain of our future products and are not aware of any material reason why we will be unable to do so. However, there can be no assurance that compliance with all provisions of the IVDD will be demonstrated and the CE mark will be obtained for all products that we desire to sell in the EU.

The Inability to Extend the Shelf Life of Our OraQuick ADVANCE^® Test Could Adversely Affect Our Business.

The shelf life of a product is the period of time from the date of manufacture during which the product is expected to perform in accordance with its specifications and labeling. In order to successfully sell our products, they need to have a shelf life that is long enough to cover the time required to distribute the product to a customer and provide the customer with a reasonable period to use that product.

Where a product has a short shelf life, our ability to sell that product may be adversely affected. In order to extend the shelf life, we may be required to submit real time stability data supporting such an extension to the FDA for approval.

Our OraQuick ADVANCE^® HIV-1/2 test has a shelf life of six months. While this shelf life has not prevented us from selling into the public health and hospital markets in the United States, it has limited our ability to sell that test internationally. We also believe a shelf life of at least 12 months will be required to sell the OraQuick ADVANCE^® test successfully into the United States OTC market.

We are working to extend the shelf life of our OraQuick ADVANCE^® test. However, there can be no assurance that we will be successful in obtaining such an extension or its approval by the FDA. If we are unsuccessful in obtaining a shelf life extension, our ability to sell the OraQuick^® test may be adversely affected and we may not be able to sell it successfully into the United States OTC market.

20

Failure to Comply With FDA or Other Regulatory Requirements May Require Us to Suspend Production of Our Products or Institute a Recall Which Could Result in Higher Costs and a Loss of Revenues.

We can manufacture and sell many of our products, both in the United States and internationally, only if we comply with regulations of government agencies such as the FDA. We have implemented quality assurance and other systems that are intended to comply with applicable regulations.

Although we believe that we have adequate processes in place to ensure compliance with these requirements, the FDA or other regulatory bodies could force us to stop manufacturing or selling our products if it concludes that we are out of compliance with applicable regulations. The FDA and other regulatory bodies could also require us to recall products if we fail to comply with applicable regulations, which could force us to stop manufacturing such products. Such actions by the FDA could adversely affect our revenues. See the Section entitled “Government Regulation” in Item 1 of this Annual Report for a further discussion of applicable regulatory requirements.

Risks Relating to Our Industry, Business and Strategy

Our Ability to Sell Products Could be Affected by Competition From New and Existing Diagnostic Products and by Treatments or Other Non-Diagnostic Products Which May be Developed.

The diagnostic industry is focused on the testing of biological specimens in a laboratory or at the point of care and is highly competitive and rapidly changing. Many of our principal competitors have considerably greater financial, technical and marketing resources. As new products enter the market, our products may become obsolete or a competitor’s products may be more effective or more effectively marketed and sold than ours. If we fail to maintain and enhance our competitive position, our customers may decide to use products developed by competitors which could result in a loss of revenues.

We also face competition from products which may be sold at a lower price. To the extent this competition arises, customers may choose to buy lower cost products from third parties or we may be forced to sell our products at a lower price, both of which could result in a loss of revenues or a lower gross margin contribution from the sale of our products.

In addition, the development and commercialization of products outside of the diagnostics industry could adversely affect sales of our product. For example, the development of a safe and effective vaccine to prevent HIV or preventative treatments for other diseases or conditions that our products are designed to detect, could reduce, or eventually eliminate, the demand for our HIV or other diagnostic products and thereby result in a loss of revenues.

Our Research, Development and Commercialization Efforts May Not Succeed and Our Competitors May Develop and Commercialize More Effective or Successful Diagnostic Products.

In order to remain competitive, we must regularly commit substantial resources to research and development and the commercialization of new products.

The research and development process generally takes a significant amount of time from inception to commercial product launch. This process is conducted in various stages. During each stage there is a substantial risk that we will not achieve our goals on a timely basis, or at all, and we may have to abandon a product in which we have invested substantial amounts.

During 2006, 2005 and 2004, we incurred $8.6 million, $5.3 million and $6.1 million, respectively, in research and development expenses. We expect to continue to incur significant costs from our research and development activities.

21

Successful products require significant development and investment, including testing, to demonstrate their cost-effectiveness or other benefits prior to commercialization. In addition, regulatory approval must be obtained before most products may be sold. Additional development efforts on these products will be required before any regulatory authority will review them. Regulatory authorities may not approve these products for commercial sale. In addition, even if a product is developed and all applicable regulatory approvals are obtained, there may be little or no market for the product. Accordingly, if we fail to develop commercially successful products, or if competitors develop more effective products or a greater number of successful new products, customers may decide to use products developed by our competitors. This would result in a loss of revenues and adversely affect our results of operations, cash flows and business.

If We Lose Our Key Personnel or Are Unable to Attract and Retain Qualified Personnel as Necessary, Our Business Could be Harmed.

Our success will depend to a large extent upon the contributions of our executive officers, management and sales, marketing, operations and scientific staff. We may not be able to attract or retain qualified employees in the future due to the intense competition for qualified personnel among medical products businesses.

If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will adversely affect our ability to effectively manufacture, sell and market our products, to meet the demands of our strategic partners in a timely fashion, or to support internal research and development programs. Although we believe we will be successful in attracting and retaining qualified personnel, competition for experienced scientists and other personnel from numerous companies and academic and other research institutions may limit our ability to do so on acceptable terms.

Future Acquisitions or Investments Could Disrupt Our Ongoing Business, Distract Our Management, Increase Our Expenses and Adversely Affect Our Business.

We may consider strategic acquisitions or investments as a way to expand our business in the future. These activities, and their impact on our business, are subject to the following risk factors:

• Suitable acquisitions or investments may not be found or consummated on terms that are satisfactory to us;

• We may be unable to successfully integrate an acquired company’s personnel, assets, management systems and technology into our business;

• Acquisitions may require substantial expense and management time and could disrupt our business;

• An acquisition and subsequent integration activities may require greater capital resources than originally anticipated at the time of acquisition;

• An acquisition may result in the incurrence of unexpected expenses, the dilution of our earnings or our existing stockholders’ percentage ownership, or potential losses from undiscovered liabilities not covered by an indemnification from the seller(s) of the acquired business;

• An acquisition may result in the loss of existing key personnel or customers or the loss of the acquired company’s key personnel or customers;

• The benefits expected to be derived from an acquisition may not materialize and could be affected by numerous factors, such as regulatory developments, general economic conditions and increased competition; and

• An acquisition of a foreign business may involve additional risks, including, but not limited to, foreign currency exposure, liability under foreign laws or regulations and not being able to successfully assimilate differences in foreign business practices or overcome language or cultural barriers.

The occurrence of one or more of the above or other factors may prevent us from achieving all or a significant part of the benefits expected from an acquisition or investment. This may adversely affect our

22

financial condition, results of operations and ability to grow our business or otherwise achieve our financial or strategic objectives.

Our Revenues Could be Affected by Third-Party Reimbursement Policies and Potential Cost Constraints.

The end-users of our products are expected to increasingly include hospitals, physicians and other healthcare providers. Use of our products could be adversely impacted if these end-users do not receive reimbursement for the cost of our products by their patients’ healthcare insurers or payors. Our net sales could also be adversely affected by changes in reimbursement policies of governmental or private healthcare payors, including in particular the level of reimbursement for our products. In the United States, healthcare providers such as hospitals and physicians who purchase diagnostic products generally rely on third-party payors, principally private health insurance plans, Medicare and Medicaid, to reimburse all or part of the cost of the product and procedure. We believe that the overall escalating cost of medical products and services has led to, and will continue to lead to, increased pressures on the healthcare industry, both foreign and domestic, to reduce the cost of products and services. Given the efforts to control and reduce healthcare costs in the United States in recent years, currently available levels of reimbursement may not continue to be available in the future for our existing products or products under development. Third-party reimbursement and coverage may not be available or adequate in either the United States or foreign markets, current reimbursement amounts may be decreased in the future and future legislation, and regulation or reimbursement policies of third-party payors may reduce the demand for our products or our ability to sell our products on a profitable basis.

Increases in Demand for Our Products Could Require Us to Expend Considerable Resources to Meet the Demand or Harm Our Customer Relationships if We are Unable to Meet Demand.

If we experience significant or unexpected increases in the demand for our products, we and our suppliers may not be able to meet that demand without expending additional capital resources. These capital resources could involve the cost of new machinery or even the cost of new manufacturing facilities. This would increase our capital costs, which could adversely affect our earnings. Our suppliers may be unable or unwilling to expend the necessary capital resources or otherwise expand their capacity. In addition, new manufacturing equipment or facilities may require FDA approval before they can be used to manufacture our products. To the extent we are unable to obtain or are delayed in obtaining such approvals, our ability to meet the demand for our products could be adversely affected.

If we or our suppliers are unable to develop necessary manufacturing capabilities in a timely manner, our net sales could be adversely affected. Failure to cost-effectively increase production volumes, if required, or lower than anticipated yields or production problems encountered as a result of changes that we or our suppliers make in our manufacturing processes to meet increased demand, could result in shipment delays or interruptions and increased manufacturing costs, which could also have a material adverse effect on our revenues and profitability.

Our inability to meet customer demand for our products could also harm our customer relationships and impair our reputation within the industry. This, in turn, could have a material adverse effect on our business and prospects.

Risks Relating to Collaborators

Our Failure to Maintain Existing Distribution Channels, or Develop New Distribution Channels, May Result in Lower Revenues.

We have marketed many of our products by collaborating with laboratories, diagnostic companies and distributors. Our sales depend to a substantial degree on our ability to sell products to these customers and on the marketing abilities of the companies with which we collaborate.

23

We currently sell our OraQuick ADVANCE^® rapid HIV-1/2 antibody test to the diagnostics division of Abbott Laboratories for distribution into the United States hospital market on an exclusive basis. Abbott recently announced that it will sell a portion of its diagnostics business to General Electric (“GE”), including its rights to the OraQuick ADVANCE^® product. This sale has not yet closed, and it is unclear what, if any, effect it may have on sales of our OraQuick ADVANCE^® test in the hospital market.

Some of our distributors or other customers may not fulfill their contractual obligations to us. Although we will try to maintain and expand our business with our distributors and customers and require that they fulfill their contractual obligations, there can be no assurance that such companies will continue to purchase or distribute our products, maintain historic order volumes or otherwise meet their purchase or other obligations, or that new distribution channels will be available on satisfactory terms. The failure of these distributors or other customers to purchase our products could adversely affect our revenues.

In September 2006, Prestige Brands, Inc., the domestic distributor of the Freeze Off^® cryosurgical wart removal product, announced that it had acquired the Wartner^® cryosurgical product, which directly competes with the Freeze Off^® product in the United States and Canadian OTC markets. We believe this acquisition constitutes a material breach of our agreement with Prestige, and we are pursuing arbitration to resolve this matter. We believe we have already suffered significant damages from this breach and Prestige’s actions may continue to impact future sales of the Freeze Off^® product. If we are unable to successfully resolve this matter with Prestige or find an alternative arrangement for distributing our cryosurgical product into the United States and Canada OTC markets, our revenues could be negatively affected.

Some of our distributors have also consolidated in recent years and such consolidation has had, and may continue to have, an adverse impact on the level of orders for our products. In addition, some distributors have experienced, and may continue to experience, pressure from their customers to reduce the price of their products and testing services. For example, several of our insurance testing laboratories are facing this pressure and are using lower cost “home brew” insurance testing assays that they have developed internally or purchased from our competitors. This has reduced our assay sales and is expected to lower sales of these products in 2007 and beyond.

The Use of Sole Supply Sources or Third Party Suppliers For Critical Components of Our Products Could Adversely Affect Our Business.

We currently purchase certain critical components of our products from sole supply sources or other third party suppliers. For example, all of the HIV antigen and nitrocellulose required to make our OraQuick ADVANCE^® rapid HIV-1/2 antibody test is purchased from sole source suppliers. In addition, the conjugates used in our MICROPLATE oral fluid drugs of abuse assays are obtained from third party suppliers.

If these suppliers are unable or unwilling to supply the required component or if they make changes in the component or do not supply materials meeting our specifications, we may need to find another source and perform additional development work. We may also need to obtain FDA or other regulatory approvals for the use of the alternative component for our products. Completing that development and obtaining such approvals could require significant time to complete and may not occur at all. The availability of critical components from sole supply sources or other third parties could also reduce our control over pricing, quality and timely delivery. These events could either disrupt our ability to manufacture and sell certain of our products, or completely prevent us from doing so or increase our costs. Any such event could have a material adverse effect on our results of operations, cash flows and business.

The Unavailability of Certain Products Distributed by a Third Party Could Adversely Affect Sales of Our OraSure^® Oral Fluid Collection Device.

In testing an oral fluid sample collected with an OraSure^® device for HIV-1 in the United States, our customers must use an HIV-1 EIA screening test approved by the FDA for use with our OraSure^® device. Where

24

an oral fluid sample screens positive for HIV-1, our customers must then use our oral fluid Western blot HIV-1 confirmatory test, which has also been approved by the FDA for use with our OraSure^® device, to confirm that positive indication.

BMX currently manufactures and sells the only oral fluid HIV-1 EIA screening test that has received FDA approval for use in detecting HIV-1 in an oral fluid specimen collected with our OraSure^® collection device. BMX also supplies the HIV-1 antigen used to manufacture our oral fluid Western blot HIV-1 confirmatory test and is the exclusive world-wide distributor of that product.

In late 2006, BMX announced that it will discontinue manufacturing the HIV-1 EIA screening test during 2007 and that, due to quality problems, it may have difficulty supplying this screening test prior to the time it ceases manufacturing. As a result, we are working with BMX, the FDA and CDC, our major laboratory customers and other potential suppliers to find or develop an alternative HIV-1 EIA screening test that can be used with oral fluid samples collected with our OraSure^® device.

In March 2007, BMX notified us that it will not renew the agreement under which it supplies the HIV-1 antigen used to manufacture our oral fluid Western blot HIV-1 confirmatory test or the agreement under which it distributes that product on an exclusive, world-wide basis. As a result, these agreements will terminate on December 31, 2007. Pursuant to the terms of the antigen supply agreement, we have the right to purchase an additional two-year supply of the antigen following termination so that we can continue to manufacture and sell our oral fluid Western blot test. When this additional two-year supply is combined with our existing inventory of the HIV-1 antigen, we believe we will have a suffucient supply of HIV-1 antigen to meet the demand for our Western blot test for three to four years after the agreement terminates. We also intend to pursue a long-term supply agreement directly with the vendor (a former affiliate of BMX) used by BMX to manufacture the HIV-1 antigen. During 2006, sales of our oral fluid Western blot HIV-1 confirmatory test totaled approximately $330,000.

If at some point in the future our customers cannot obtain either an HIV-1 EIA screening test or a Western blot or other HIV-1 confirmatory test that has been approved by the FDA for use with our OraSure^® collection device, sales of our OraSure^® device could be negatively affected.

We May Need Strategic Partners to Assist in Developing and Commercializing Some of Our Diagnostic Products.

Although we intend to pursue some product opportunities independently, opportunities that require a significant level of investment for development and commercialization or a distribution network beyond our existing sales force may necessitate involving one or more strategic partners. Our strategy for development and commercialization of products may entail entering into arrangements with distributors or other corporate partners, universities, research laboratories, licensees and others. We may be required to transfer material rights to such strategic partners, licensees and others. While we expect that our current and future partners, licensees and others have and will have an economic motivation to succeed in performing their contractual responsibilities, there is no assurance that they will do so and the amount and timing of resources to be devoted to these activities will be controlled by others. Consequently, there can be no assurance that any revenues or profits will be derived from such arrangements.

We may need to collaborate with one or more third parties or find new product distribution channels in order to commercialize our OraQuick ADVANCE^® HIV-1/2 test should we receive approval from the FDA for use in the United States OTC market. In order to successfully commercialize our OraQuick ADVANCE^® test in the OTC market, we may need to invest significantly in advertising and promotion and obtain distribution channels to the OTC market. If we are unable to collaborate with a third party having sufficient resources to assist in these efforts or find alternative distribution channels to access the OTC market, we may need to incur significant costs for advertising and promotion, and our ability to maximize our future revenues for this opportunity could be adversely affected.

25

Risks Relating to Our Financial Results, Structure and Need for Financing

We Have a History of Losses Prior to 2005.

We achieved our first full years of profitability in 2005 and 2006. However, as of December 31, 2006, the Company had an accumulated deficit of $98.4 million.

Our ability to achieve continued profitability in the future will be dependent upon a number of factors including, without limitation, the following:

• Creating market acceptance for and selling increasing volumes of our OraQuick ADVANCE^® rapid HIV-1/2 antibody test, Intercept^® drug testing product and OraSure^® collection device;

• The degree to which certain of our new products may replace sales of our existing products and the financial impact of that change, including the degree to which our OraQuick ADVANCE^® test will replace our OraSure^® collection device for HIV-1 testing or sales of our cryosurgical wart removal products in the OTC market will replace sales of our Histofreezer^® product to physicians’ offices or other professional markets;

• The degree to which our major distributors comply with their contractual obligations, including minimum purchase commitments;

• Whether we are able to extend the shelf life of our OraQuick ADVANCE^® HIV-1/2 test;

• Our ability to successfully resolve claims or litigation, including patent infringement litigation;

• The level of expenditures we are required to make in order to develop and obtain regulatory approvals for our new products, including our OraQuick ADVANCE^® HIV-1/2 test for use in the OTC market and an OraQuick^® HCV test for professional use;

• Achieving growth in sales of our wart removal products in the OTC market and selling other products, such as our OraQuick ADVANCE^® HIV-1/2 test, in the OTC market;

• Whether we are able to find a replacement for the BMX HIV-1 EIA screening test for use in connection with oral fluid samples collected with our OraSure^® device;

• Achieving growth in international markets with our OraQuick ADVANCE^® HIV-1/2 test, cryosurgical wart removal products and other products;

• Changes in the level of competition, such as would occur if larger and financially stronger competitors introduced new or lower priced products to compete with our products;

• Changes in economic conditions in domestic or international markets, such as economic downturns, reduced demand, inflation and currency fluctuations;

• Failure to achieve our targets for growth in revenues;

• Changes in distributor buying patterns or a buildup of significant quantities in our distributors’ inventories or distribution channels; and

• Commercially developing, and obtaining regulatory approvals and creating market acceptance for new products in a time frame consistent with our objectives.

Even though we achieved profitability for 2005 and 2006, there can be no assurance that we will be able to sustain such profitability in the future.

Utilization of Our Deferred Tax Assets May Be Limited and is Dependent on Future Taxable Income.

As of December 31, 2006, we had federal net operating loss (“NOL”) carryforwards of $53.0 million for federal income tax purposes. The Tax Reform Act of 1986 contains provisions under Section 382 of the Internal

26

Revenue Code that limit the NOLs that may be used in any given year in the event of specified occurrences, including significant ownership changes. If these specified events occur, we may lose some or all of the tax benefits of these carryforwards.

During 2005, we determined, based on our assessment of both positive and negative evidence, which takes into consideration our forecasted taxable income, that it was more likely than not that we will benefit from the use of a significant portion of our deferred tax assets, and therefore we reduced our valuation allowance on our deferred tax assets related to these NOLs. If in the future we determine, based on our assessment of both positive and negative evidence, that it is more likely than not that we will not realize all or a portion of the deferred tax assets, we will record a valuation allowance on the deferred tax assets which would result in recognition of income tax expense.

We May Require Future Additional Capital.

Our future liquidity and ability to meet our future capital requirements will depend on numerous factors, including, but not limited to, the following:

• The costs and timing of the expansion of our manufacturing capacity;

• The success of our research and product development efforts;

• The magnitude of capital expenditures;

• Changes in existing and potential relationships with distributors and other business partners;

• The time and cost of obtaining regulatory approvals;

• The costs involved in obtaining and enforcing patents, proprietary rights and necessary licenses;

• The costs and liability associated with patent infringement or other types of litigation;

• The costs and timing of expansion of sales and marketing activities;

• The timing of the commercial launch of new products;

• The extent to which existing and new products gain market acceptance;

• The scope and results of clinical testing;

• Competing technological and market developments; and

• The scope and timing of strategic acquisitions.

If additional financing is needed, we may seek to raise funds through the sale of equity or other securities or through bank borrowings. There can be no assurance that financing through the sale of securities, bank borrowings or otherwise, will be available to us on satisfactory terms, if at all.

An Economic Downturn, Terrorist Attacks or National Disasters May Adversely Affect Our Business.

Changes in economic conditions could adversely affect our business. For example, in a difficult economic environment, customers may be unwilling or unable to invest in new diagnostic products, may elect to reduce the amount of their purchases or may perform less drug testing because of declining employment levels or the issuance of fewer life insurance policies. A weakening business climate could also cause longer sales cycles and slower growth, and could expose us to increased business or credit risk in dealing with customers or suppliers adversely affected by economic conditions.

Terrorist attacks such as those occurring on September 11, 2001, or national disasters such as Hurricane Katrina, and subsequent governmental responses to these events could cause economic instability. These actions

27

could adversely affect economic conditions both within and outside the United States and reduce demand for our products. Terrorist attacks and natural disasters could cause governments and regulatory agencies, such as the FDA or agencies that perform similar functions outside the United States, to focus their resources on other matters, such as relief efforts or vaccines or other products intended to address the threat of biological or chemical warfare. This diversion of resources could eliminate or delay the bulk procurement of our products by government agencies or delay our ability to obtain regulatory approvals required to manufacture, market or sell our products in the United States and other countries. These events could also disrupt the operations of our customers and suppliers and eliminate, reduce or delay our customers’ ability to purchase and use our products and our suppliers’ ability to provide raw materials and finished products.

Our Stock Price Could Continue to be Volatile.

Our stock price has been volatile, has fluctuated substantially in the past and may be volatile in the future and could experience substantial declines. The following factors, among others, could have a significant impact on the market for our Common Stock:

• Future announcements concerning us or our products;

• Future announcements concerning our competitors or industry;

• Developments in patent or other proprietary rights;

• Litigation or threatened litigation;

• Public concern as to the performance or safety of products that we or others have developed or sold;

• Failure to achieve, or changes in, financial estimates by securities analysts and comments or opinions about us by securities analysts or major stockholders;

• Governmental regulation;

• Clinical results with respect to our products in development or those of our competitors;

• Changes in the level of competition;

• Loss of or declines in sales to major distributors or customers;

• The relatively low trading volume for our Common Stock;

• Period to period fluctuations in our operating results;

• General market and economic conditions; and

• Terrorist attacks, civil unrest, war and national disasters.

Future Sales of Our Common Stock by Existing Stockholders, Executive Officers or Directors Could Depress the Market Price of Our Common Stock and Make It More Difficult For Us to Sell Stock in the Future.

Sales of our Common Stock in the public market, or the perception that such sales could occur, could negatively impact the market price of our Common Stock. We are unable to estimate the number of shares of our Common Stock that may actually be resold in the public market since this will depend on the market price for our Common Stock, the individual circumstances of the sellers and other factors.

We have a number of institutional stockholders that own significant blocks of our Common Stock. If one or more of these stockholders sell large portions of their holdings in a relatively short time, for liquidity or other reasons, the prevailing market price of our Common Stock could be negatively affected. In addition, it is possible that one or more of our executive officers or non-employee members of our Board of Directors could sell shares of our Common Stock during an open trading window under our Insider Trading Policy. These transactions and

28

the perceived reasons for these transactions could have a negative effect on the prevailing market price of our Common Stock.

Our Reported Financial Results May be Adversely Affected by Changes in Accounting Principles Generally Accepted in the United States.

We prepare our financial statements in conformity with accounting principles generally accepted in the United States. These accounting principles are subject to creation or interpretation by the Financial Accounting Standards Board, the SEC and various bodies formed to interpret and create appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, and could affect the reporting of transactions completed before the announcement of a change.

Risks Relating to Intellectual Property

Our Success Depends on Our Ability to Protect Our Proprietary Technology.

The diagnostics industry places considerable importance on obtaining patent, trademark and trade secret protection, as well as other intellectual property rights, for new technologies, products and processes. Our success depends, in part, on our ability to develop and maintain a strong intellectual property portfolio or obtain licenses to patents for products and technologies both in the United States and in other countries.

As appropriate, we intend to file patent applications and obtain patent protection for our proprietary technology. These patent applications and patents will cover, as applicable, compositions of matter for our products, methods of making those products, methods of using those products and apparatus relating to the use or manufacture of those products. We will also rely on trade secrets, know-how and continuing technological advancements to protect our proprietary technology.

We have entered, and will continue to enter, into confidentiality agreements with our employees, consultants, advisors and collaborators. However, these parties may not honor these agreements and we may not be able to successfully protect our rights to unpatented trade secrets and know-how. Others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and know-how.

Many of our employees, including scientific and management personnel, were previously employed by competing companies. Although we encourage and expect all of our employees to abide by any confidentiality agreement with a prior employer, competing companies may allege trade secret violations and similar claims against us.

We may collaborate with universities and governmental research organizations which, as a result, may acquire part of the rights to any inventions or technical information derived from collaboration with them.

To facilitate development and commercialization of a proprietary technology base, we may need to obtain licenses to patents or other proprietary rights from other parties. Obtaining and maintaining such licenses may require the payment of substantial amounts. In addition, if we are unable to obtain these types of licenses, our product development and commercialization efforts may be delayed or precluded.

We may incur substantial costs and be required to expend substantial resources in asserting or protecting our intellectual property rights, or in defending suits against us related to intellectual property rights. Disputes regarding intellectual property rights could substantially delay product development or commercialization activities. Disputes regarding intellectual property rights might include state, federal or foreign court litigation, as well as patent interference, patent reexamination, patent reissue, or trademark opposition proceedings in the

29

United States Patent and Trademark Office. Opposition or revocation proceedings could be instituted in a foreign patent office. An adverse decision in any proceeding regarding intellectual property rights could result in the loss or limitation of our rights to a patent, an invention or trademark.

We are Involved in Pending, and May Become Involved in Future, Intellectual Property Infringement Disputes, Which are Costly and Could Limit or Eliminate Our Ability to Sell Our Products or Use Certain of Our Technologies in the Future.

From time to time, we may seek to enforce our patents or other intellectual property rights through litigation. In addition, there are a large number of patents and patent applications in our product areas, and additional patents may be issued to third parties relating to our product areas. We may be sued for infringement of patents or misappropriation of other intellectual property rights with respect to one or more of our products. Litigation in our industry regarding patent and other intellectual property rights is prevalent and is expected to continue.

Our involvement in litigation with respect to patents or other intellectual property or to determine rights in proprietary technology, either as a plaintiff or defendant, could adversely affect our revenues, market share, results of operations and business because:

• As is common with major litigation, it could consume a substantial portion of managerial and financial resources;

• Its outcome would be uncertain and a court may find that our patents are invalid or unenforceable in response to claims by another party or that the third-party patent claims are valid and infringed by our products;

• An adverse outcome could subject us to the loss of the protection of our patents or to liability in the form of past royalty payments, penalties, special and punitive damages, or future royalty payments significantly affecting our future earnings;

• Failure to obtain a necessary license upon an adverse outcome could prevent us from selling our current products or other products we may develop or acquire; and

• A court could award a preliminary and/or permanent injunction which would prevent us from selling our current or future products.

We have sued Schering-Plough for infringement of several of our patents related to the technology for the cryosurgical removal of warts and other benign skin lesions. This litigation has been costly to prosecute, and there is no assurance that we will be successful in our obtaining either injunctive relief or an award of damages in this matter. It is also possible, based on the defenses asserted by Schering-Plough, that one or more of our patents could be found to be invalid or unenforceable. For a further description of the Schering-Plough litigation, see Item 3, “Legal Proceedings,” in this Annual Report.

The Sales Potential for OraQuick ADVANCE^® Could be Affected by Our Ability to Obtain Certain Licenses.

Our OraQuick ADVANCE^® test is a lateral flow assay device that tests for specific antibodies or other substances. The term “lateral flow” generally refers to a test strip through which a sample flows and which provides a test result on a portion of the strip downstream from where the sample is applied. There are numerous patents in the United States and other countries which claim lateral flow assay methods and devices. Some of these patents may broadly cover the technology used in the OraQuick ADVANCE^® test and are in force in the United States and other countries. We may not be able to make or sell the OraQuick ADVANCE^® test in the United States or other countries where these patents are in force.

We have obtained licenses under several lateral flow patents, which we believe should be sufficient to permit the manufacturing and sale of the OraQuick ADVANCE^® device as currently contemplated. However,

30

licenses under additional patents may be required and it is possible that a third party could seek to enforce one or more lateral flow patents against us. In the event that we are unable to successfully defend against such litigation or it is determined that a license is required and it is not possible to negotiate or otherwise obtain a license agreement on reasonable terms under a necessary patent, our ability to manufacture and sell the OraQuick ADVANCE^® device could be limited. In such case, we may be able to modify the OraQuick ADVANCE^® test such that a license would not be necessary. However, this alternative could delay or limit our ability to sell the OraQuick ADVANCE^® test in the United States and other markets, which would adversely affect our results of operations, cash flows and business.

Risks Relating to Products, Marketing and Sales

A Market for Our Products May Not Develop.

Our future success will depend, in part, on the market acceptance, and the timing of such acceptance, of our products such as the OraQuick ADVANCE^® rapid HIV-1/2 antibody test, the Intercept^® drug test and other new products or technologies that may be developed or acquired. To achieve market acceptance, we must make substantial marketing efforts and spend significant funds to inform potential customers and the public of the perceived benefits of these products. There may be limited evidence on which to evaluate the market reaction to products that may be developed, and there can be no assurance that any products will obtain market acceptance and fill the market need that is perceived to exist.

If Acceptance and Adoption of Our Oral Fluid Testing Does Not Continue, Our Future Results May Suffer.

We have made significant progress in gaining acceptance of oral fluid testing for HIV in the insurance, public health and other markets. We have also made significant progress in gaining acceptance of oral fluid testing for drugs of abuse in the workplace and criminal justice testing markets. However, the ultimate degree of acceptance in these markets is uncertain, and other markets may resist the adoption of oral fluid testing as a replacement for other testing methods in use today. In addition, certain state laws prohibit or restrict the use of oral fluid testing for drugs of abuse in certain markets or the rapid, point-of-care testing for HIV. As a result, there can be no assurance that we will be able to expand the use of our oral fluid testing products in these or other markets.

We May be Sued for Product Liabilities for Injuries Resulting From the Use of Our Products.

We may be held liable if any of our products, or any product which is made with the use or incorporation of any of our technologies, causes injury of any type or is found otherwise unsuitable during product testing, manufacturing, marketing, sale or usage. Although we have obtained product liability insurance, this insurance may not fully cover potential liabilities. As we bring new products to market, we may need to increase our product liability coverage.

We are selling cryosurgical wart removal products in the consumer or OTC market in the United States, Canada, and Europe. We expect to expand the OTC sales of these products to other countries and to eventually distribute other types of products in the domestic and international OTC markets, such as our OraQuick ADVANCE^® HIV-1/2 test. We believe the sale of products in the OTC market increases the risk of potential product liability exposure and possibly the required level of insurance coverage that we will need to maintain. Inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to protect against potential product liability claims could affect our decision to commercialize new products and our results of operations.

Performance of Our Products May Affect Our Revenues and Stock Price.

Our products are generally sold with labeling that contains performance claims approved or cleared by the FDA or other regulators. If our products fail to perform in accordance with the applicable label claims or

31

otherwise in accordance with the expectations or needs of our customers, customers may switch to a competing product or otherwise stop using our products, and our revenues could be adversely affected. In addition, poor performance by one or more of our products and publicity surrounding such performance could have an adverse effect on our reputation, our continuing ability to sell products and the prevailing market price of our Common Stock.

Our Increasing International Presence May be Affected by Regulatory, Cultural or Other Restraints.

We intend to increase revenue derived from international sales of our products. Our international sales accounted for $11.4 million or 17% of total revenues for 2006, $9.5 million or 14% of total revenues for 2005, and $6.2 million or 11% of total revenues for 2004.

A number of factors can slow or prevent international sales, or substantially increase the cost of international sales, including those set forth below:

• Regulatory requirements (including compliance with applicable customs regulations) may slow, limit, or prevent the offering of products in foreign countries;

• The unavailability of licenses to certain patents in force in a foreign country which cover our products may restrict our ability to sell into that country;

• The inability to maintain ISO certification for our or our suppliers’ manufacturing facilities could preclude, interrupt or delay our ability to manufacture products for sale in Europe or other international territories;

• Our inability to obtain the CE mark on our products in a timely manner may preclude or delay our ability to sell products in the European Union;

• Our inability to identify international distributors and negotiate acceptable terms for distribution agreements may delay or reduce our sales;

• Cultural and political differences may make it difficult to effectively market, sell and gain acceptance of products in foreign countries;

• Inexperience in international markets may slow or limit our ability to sell products in foreign countries;

• Exchange rates, currency fluctuations, tariffs and other barriers, extended payment terms and dependence on and difficulties in managing international distributors or representatives may affect our revenues even when product sales occur;

• The creditworthiness of foreign distributors may be less certain and foreign accounts receivable collection may be more difficult;

• Economic conditions, the absence of available funding sources, terrorism, civil unrest, war and natural disasters may slow or limit our ability to sell our products in foreign countries;

• Our exposure to liability under the Foreign Corrupt Practices Act and various other laws, rules and/or regulations applicable to us as a result of our international sales may affect our ability to sell into international markets;

• International markets often have long sales cycles, especially for sales to foreign governments, quasi-governmental agencies and international public health agencies, thereby delaying or limiting our ability to sell our products; and

• We may be at a disadvantage if competitors in foreign countries sell competing products at prices at or below such competitors’ or our cost.

In addition, we have entered into a contract for the manufacture and supply of our OraQuick^® HIV-1/2 test in Thailand, and the Histofreezer^® and Freeze Off^® cryosurgical products are currently manufactured in The

32

Netherlands. We may enter into agreements to manufacture other products in foreign countries as well. However, factors such as economic and political conditions and foreign regulatory requirements may slow or prevent the manufacture of our products in countries other than the United States. Interruption of the supply of our products could reduce revenues or cause us to incur significant additional expenses in finding an alternative source of supply. In addition, foreign currency fluctuations and economic conditions in foreign countries could increase the costs of manufacturing our products in foreign countries.

ITEM 1B.    Unresolved Staff Comments.

Not Applicable.

ITEM 2.    Properties.

We own a 48,000 square foot facility, which is our primary corporate office and manufacturing facility, and a second 31,700 square foot facility that houses our sales and marketing and research and development offices. Both of these facilities are located in Bethlehem, Pennsylvania. These facilities were previously leased until we exercised our option to purchase them on June 30, 2006.

We also own an additional 33,500 square foot building in Bethlehem, Pennsylvania, which is used for manufacturing activities.

We rent additional warehouse space on an as-needed basis. We also lease space for a small sales office in Reeuwijk, The Netherlands.

We believe that the facilities described above are adequate for our current requirements.

ITEM 3.    Legal Proceedings.

Schering-Plough Patent Infringement Litigation

On July 23, 2004, we filed a lawsuit against Schering-Plough for infringement of several of our patents relating to technology for the cryosurgical removal (i.e., freezing) of warts and other benign skin lesions. The suit was commenced in the United States District Court for the Eastern District of Pennsylvania, and alleges that Schering-Plough’s manufacture and sale of its Dr. Scholls^® Freeze Away^® cryosurgical wart removal product in the United States OTC market infringes the following United States patents: Nos. 5,738,682; 6,092,527 and 4,865,028. We are requesting permanent injunctive relief and the payment of damages. Schering-Plough has asserted various defenses in this matter, including that its Dr. Scholls^® Freeze Away^® product does not infringe our patents and that one or more of our patents are invalid and unenforceable.

On November 2, 2005, an initial pretrial conference was held on this matter, at which the Court heard oral argument on motions for summary judgment and certain evidentiary and other motions filed by the parties. Those motions remain pending. We expect the Court to set a final trial schedule once a decision on the motions has been rendered.

Prestige Brands Dispute

Prestige, through an affiliate, is the exclusive distributor of our cryosurgical wart removal product in the OTC market in the United States and Canada. Prestige distributes this product under its Compound W Freeze Off^® trade name. In September 2006, Prestige announced that it had acquired the Wartner^® cryosurgical wart removal product line, which directly competes with the Freeze Off^® product in the OTC market.

Our distribution agreement with Prestige contains a covenant not to compete which precludes Prestige from acquiring, manufacturing, distributing or selling a cryosurgical product that directly competes with the Freeze

33

Off^® product. We notified Prestige that its acquisition of the Wartner product constitutes a material breach of the distribution agreement and that certain of its other actions constitute additional breaches under the agreement.

On September 27, 2006, we filed a special petition and application with the Supreme Court of the State of New York, New York County, for a preliminary injunction against Prestige pursuant to New York Civil Practice Law and Rules § 7502(c) in support of the arbitration to be commenced between the parties. On November 8, 2006, the Court issued a decision dated October 30, 2006 finding that Prestige had breached the covenant not to compete, but denied our application. By decision dated December 20, 2006, the Court denied our motion for reargument and reconsideration of its October 30 decision. We have since filed an appeal of the Court’s denial of our request for a preliminary injunction with the Appellate Division—First Department of the New York Supreme Court and that appeal remains pending.

We have also initiated the alternative dispute resolution procedures required under our agreement with Prestige, which include mediation and binding arbitration. The parties’ efforts to resolve this matter through mediation were not successful, and an arbitration pursuant to the rules of the American Arbitration Association has been commenced, pursuant to the terms of the agreement.

Unless we are able to resolve this matter with Prestige, we intend to vigorously enforce our rights and remedies under the agreement, including seeking specific performance of the covenant not to compete.

ITEM 4.    Submission of Matters to a Vote of Security Holders.

No matters were submitted to a vote of security holders during the fourth quarter of the year ended December 31, 2006.

34

PART II

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our Common Stock is listed for trading on the Global Market tier of The Nasdaq Stock Market LLC (“NASDAQ”) under the symbol OSUR. High and low sales prices reported by NASDAQ during the periods indicated are shown below.

	Year ended December 31,
	2006				2005
	High		Low		High		Low
First Quarter	$	11.67	$	8.80	$	7.45	$	5.35
Second Quarter		10.89		7.89		10.23		6.91
Third Quarter		10.16		6.15		11.83		8.42
Fourth Quarter		8.70		7.27		14.14		7.74

On March 1, 2007, there were 578 holders of record and approximately 16,000 holders in street name of the Common Stock, and the closing price of the Common Stock was $7.76 per share.

Dividends

We have never paid any cash dividends and our Board of Directors does not anticipate paying cash dividends in the foreseeable future. We are generally not permitted to pay dividends or make other distributions to our stockholders under the terms of our credit facilities with Comerica Bank, without first obtaining Comerica’s consent. We intend to retain any future earnings to provide funds for the operation and expansion of our business.

35

Performance Graph

The following graph compares the cumulative total returns to investors in the Company’s Common Stock, the NASDAQ Composite Index and the NASDAQ Biotechnology Index for the period from December 31, 2001 through December 31, 2006. The graph assumes that $100 was invested on December 31, 2001 in the Company’s Common Stock and in each of the above-mentioned indices, and that all dividends were reinvested.

The NASDAQ Composite Index was chosen because it is a broad index of companies whose equity securities are traded on the NASDAQ Stock Market. The NASDAQ Biotechnology Index was chosen because it includes a number of our competitors. Stockholders are cautioned that the graph shows the returns to investors only as of the dates noted and may not be representative of the returns for any other past or future period.

	12/2001	12/2002	12/2003	12/2004	12/2005	12/2006
OraSure Technologies, Inc.	100.00	44.86	65.51	55.31	72.59	67.98
NASDAQ Composite Index	100.00	71.97	107.18	117.07	120.50	137.02
NASDAQ Biotechnology Index	100.00	62.08	90.27	99.08	111.81	110.06

The performance graph set forth above shall not be deemed “soliciting material” or “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that Section. This graph will not be deemed “incorporated by reference” into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether such filing occurs before or after the date hereof, regardless of any general incorporation language in such filing.

36

ITEM 6.    Selected Financial Data.

The following table sets forth selected financial data of the Company. This information should be read in conjunction with the Financial Statements and notes thereto included in Item 15 and the information set forth in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Selected Financial Data

(In thousands, except per share data)

	Year ended December 31,
	2006			2005			2004			2003			2002
Operating Results:
Revenues	$	68,155		$	69,366		$	54,008		$	40,451		$	32,010
Costs and expenses		62,692			61,793			55,365			41,737			35,550
Operating income (loss)		5,463			7,573			(1,357	)		(1,286	)		(3,540	)
Other income (expense), net		3,599			2,146			797			177			198
Income tax provision (benefit)		3,794			(17,729	)1		—			27			—
Net income (loss)		5,268			27,448	1		(560	)		(1,136	)		(3,342	)
Earnings (loss) per share
Basic	$	0.11		$	0.61		$	(0.01	)	$	(0.03	)	$	(0.09	)
Diluted	$	0.11		$	0.59		$	(0.01	)	$	(0.03	)	$	(0.09	)
Shares used in computing earnings (loss) per share
Basic		45,910			45,110			44,464			39,794			37,583
Diluted		46,580			46,147			44,464			39,794			37,583
Cash Flow:
Cash flow provided by (used in) operating activities	$	16,886		$	10,392		$	3,438		$	2,702		$	(518	)
	December 31,
	2006			2005			2004			2003			2002
Financial Position:
Cash, cash equivalents, and short-term investments	$	91,001		$	77,620		$	66,723		$	64,024		$	14,908
Working capital		95,979			90,670			68,910			67,171			18,931
Deferred tax asset		23,522			26,708			—			—			—
Total assets		156,565			130,747			88,064			86,151			35,737
Long-term debt, excluding current portion		10,031			884			1,334			2,456			3,409
Accumulated deficit		(98,414	)		(103,682	)		(131,130	)		(130,570	)		(129,435	)
Stockholders’ equity		129,504			118,919			75,577			73,509			26,019

¹ Includes an income tax benefit of $18,165 resulting from the elimination of a significant portion of the valuation allowance on our deferred tax assets (see Note 9 to the Notes to Financial Statements).

37

ITEM 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Statements below regarding future events or performance are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results could be quite different from those expressed or implied by the forward-looking statements. Factors that could affect results are discussed more fully under the Item 1A, entitled “Risk Factors,” and elsewhere in this Annual Report. Although forward-looking statements help to provide complete information about us, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements.

The following discussion should be read in conjunction with the financial statements contained herein and the notes thereto, along with the Section entitled “Critical Accounting Policies and Estimates,” set forth below.

Overview

We operate primarily in the worldwide $22 billion in vitro diagnostics business. We develop, manufacture and market oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays, and other in vitro diagnostic tests. We also manufacture and sell medical devices for the removal of warts and other benign skin lesions by cryosurgery, or freezing.

Our diagnostic product offerings primarily target the infectious disease and substance abuse testing segments of the larger in vitro diagnostic market, and are used in both laboratories as well as the emerging, and rapidly growing, point-of-care marketplace. Our OraSure^® and Intercept^® oral fluid collection devices, and their related assays, are processed in a laboratory, while the OraQuick ADVANCE^® rapid HIV-1/2 antibody test is designed for use at the point-of-care. Our cryosurgical products are also used at the point-of-care.

In vitro diagnostics have traditionally used blood or urine as the bodily fluids upon which tests are conducted. However, we have targeted the use of oral fluid in our products as a differentiating factor and believe that it provides a significant competitive advantage over blood and urine. Our oral fluid tests have sensitivity and specificity comparable to blood and/or urine tests. When combined with their ease of use, non-invasive and dignified nature, and cost effectiveness, our oral fluid tests represent a very competitive alternative to the more traditional testing methods in the diagnostic space.

During the year ended December 31, 2006, our total revenues were $68.2 million, which represents a 2% decrease from 2005. Our net income for 2006 was $5.3 million and includes a pre-tax charge of $3.4 million for stock options which are now required to be expensed under the new accounting rules. Our liquidity continued to improve, as we reported $16.9 million in cash flow from operating activities in 2006 and a balance of $91.0 million in cash, cash equivalents and short-term investments as of December 31, 2006.

Sales into the infectious disease testing market segment increased significantly in 2006 due to the continued market acceptance of our OraQuick ADVANCE^® HIV-1/2 test. This increase resulted largely from sales directly to various public health organizations and sales through Abbott into the hospital market. These increases were offset by the absence of government bulk purchases by SAMHSA and the CDC.

In February 2005, we entered into an agreement for the distribution of OraQuick ADVANCE^® with Abbott. Under this agreement, Abbott was appointed as our exclusive distributor in the U.S. hospital market and as a non-exclusive distributor in the U.S. physicians’ office marketplace. As our exclusive distributor to hospitals, Abbott sells OraQuick ADVANCE^® to federal hospitals under the terms and conditions of our Federal Supply Schedule that is on file with the U.S. General Services Administration. We have retained exclusive rights to all other markets, including the public health and criminal justice markets, the military, the CDC, SAMHSA and other government agencies. We utilize a small internal sales force to support Abbott and work together with them to maximize the penetration of OraQuick ADVANCE^® in the hospital market.

38

Competition in the market for HIV testing is intense and is expected to increase. We believe that the principal competition will come from existing laboratory-based blood tests, point-of-care rapid blood tests, laboratory-based urine assays or other oral fluid-based tests that may be developed. Our competitors include specialized biotechnology firms, as well as pharmaceutical companies with biotechnology divisions and medical diagnostic companies.

Significant competitors for our OraQuick ADVANCE^® rapid test, such as the Ortho Diagnostics division of Johnson & Johnson, Bio-Rad Laboratories, Abbott and BMX, sell laboratory-based HIV-1/2 EIAs, and Maxim Biomedical (formerly Calypte, Inc.) sells an HIV-1 screening test for urine, in the United States. MedMira and Trinity Biotech each sell competing rapid HIV-1 blood tests, and Bio-Rad Laboratories and Chembio sell competing rapid HIV-1/2 blood tests in the United States. These tests compete with our OraQuick ADVANCE^® test in hospitals or other laboratory settings. In addition, Trinity Biotech and Chembio have received CLIA waivers for their rapid HIV tests and these tests compete with our OraQuick ADVANCE^® test in the markets outside of the traditional hospital and laboratory settings. These companies, or others, may continue to expand the bodily fluids with which a rapid HIV test may be performed, or develop and commercialize new rapid HIV tests, which would provide further competition for our OraQuick ADVANCE^® test. We believe other companies may also seek FDA approval to sell competing rapid HIV tests in the future.

Sales to the substance abuse testing market also increased during 2006, reflecting the growing acceptance of our Intercept^® collection device and related oral fluid drug assays, as both domestic and international corporate customers continued to adopt oral fluid based drug testing and shift away from traditional urine-based drug testing. We expect continued growth in the utilization of our Intercept^® product line, primarily in the United States.

In April 2004, SAMHSA published proposed guidelines that would, if adopted, include oral fluid testing as an accepted drug testing method for federal employees. During the summer of 2006, these proposed guidelines were withdrawn with no action taken and it is unclear when further action, if any, will be taken to permit the use of oral fluid as an accepted drug testing method in this market.

Sales to the cryosurgical systems market declined during 2006. The cryosurgical systems market represents sales of Histofreezer^® into both the domestic and international physicians’ office markets and sales of the OTC formulation of this product to our domestic distributor, Prestige, and our international distributor, SSL. Prestige distributes our cryosurgical wart removal product under its Compound W Freeze Off^® tradenames in the OTC market in the United States and Canada. SSL distributes a similar product under its Scholl’s and Dr. Scholl trademarks in the OTC footcare market in several European countries. Sales in the U.S. OTC cryosurgery marketplace declined primarily as a result of the disappointing performance by Prestige. Sales to Prestige for 2006 were $5.2 million, or more than 50% less than the $11.6 million in sales recorded for 2005.

In September 2006, Prestige announced that it had acquired the Wartner^® cryosurgical wart removal product line, which directly competes with the Freeze Off^® product in the OTC market. Our distribution agreement with Prestige contains a covenant not to compete which precludes Prestige from acquiring, manufacturing, distributing or selling a cryosurgical product that directly competes with the Freeze Off^® product. We notified Prestige that its acquisition of the Wartner product constitutes a material breach of the distribution agreement and that certain of its other actions constitute additional breaches under the agreement. We initiated the alternative dispute resolution procedures required under the agreement, which include mediation and binding arbitration. The parties’ efforts to resolve this matter through mediation were not successful and an arbitration pursuant to the rules of the American Arbitration Association has been commenced, pursuant to the terms of the agreement. We are evaluating alternative arrangements for distributing this product in the event a resolution with Prestige cannot be reached. As a result of this ongoing dispute, it is not possible to predict at this time the potential impact this matter may have on sales of Freeze Off^® in 2007 or beyond.

In July 2004, we filed a lawsuit against Schering-Plough for infringement of several of our patents relating to the technology for the cryosurgical removal (i.e., freezing) of warts and other benign skin lesions. The suit was

39

commenced in the United States District Court for the Eastern District of Pennsylvania and alleges that Schering- Plough’s manufacture and sale of its Dr. Scholl’s^® Freeze Away^® cryosurgical wart removal product in the OTC market infringes three of our patents. We are seeking injunctive relief and the payment of damages and Schering-Plough has raised several defenses, including that their Freeze Away^® device does not infringe our patents and that one or more of our patents are either invalid or unenforceable. On November 2, 2005, a pretrial conference was held in this matter, at which the Court heard oral argument on motions for summary judgment filed by the parties. These motions remain pending. We expect a new trial schedule to be set after the Court rules on these motions.

Sales to the insurance risk assessment market continued to decline in 2006, primarily because of a reduction in the number of applications for life insurance and changes in underwriting requirements. For higher face-value policies, it appears insurance companies are more likely to use a blood test for multiple risk factors, rather than an oral-fluid test. We currently expect that our 2007 revenues in this market will decline, or at best, remain at approximately the levels attained in 2006.

Because of the regulatory approvals needed for most of our products, we often are required to rely on sole source providers for critical components and materials and on related products supplied by third parties. This is particularly true for our OraQuick ADVANCE^® test, our OraSure^® oral fluid collection device and our oral fluid Western blot HIV-1 confirmatory product. If we are unable to obtain necessary components or materials from these sole sources, the time required to develop replacements and obtain the required FDA approvals could disrupt our ability to sell the affected products.

BMX currently manufactures and sells the only oral fluid HIV-1 screening test that has received FDA approval for use in detecting HIV-1 in an oral fluid specimen collected with our OraSure^® collection device. BMX also supplies the HIV-1 antigen used to manufacture our oral fluid Western blot HIV-1 confirmatory test and is the exclusive world-wide distributor of that product. BMX recently notified us that they intend to discontinue manufacturing their HIV-1 EIA screening test during 2007. BMX also notified us that it has elected not to renew the Western blot agreements beyond December 31, 2007. We are working closely with BMX, the FDA and CDC, our main laboratory customers and other potential suppliers to find or develop an alternative HIV-1 EIA screening test and confirmatory test for use with our OraSure^® collection device. If our customers cannot obtain an HIV-1 EIA screening test or a confirmatory test that has been approved by the FDA for use in connection with our OraSure^® collection device, these customers would likely stop purchasing our OraSure^® device and our revenues would be adversely affected.

We also rely heavily on distributors to purchase and resell many of our products. For example, Prestige has exclusive distribution rights to the Freeze Off^® product in the OTC markets in United States and Canada and SSL has exclusive rights to a similar product in the OTC footcare market in Europe, Australia and New Zealand. Similarly, Abbott has exclusive rights to distribute our OraQuick ADVANCE^® test to hospitals in the U.S. We expect to enter into additional distribution agreements for new and future products, for distribution in the U.S. and internationally. If our distributors are unable or unwilling to meet the minimum purchase commitments set forth in their agreements or otherwise substantially reduce the volume of their purchases, our revenues and results of operations could be adversely affected.

We generated 83% of our 2006 revenues in the U.S. marketplace. Consequently, we are evaluating strategies to increase our sales penetration in markets outside the U.S. As our business in foreign countries increases, we could be exposed to other economic, political, exchange rate, regulatory and cultural risks.

Results of Operations

Year Ended December 31, 2006 Compared to December 31, 2005

Total revenues decreased by 2% to $68.2 million in 2006 from $69.4 million in 2005, primarily as a result of declines in domestic OTC cryosurgical product revenues and insurance risk assessment revenues, partially

40

offset by increased sales of our OraQuick ADVANCE^® rapid HIV-1/2 antibody test, our Intercept^® oral fluid collection device and related drug assays, and our international cryosurgical products. Revenues derived from products sold in countries outside the U.S. were $11.4 million and $9.5 million, or 17% and 14% of total revenues, for the years ended December 31, 2006 and 2005, respectively.

The table below shows the amount of our total revenues (in thousands, except %) generated in each of our principal markets and by licensing and product development activities.

	Year ended December 31,
	Dollars				% Change		Percentage of Total Revenues
Market	2006		2005				2006		2005
Infectious disease testing	$	29,180	$	25,988	12	%	43	%	37	%
Substance abuse testing		15,752		13,519	17		23		19
Cryosurgical systems		17,333		22,744	(24	)	25		33
Insurance risk assessment		5,565		6,815	(18	)	8		10
Product revenues		67,830		69,066	(2	)	99		99
Licensing and product development		325		300	8		1		1
Total revenues	$	68,155	$	69,366	(2	)%	100	%	100	%

Sales to the infectious disease testing market increased 12% to $29.2 million in 2006, primarily as a result of higher sales of our OraQuick^® HIV-1/2 test in both the public health and hospital markets through our distributor, Abbott. OraQuick^® and OraSure^® sales during 2006 totaled $25.6 million and $3.6 million, as compared to $21.6 million and $4.4 million in 2005, respectively.

The table below shows a breakdown of our total OraQuick^® revenues (in thousands, except %) during 2006 and 2005.

	Years ended December 31,				% Change
Customers	2006		2005
Direct to U.S. Public Health	$	15,268	$	8,292	84	%
Abbott		6,897		4,929	40
SAMHSA		406		3,741	(89	)
CDC		1,291		2,322	(44	)
International		1,694		1,530	11
Direct to Hospitals		—		740	—
Total OraQuick® revenues		$25,556		$21,554	19%

During 2006, OraQuick^® revenue derived from direct sales to the U.S. public health market increased by 84% as compared to 2005. This increase is the result of continued growth in usage of the OraQuick ADVANCE^® rapid HIV-1/2 antibody test in public health settings, including city-wide testing programs.

For the year ended December 31, 2006, sales to our hospital distributor, Abbott, grew 40% to $6.9 million, as compared to $4.9 million in 2005. This increase is a result of continued penetration of the hospital market by Abbott. Abbott recently announced that it will sell part of its diagnostics business, including its rights to distribute OraQuick ADVANCE^®, to General Electric (“GE”). This transaction is expected to close during the first half of 2007. We intend to meet with executives from GE to discuss their plans for the OraQuick ADVANCE^® product.

During 2006, we shipped a total of $1.7 million in OraQuick ADVANCE^® HIV-1/2 tests to the CDC and SAMHSA, as compared to $6.1 million in 2005. We believe that federal, state and other governmental agencies

41

may make future bulk purchases of OraQuick ADVANCE^® for further distribution to the public health and other markets throughout the United States. There is no assurance, however, that comparable-size bulk purchase orders from these governmental entities or others will be received in the future. Likewise, any delay in receiving or deploying such bulk orders could adversely affect our financial performance.

We believe that our OraQuick ADVANCE^® device, which is FDA-approved for detecting antibodies to both HIV-1 and HIV-2 in oral fluid, finger-stick and venous whole blood, and plasma samples, and is CLIA-waived for use with all sample types except plasma, provides a significant competitive advantage, thereby enabling us to fully implement a strategy for selling OraQuick^® internationally. We recently received notification that our OraQuick ADVANCE^® product will be recommended to receive a CE mark, pending successful completion of a facility inspection. CE-marking will allow us to sell our product in Europe. Our goal is to complete the facility inspection in the immediate future, secure a CE mark for OraQuick ADVANCE^®, and then obtain several country-specific registrations in order to permit the launch of this product in Europe as soon as possible.

We are beginning to see evidence that sales of OraQuick ADVANCE^® are negatively impacting sales of our OraSure^® oral fluid collection device in the infectious disease testing market. Some customers who have purchased our OraSure^® device for laboratory HIV-1 testing in the past are now electing instead to purchase our OraQuick ADVANCE^® test. It is not possible at this time to estimate the extent of such change in purchasing patterns or the financial impact of replacing OraSure^® sales with sales of our OraQuick ADVANCE^® test.

Sales to the substance abuse testing market increased 17% to $15.8 million in 2006, as a result of increased sales of both our Intercept^® oral fluid drug testing service and our Q.E.D.^® rapid oral fluid alcohol test. Intercept^® sales increased as a result of continued growth for this product, especially in the workplace and international markets. Increased sales of our Q.E.D.^® test are attributed to a change in government regulations, which increased demand for this product.

The table below shows a breakdown of our total Intercept^® revenues (in thousands, except %) generated in each market during 2006 and 2005.

	Years ended December 31,				% Change
Market	2006		2005
Workplace testing	$	6,616	$	5,661	17	%
Criminal Justice		2,398		2,269	6
International		2,314		1,956	18
Direct		728		563	29
Total Intercept® revenues	$	12,056	$	10,449	15	%

We expect continued growth in Intercept^® sales in 2007 as customers continue to shift from urine-based to oral-fluid based testing methods. However, our microplate oral fluid drug assays, which are sold for use with the Intercept^® collection device, are expected to come under increasing competitive pressure in the future from “home-brew” assays developed internally by our laboratory customers. In addition, our oral fluid microplate assays compete with urine-based homogeneous assays that are run on fully-automated, random access analyzers. We believe our competitors are developing oral fluid tests suitable for use on these fully automated homogeneous assay systems and these assays, if and when they are developed and commercialized, could represent a significant competitive threat to our oral fluid microplate business. In order to meet this competition, we recently signed a letter of intent to negotiate an agreement with Roche Diagnostics to jointly develop and commercialize fully-automated homogeneous oral fluid drugs of abuse assays for use with our Intercept^® device.

Sales of our products in the cryosurgical systems market (which includes both the physicians’ office and OTC markets) decreased 24% to $17.3 million in 2006. This decrease was primarily the result of lower sales of our domestic OTC and professional cryosurgical products when compared to 2005.

42

The table below shows a breakdown of our total cryosurgery revenues (in thousands, except %) generated in each market during 2006 and 2005.

	Years ended December 31,				%
Market	2006		2005		Change
Professional domestic	$	5,360	$	5,888	(9	)%
Professional international		2,284		2,018	13
OTC domestic		5,174		10,560	(51	)
OTC international		4,515		4,278	6
Total cryosurgery revenues	$	17,333	$	22,744	(24	)%

Our domestic OTC cryosurgical product, called Freeze Off^® , is distributed in the United States and Canada by Prestige, owner of the Compound W^® line of wart removal products. In September 2006, Prestige announced that it had acquired the Wartner^® cryosurgical wart removal product line, which directly competes with the Freeze Off^® product in the OTC market. Our distribution agreement with Prestige contains a covenant not to compete which precludes Prestige from acquiring, manufacturing, distributing or selling a cryosurgical product that directly competes with the Freeze Off^® product. We notified Prestige that its acquisition of the Wartner product constitutes a material breach of the distribution agreement and that certain of its other actions constitute additional breaches under the agreement. Efforts to resolve this matter through mediation were not successful and an arbitration pursuant to the rules of the American Arbitration Association has been commenced, pursuant to the terms of the agreement. Sales to Prestige were $5.2 million and $11.6 million, in 2006 and 2005, respectively. We are evaluating alternative arrangements for distributing this product in the event a resolution with Prestige cannot be reached. As a result of this ongoing dispute, it is not possible to predict at this time the potential impact this matter may have on sales of Freeze Off^® in 2007 or beyond.

In June 2005, we entered into an agreement with SSL under which we manufacture and supply, and SSL distributes on an exclusive basis, the Company’s cryosurgical wart removal product in the OTC footcare market in Europe, Australia and New Zealand. The product is manufactured and sold under SSL’s Scholl and Dr. Scholl trademarks and initially was made available for retail purchase in pharmacies and other outlets in several European countries during the fourth quarter of 2005. Sales to SSL under the distribution agreement were $4.5 million and $3.2 million in 2006 and 2005, respectively. SSL continues to build distribution networks in pharmacies and mass merchandisers throughout Europe and expects to launch the OTC product in additional countries during 2007. We expect revenues from SSL to increase significantly in 2007. During 2007, we have agreed to co-invest in SSL’s marketing activities and will reimburse SSL for certain out-of-pocket costs of advertising and promoting this product in the international OTC market.

We have also launched our OTC cryosurgical wart removal product in Mexico and intend to establish distributor relationships for similar products in OTC markets in other Latin American countries.

Sales of our Histofreezer^® product to physicians’ offices in the United States decreased 9% to $5.4 million in 2006, as compared to $5.9 million in 2005. Sales of Histofreezer^® in the international market increased 13% to $2.3 million in 2006, as compared to $2.0 million in 2005. We believe these changes were due to fluctuations in distributor ordering patterns and inventory levels during 2006 and, in the case of domestic Histofreezer^® sales, increased competition.

We are beginning to see some evidence that sales of our OTC cryosurgical products may reduce the number of individuals that will seek to obtain treatment of their warts by a physician, which in turn could negatively affect sales of our Histofreezer^® product in the professional market. However, it is not possible at this time to estimate the magnitude of the financial impact of this change.

43

Sales to the insurance risk assessment market declined by 18% to $5.6 million in 2006 from $6.8 million in 2005, primarily because of a reduction in the number of applications for life insurance and changes in underwriting requirements. For higher face-value policies, it appears insurance companies are more likely to use a blood test for multiple risk factors, rather than an oral fluid test. We currently expect that our 2007 revenues in this market will decline, or at best, remain at approximately the levels attained in 2006.

Licensing and product development revenues increased 8% to $325,000 in 2006, from $300,000 in 2005. Licensing and product development revenues in both years were primarily related to our collaborative oral fluid research project with the University of Pennsylvania and New York University, under a grant awarded by the National Institutes of Health. This grant expired in June 2006. In January 2007, the Company entered into a collaboration agreement with Schering-Plough Corporation, for the development and promotion of a rapid oral fluid test for the detection of antibodies to the hepatitis C virus (HCV). As a result of this agreement, licensing and product development revenues are expected to increase to approximately $2.0 million during 2007.

Quest and Abbott accounted for 14% and 10% of total revenues for 2006, respectively.

The Company’s gross margin was 64% in 2006, compared to 60% in 2005. Our 2006 gross margin was positively impacted by the absence of a $1.5 million charge related to the Company’s UPlink^® assets, which was recorded in 2005, and increased efficiencies in manufacturing operations.

Research and development expenses increased 64% to $8.6 million in 2006, from $5.3 million in 2005, primarily as a result of costs associated with the development of an OraQuick^® HCV test, preparation for OTC clinical trials for our OraQuick ADVANCE^® HIV-1/2 test, a $1.0 million charge for acquired in-process research and development related to future HIV-related products, costs related to additional research personnel hired during 2006 and charges for stock-based compensation expense. Research and development costs are expected to increase by approximately $8.0 million in 2007. The vast majority of this expected increase is related to the clinical trial work associated with the development of our OraQuick ADVANCE^® HIV-1/2 OTC test and our OraQuick^® HCV test. This amount also includes costs expected to be incurred for FDA approval of new cryosurgical offerings, product registrations in foreign countries and development of fully-automated homogeneous oral fluid drugs of abuse assays.

Sales and marketing expenses decreased 1% to $15.9 million in 2006 from $16.1 million in 2005. This decrease was primarily the result of lower market research, commission, consulting and advertising expenses, partially offset by higher staffing costs and charges for stock-based compensation expense. Included in advertising expense was $540,000 and $1.8 million for 2006 and 2005, respectively, paid to Prestige as reimbursement for marketing expenses incurred for the Compound W^® Freeze Off^® product. We expect that sales and marketing expenses will increase in 2007 as we add sales personnel for the infectious disease market in order to drive OraQuick ADVANCE^® sales in the public health, hospital and international markets. During 2007, we also expect to co-invest in SSL’s marketing activities and reimburse SSL for certain out-of-pocket costs of advertising and promoting our cryosurgical product in the international OTC market.

General and administrative expenses increased 7% to $13.4 million in 2006 from $12.5 million in 2005. This increase was primarily attributable to charges for stock-based compensation expense, higher staffing costs and certain consulting costs related to implementation of a new enterprise resource planning system. This increase was partially offset by a reduction in legal fees associated with delays in the Schering-Plough litigation and a reduction in rent expense due to the purchase of two of our Bethlehem, PA facilities in June 2006. General and administrative expenses are expected to increase in 2007, as a result of increased legal expense related to both the Prestige dispute and the Schering-Plough patent infringement matter, as well as increased costs related to full-year staffing levels.

Interest expense increased to $405,000 in 2006 from $97,000 in 2005, as a result of higher outstanding debt balances during the second half of the year, resulting from the financing for our purchase of two previously

44

leased facilities in Bethlehem, PA in June 2006. Interest expense will increase in 2007, as our borrowings for the building purchase will be outstanding for a full year. Interest income increased to $4.1 million in 2006 from $2.2 million in 2005, as a result of higher yields on our investment portfolio and larger balances available for investment.

We purchase some of our cryosurgical products from, or utilize the services of, vendors located in The Netherlands. As a result of the decline in the exchange rate between the United States dollar and the Euro, we recorded a $94,000 loss on foreign currency transactions for the year ended December 31, 2006, versus a $57,000 gain on foreign currency transactions recorded for the year ended December 31, 2005.

During 2006, we provided for income taxes at a rate equivalent to our estimated combined federal and state effective rates. As such, we recorded a $3.8 million provision for income taxes in 2006, which represents a 41.9% effective tax rate. During 2005, a net income tax benefit of $17.7 million was recorded, which reflected the release of a significant portion of the previous valuation allowance on our deferred tax asset. At December 31, 2005, the Company had federal net operating loss (“NOL”) carryforwards of $66.6 million. Prior to December 31, 2005, a valuation allowance had been established for the full amount of the deferred tax asset created by these carryforwards and other items. Based on taxable income in 2005 and future forecasted taxable earnings, a significant portion of the valuation allowance was released in the fourth quarter of 2005. This resulted in the recognition of $26.7 million of the deferred tax asset, of which $18.2 million was recorded as an income tax benefit in the statement of operations and $8.5 million was recorded directly as an increase in stockholders’ equity. Partially offsetting this benefit was an income tax provision of $436,000 that was recorded for the year ended December 31, 2005.

Year Ended December 31, 2005 Compared to December 31, 2004

Total revenues increased 28% to $69.4 million in 2005 from $54.0 million in 2004, primarily as a result of increased sales of our OraQuick ADVANCE^® rapid HIV-1/2 antibody test, our Intercept^® oral fluid collection device and related drug assays, and our international OTC cryosurgical product, partially offset by declines in domestic OTC cryosurgical product revenues and revenues in the insurance risk assessment market. Revenues derived from products sold in countries outside the U.S. were $9.5 million and $6.2 million, or 14% and 11% of total revenues for the years ended December 31, 2005 and 2004, respectively.

The table below shows the amount of our total revenues (in thousands, except %) generated in each of our principal markets and by licensing and product development activities.

	Years ended December 31,
	Dollars				% Change		Percentage of Total Revenues
Market	2005		2004				2005		2004
Infectious disease testing	$	25,988	$	15,526	67	%	37	%	29	%
Substance abuse testing		13,519		10,108	34		19		19
Cryosurgical systems		22,744		20,193	13		33		37
Insurance risk assessment		6,815		7,777	(12	)	10		14
Product revenues		69,066		53,604	29		99		99
Licensing and product development		300		404	(26	)	1		1
Total revenues	$	69,366	$	54,008	28	%	100	%	100	%

Sales to the infectious disease testing market increased 67% to $26.0 million in 2005, primarily as a result of higher sales of our OraQuick^® rapid HIV-1/2 antibody test. OraQuick^® and OraSure^® sales during 2005 totaled $21.6 million and $4.4 million, respectively, as compared to $10.2 million and $5.3 million, respectively, for 2004.

45

The table below shows a breakdown of our total OraQuick^® revenues (in thousands, except %) during 2005 and 2004.

	Years ended December 31,				% Change
Customers	2005		2004
Direct to U.S. Public Health	$	8,292	$	4,093	103	%
Abbott		4,929		1,983	149
SAMHSA		3,741		—	N/A
CDC		2,322		2,327	—
International		1,530		1,178	30
Direct to Hospitals		740		649	14
Total OraQuick® revenues	$	21,554	$	10,230	111	%

During 2004, we received a total of $6.3 million in purchase orders from the CDC and SAMHSA for OraQuick ADVANCE^® rapid HIV-1/2 antibody tests, of which $6.1 million and $72,000 were shipped in 2005 and 2004, respectively.

Sales to the substance abuse testing market increased 34% to $13.5 million in 2005, as a result of higher sales of our Intercept^® oral fluid collection device and related drug assays in all marketplaces.

The table below shows a breakdown of our total Intercept^® revenues (in thousands, except %) generated in each market during 2005 and 2004.

	Years ended December 31,				% Change
Market	2005		2004
Workplace testing	$	5,661	$	3,030	87	%
Criminal Justice		2,269		1,566	45
International		1,956		1,684	16
Direct		563		378	49
Total Intercept® revenues	$	10,449	$	6,658	57	%

Revenues from our UPlink^® rapid point-of-care oral fluid drug detection system were $286,000 and $564,000 in 2005 and 2004, respectively. As part of a strategic business review we completed in late 2004, we concluded that the roadside drugs-of-abuse testing market for UPlink^® may not be as attractive as a number of other opportunities we are pursuing. During the first half of 2005, we explored our options with respect to the UPlink^® product, including transitioning the manufacturing of the product to our distribution partner, Dräger Safety. Throughout this period, we were not able to reach an agreement with Dräger Safety or determine an alternative outlet for this product. In addition, we were advised that Dräger will no longer promote the sale of the UPlink^® product. As a result, we recorded a $1.5 million charge in June 2005 to reflect a provision on inventory and fixed assets related to our UPlink^® product. We subsequently terminated our existing research, development and distribution agreements with Dräger for the UPlink^® product.

Sales of our products in the cryosurgical systems market (which includes both the physicians’ office and OTC markets) increased 13% to $22.7 million in 2005.

46

The table below shows a breakdown of our total cryosurgery revenues (in thousands, except %) generated in each market during 2005 and 2004.

	Years ended December 31,				% Change
Market	2005		2004
Professional domestic	$	5,888	$	5,225	13	%
Professional international		2,018		1,634	24
OTC domestic		10,560		13,334	(21	)
OTC international		4,278		—	N/A
Total cryosurgery revenues	$	22,744	$	20,193	13	%

The increase in total cryosurgery revenues was primarily due to the international launch of our OTC cryosurgical product pursuant to our agreement with SSL, the launch of the Freeze Off^® product by Prestige in Canada, and an increase in sales of Histofreezer^® to both United States and international physicians’ offices. This increase was partially offset by a reduction in sales of the Freeze Off^® product to Prestige for distribution in the United States, to $10.6 million in 2005, compared to $13.3 million during 2004.

The Freeze Off^® product is being sold under Prestige’s Compound W^® trademark. The distribution agreement with Prestige, which was initiated in 2003, requires minimum purchases of at least $2.0 million each year over the life of the contract in order for Prestige to maintain its exclusive distribution rights to the OTC market in the United States. During the second half of 2005, Prestige also launched our OTC cryosurgical product in Canada. Sales of our cryosurgical product to Prestige for distribution in Canada were $1.0 million in 2005.

In June 2005, we entered into an agreement with SSL under which we manufacture and supply, and SSL distributes on an exclusive basis, the Company’s cryosurgical wart removal product in the OTC footcare market in Europe, Australia and New Zealand. The product is manufactured and sold under SSL’s Scholl and Dr. Scholl trademarks, and was made initially available for retail purchase in pharmacies and retail outlets in several European countries during the fourth quarter of 2005. Sales to SSL under the distribution agreement were $3.2 million in 2005.

Sales of our Histofreezer^® product to physicians’ offices in the U.S. and international markets increased 13% and 24% to $5.9 million and $2.0 million, respectively, in 2005, when compared to 2004, primarily as a result of higher distributor purchases.

Sales to the insurance risk assessment market declined by 12% to $6.8 million in 2005 from $7.8 million in 2004, primarily as a result of decreased OraSure^® device purchases by our insurance lab testing partners. We believe this decrease was a result of an overall reduction in life insurance application activity in the United States and changes in underwriting requirements.

Licensing and product development revenues decreased 26% to $300,000 in 2005, from $404,000 in the comparable period in 2004. Licensing and product development revenues in both years were primarily related to our collaborative oral fluid research project with the University of Pennsylvania and New York University, under a grant awarded by the National Institutes of Health.

We had two customers, Prestige and Quest, which accounted for 17% and 13% of total revenues for 2005, respectively.

The Company’s gross margin was 60% in 2005, compared to 59% in 2004. Our 2005 gross margin was positively impacted by more efficient utilization of the Company’s manufacturing capacity and renegotiated terms for the assembly and supply of the U.S. OTC cryosurgical product, offset by a less favorable product sales mix and the $1.5 million charge related to the Company’s UPlink^® assets.

47

Research and development expenses decreased 13% to $5.3 million in 2005, from $6.1 million in 2004, primarily as a result of lower overall staffing costs and lower expenses for clinical trials, partially offset by fees paid and restricted stock granted to recruit and relocate the Company’s new Chief Science Officer and Senior Vice President, Regulatory Affairs/Quality Assurance.

Sales and marketing expenses increased 6% to $16.1 million in 2005 from $15.2 million in 2004. This increase was primarily the result of increased levels of staffing, market research, travel and commission expenses, partially offset by lower advertising expenses. Included in advertising expenses was $1.8 million and $2.9 million for 2005 and 2004, respectively, paid to Prestige as reimbursement for marketing expenses incurred for the Compound W^® Freeze Off^® product.

General and administrative expenses increased 4% to $12.5 million in 2005 from $12.0 million in 2004. This increase was primarily attributable to legal fees associated with the Schering-Plough litigation, increased amortization of restricted stock grants to management, and increased staffing related expenses. This increase was partially offset by a reduction in consulting expenses, a reduction in transition expenses related to the Company’s former Chief Executive Officer, and a reduction in rent expense due to the expiration of the lease for our Oregon facilities in January 2005. Legal fees associated with the Schering-Plough patent infringement litigation were $2.4 million and $1.2 million in 2005 and 2004, respectively.

Interest expense decreased to $97,000 in 2005 from $134,000 in 2004, as a result of lower outstanding debt balances. Interest income increased to $2.2 million in 2005 from $984,000 in 2004, as a result of higher yields on our investment portfolio and larger balances available for investment.

A gain on foreign currency transactions of $57,000 was recorded for the year ended December 31, 2005, versus a loss on foreign currency transactions of $53,000 recorded for the year ended December 31, 2004.

During the year ended December 31, 2005, a net income tax benefit of $17.7 million was recorded, while no provision or benefit was recorded in 2004. The tax benefit recorded during 2005 reflects the release of a significant portion of the valuation allowance on our deferred tax asset. At December 31, 2005, the Company had federal net operating loss (“NOL”) carryforwards of $66.6 million. Our ability to use the NOLs and tax credit carryforwards to offset future income tax obligations could be limited by changes in the ownership of the Company’s capital stock. Internal Revenue Code Section 382 (“Section 382”) contains provisions that limit the amount of NOLs and tax credit carryforwards that can be used in any given year, in the event of a significant ownership change. In the fourth quarter of 2005, the Company engaged in an analysis, with the assistance of independent tax specialists, to determine if any Section 382 ownership changes have occurred that would limit the amount of NOLs that could be utilized to offset future taxable income. As a result of this analysis, the Company concluded that prior period ownership changes may impose a limitation on the amount of NOLs that can be utilized in a given year. The Company does not believe, however, that this limitation will impair our future ability to utilize NOLs to offset our forecasted taxable income or to realize the related deferred tax asset.

Prior to December 31, 2005, a valuation allowance had been established for the full amount of the deferred tax asset created by these carryforwards and other items. Based on the 2005 and forecasted taxable earnings, a significant portion of the valuation allowance was released in the fourth quarter of 2005, resulting in the recognition of $26.7 million of the deferred tax asset of which $18.2 million was recorded as an income tax benefit in the statement of operations and $8.5 million was recorded directly as an increase in stockholders’ equity. Partially offsetting this benefit was an income tax provision of $436,000 that was recorded for the year ended December 31, 2005 related to certain state income taxes and federal alternative minimum tax.

48

Liquidity and Capital Resources

	December 31, 2006		December 31, 2005
	(In thousands)
Cash and cash equivalents	$	19,950	$	32,827
Short-term investments		71,051		44,793
Working capital		95,979		90,670

Our cash, cash equivalents and short-term investments increased $13.4 million during 2006 to $91.0 million at December 31, 2006, primarily as a result of $16.9 million in positive cash flow from operating activities, $10.0 million in borrowings of long-term debt, and $457,000 in proceeds from the exercise of stock options, partially offset by $701,000 of debt repayments, $12.6 million of property and equipment purchases, and $632,000 associated with the retirement of common stock to pay minimum tax withholding obligations on the vesting of restricted shares. At December 31, 2006, our working capital was $96.0 million.

Net cash provided by operating activities was $16.9 million in 2006, primarily generated by our net income of $5.3 million for the year, non-cash charges for depreciation and amortization of $1.9 million, stock-based compensation expense of $5.6 million, and a deferred income tax provision of $3.1 million resulting from utilization of our NOL carryforwards. Other factors which contributed to the $16.9 million in net cash provided by operating activities at December 31, 2006, also included a non-cash provision for excess and obsolete inventories of $750,000, $1.0 million in acquired in-process technology, an increase of $600,000 in accounts payable and accrued expenses primarily related to increased accruals for royalties, legal fees and customer prepayments, and a decrease in accounts receivable of $1.3 million resulting from increased collection efforts and lower outstanding balances due from Prestige and SSL. Offsetting these sources of operating cash were a $2.2 million increase in inventories primarily related to higher levels of raw material purchases associated with our OTC cryosurgical product for SSL and our OraQuick ADVANCE^® test, and a $453,000 increase in prepaid expenses resulting from the timing of prepayments for insurance and real estate taxes.

Net cash used in investing activities during 2006 was $38.9 million, of which $26.1 million was for the purchase of short-term investments. We invested $12.6 million in additions to property and equipment, of which $9.1 million related to the purchase of our two previously leased facilities in Bethlehem, PA. We also paid $200,000 for certain acquired in-process technology.

During the year ending December 31, 2007, we expect to invest $7.5 million in capital expenditures, primarily to purchase additional equipment, upgrade certain older equipment and make improvements to our facilities.

Net cash provided by financing activities was $9.1 million for the year ended December 31 2006, reflecting the $10.0 million in new borrowings from Comerica Bank to finance the purchase of our two previously leased facilities and $457,000 received from the exercise of stock options. Partially offsetting these sources of cash were $701,000 of loan principal repayments and $632,000 used for the purchase and retirement of common stock.

During 2006, we had in place an $11.9 million credit facility (the “Credit Facility”) with Comerica Bank, which is comprised of an $887,000 mortgage loan, a $3.0 million term loan, a $4.0 million non-revolving line of credit for the purchase of both capital equipment and software, and a $4.0 million revolving working capital line of credit. Interest on outstanding borrowings under the non-revolving line of credit accrues at a rate, selected at our option, equal to the bank’s prime rate, 180-day or 360-day LIBOR plus 2.625%, or the 4-year Treasury Note rate plus 2.30%, determined at the time of initial borrowing. Interest on outstanding borrowings under the revolving working capital line of credit accrues at a rate, selected at our option, equal to the bank’s prime rate less 0.25%, or 30-day LIBOR plus 2.55%, determined at the time of initial borrowing.

On June 27, 2006, we executed an amendment to our Credit Facility, pursuant to which we are permitted to borrow up to an additional $15.0 million in advances in order to fund the purchase and future expansion of two

49

previously leased facilities in Bethlehem, Pennsylvania. On June 29, 2006, we borrowed $10.0 million under the terms of this Credit Facility, as amended, and purchased our two Bethlehem facilities. We can borrow the remaining $5.0 million at any time before June 30, 2007. At our option, interest on outstanding borrowings is payable monthly at either a fixed rate equal to the five-year U.S. Treasury Note rate plus 1.03% to 1.73%, or a variable rate equal to the 30, 180, or 360-day LIBOR rate plus 0.55% to 1.25%. In each case, the interest rate is determined at the date of the advance and is based upon the amount of cash and cash equivalents we invest and retain at Comerica Securities, Inc. We can also choose the fixed rate option, without penalty, at the expiration of a previously elected LIBOR period. Principal is repayable in periodic installments, based upon the rate option that we elect, with the remaining balance of unpaid principal due on June 27, 2011. This amendment also extended the maturity date of our $4.0 million revolving working capital line of credit to June 29, 2007. All other terms of the Credit Facility, as previously amended, remain in effect, except for our financial covenant related to liquidity, which was modified to require a minimum liquidity, as defined by Comerica, of not less than $25.0 million, of which at least $15.0 million must be held by Comerica or its affiliates.

At December 31, 2006, interest on the new $10.0 million borrowing was payable monthly, at the 360-day LIBOR rate plus 0.9%, or 6.1894%. Principal is repayable in installments, due at the end of each LIBOR rate period, based upon a twenty-year amortization schedule and the number of months in the expiring LIBOR rate period. Accordingly, on December 27, 2007, we will be required to make a $500,000 principal repayment and the interest rate on this loan will reset. The outstanding balance of the loan at December 31, 2006 was $9.75 million.

As of December 31, 2006, we had no outstanding borrowings under the $3.0 million term loan, the $4.0 million non-revolving line of credit, or the $4.0 million revolving working capital line of credit.

All borrowings under the Credit Facility are collateralized by a first priority security interest in all of our assets, including present and future accounts receivable, chattel paper, contracts and contract rights, equipment and accessories, general intangibles, investments, instruments, inventories, and a mortgage on our three facilities in Bethlehem, Pennsylvania. Borrowings under the equipment and software non-revolving line and the revolving working capital line are limited to commercially standard percentages of equipment and software purchases and accounts receivable, respectively. The Credit Facility contains certain covenants that set forth minimum requirements for our quick ratio, liquidity and tangible net worth. We were in full compliance with all covenants at December 31, 2006 and expect to remain in compliance with all covenants during 2007. The Credit Facility also restricts our ability to pay dividends, to make certain investments, to incur additional indebtedness, to sell or otherwise dispose of a substantial portion of assets and to merge or consolidate operations with an unaffiliated entity, without the consent of Comerica.

At December 31, 2006, we had NOL carryforwards of $53.0 million for federal income tax purposes. During the fourth quarter of 2005, the Company retained independent tax specialists to perform an ownership change study and analysis to determine the annual limitation amount applicable to utilization of the NOL carryforwards due to past ownership changes, as defined in Section 382 of the Internal Revenue Code. As a result of this study, we do not believe that the ownership change limitations would impair our ability to use our NOLs against our current forecasted taxable income.

The combination of our current cash position, cash flow from operations and available borrowings under our Credit Facility is expected to be sufficient to fund our operating and capital needs for at least the next twelve months. However, our cash requirements may vary materially from those now planned due to many factors, including, but not limited to, the scope and timing of strategic acquisitions, the cost and timing of the expansion of our manufacturing capacity, the progress of our research and development programs, the scope and results of clinical testing, the magnitude of capital expenditures, changes in existing and potential relationships with business partners, the time and cost of obtaining regulatory approvals, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, the timing of market launch of new products, market acceptance of new products, competing technological and market developments and other factors.

50

Recent Accounting Pronouncements

In July 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation (“FIN”) No. 48, “Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No. 109,” which clarifies what criteria must be met prior to recognition of the financial statement benefit of a position taken in a tax return. FIN No. 48 will require companies to include additional qualitative and quantitative disclosures within their financial statements. The disclosures will include potential tax benefits from positions recognized for tax return purposes but not recognized for financial reporting purposes, as well as a tabular presentation of significant changes in such benefits during each period. The disclosures will also include a discussion of the nature of uncertainties, factors that could cause a change, and an estimated range of reasonably possible changes in tax uncertainties. FIN No. 48 will require a company to recognize a financial statement benefit for a position taken for tax return purposes when it will be more-likely-than-not that the position will be sustained. FIN No. 48 is effective for fiscal years beginning after December 15, 2006. We are currently assessing the impact FIN No. 48 will have on our financial statements.

In September 2006, the United States Securities and Exchange Commission (“SEC”) issued Staff Accounting Bulletin (“SAB”) No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements.” SAB No. 108 requires companies to evaluate the materiality of identified unadjusted errors using both the income statement approach and the balance sheet approach. In the initial year of adoption, if a company determines that an adjustment to prior year financial statements is required under either approach, SAB No. 108 allows for a one-time cumulative-effect adjustment to beginning retained earnings. SAB No. 108 is effective for interim periods of the first fiscal year ending after November 15, 2006. The adoption of SAB No. 108 did not have any impact on our financial statements.

In September 2006, the FASB issued Statement of Financial Accounting Standards (“SFAS”) No. 157, “Fair Value Measurements.” This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. We are currently assessing the impact, if any, that SFAS No. 157 will have on our financial statements.

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115.” SFAS No. 159 permits entities to elect to measure many financial instruments and certain other items at fair value. Unrealized gains and losses on items for which the fair value option has been elected will be recognized in earnings at each subsequent reporting date. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. We are currently assessing the impact SFAS No. 159 will have on our financial statements.

Contractual Obligations and Commercial Commitments.    The following sets forth our approximate aggregate obligations at December 31, 2006 for future payments under contracts and other contingent commitments, for the years 2007 and beyond:

Contractual Obligations	Total		Payments due by December 31,
			2007		2008		2009		2010		2011		Thereafter
Long-term debt1	$	10,639,136	$	608,595	$	593,087	$	597,346	$	552,670	$	7,796,730	$	490,708
Operating leases2		161,759		81,866		68,480		11,413		—		—
Employment contracts3		2,529,425		1,804,625		724,800		—		—		—		—
Purchase obligations4		5,349,799		5,349,799		—		—		—		—		—
Minimum commitments under contracts5		5,791,667		500,000		500,000		500,000		500,000		500,000		3,291,667
Total contractual obligations	$	24,471,786	$	8,344,885	$	1,886,367	$	1,108,759	$	1,052,670	$	8,296,730	$	3,782,375

51

1 Represents principal repayments required under notes payable to our lenders. See Note 8 to the financial statements included herein.

2 Represents payments required under our operating leases.

3 Represents salary payments payable under the terms of employment agreements executed by us with certain executives. See Note 11 to the financial statements included herein.

4 Represents payments required by non-cancellable purchase orders related to inventory, capital expenditures and other goods or services. See Note 11 to the financial statements included herein.

5 Represents payments required pursuant to certain, licensing agreements executed by the Company. These agreements are cancellable within a specified number of days after communication by the Company of its intent to terminate. See Note 11 to the financial statements included herein. Additional payments of up to $5,500,000 may be required pursuant to one of these licensing agreements for the achievement of specific development and/or commercial milestones.

Off-Balance Sheet Arrangements.    We do not have any off-balance sheet arrangements, as defined in Item 303(a) (4) (ii) of Regulation S-K under the Securities Exchange Act of 1934, as amended.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our judgments and estimates, including those related to bad debts, inventories, investments, intangible assets, income taxes, revenue recognition, restructuring costs, contingencies and litigation. We base our judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in Note 2 to the financial statements included in Item 15 of this Annual Report. We consider the following accounting estimates, which have been discussed with our Audit Committee, to be most critical in understanding the more complex judgments that are involved in preparing our financial statements and the uncertainties that could impact our results of operations, financial condition and cash flows.

Revenue Recognition.    We follow SAB No. 104, “Revenue Recognition.” This bulletin draws on existing accounting rules and provides specific guidance on revenue recognition for up-front non-refundable licensing and development fees. We license certain products or technology to outside third parties, in return for which we receive up-front licensing fees. Some of these fees can be significant. In accordance with SAB No. 104, we recognize this revenue ratably over the related license period.

We also enter into research and development contracts with corporate, government and/or private entities. These contracts generally provide for payments to us upon achievement of certain research or development milestones. Product development revenues from these contracts are recognized only if the specified milestone is achieved and accepted by the customer and payment from the customer is probable. Any amounts received prior to the performance of product development efforts are recorded as deferred revenues. Recognition of revenue under these contracts can be sporadic, as it is the result of achieving specific research and development milestones. Furthermore, revenue from future milestone payments will not be recognized if the underlying research and development milestone is not achieved.

52

We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are net of allowances for any discounts or rebates. We do not grant price protection or product return rights to our customers, except for warranty returns. Where a product fails to comply with its limited warranty, we can either replace the product or provide the customer with a refund of the purchase price or credit against future purchases. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred. While such returns have been immaterial in the past, we cannot guarantee that we will continue to experience the same rate of warranty claims as we have in the past. Any significant increase in product warranty claims could have a material adverse impact on our operating results for the period in which the claims occur.

Allowance for Uncollectible Accounts Receivable.    Accounts receivable are reduced by an estimated allowance for amounts that may become uncollectible in the future. On an ongoing basis, we perform credit evaluations of our customers and adjust credit limits based upon the customer’s payment history and creditworthiness, as determined by a review of their current credit information. We also continuously monitor collections and payments from our customers.

Based upon historical experience and any specific customer collection issues that are identified, we use our judgment to establish and evaluate the adequacy of our allowance for estimated credit losses, which was $200,094 at December 31, 2006. While credit losses have been within our expectations and the allowance provided, these losses can vary from period to period ($16,022, ($4,771), and $3,541 in 2006, 2005 and 2004, respectively). Furthermore, there is no assurance that we will experience credit losses at the same rates as we have in the past. Also, at December 31, 2006, $4.5 million, or 44% of our accounts receivable, was due from four major customers. Any significant changes in the liquidity or financial position of these customers, or others, could have a material adverse impact on the collectibility of our accounts receivable and future operating results.

Inventories.    Our inventories are valued at the lower of cost or market, determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate the carrying value of our inventories and when, in the opinion of management, factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off. We base these decisions on the level of inventories on hand in relation to our estimated forecast of product demand, production requirements over the next twelve months and the expiration dates of raw materials and finished goods. During 2006, 2005 and 2004, we wrote-off inventory which had a cost of $751,000, $2.1 million and $839,000, respectively, as a result of scrap and product expiration issues and a $1.3 million provision for loss on our UPlink^® product in 2005. Although we make every effort to ensure the accuracy of our forecasts of future product demand, any significant unanticipated changes in demand could have a significant impact on the carrying value of our inventories and reported operating results.

Stock-based Compensation.    Commencing January 1, 2006, we adopted SFAS No. 123 (revised 2004), “Share-Based Payment,” which requires us to recognize the fair value of equity-based awards as compensation expense in our statement of operations. The fair value of our stock option awards was estimated using a Black-Scholes option valuation model. This valuation model incorporates highly subjective assumptions, such as the expected stock price volatility and the estimated life of each award, in the model’s computations. The fair value of awards, after considering the effect of expected forfeitures, is then amortized, generally on a straight-line basis, over the related vesting period of the award.

Long-lived and Intangible Assets.    Our long-lived assets are comprised of property and equipment and an investment in a nonaffiliated entity, and our intangible assets primarily consist of patents and product rights. Together, these assets have a net book value of $24.0 million, or 15.4% of our total assets, at December 31, 2006.

53

Our investment in a privately-held nonaffiliated company is recorded under the cost method of accounting because we do not have a controlling interest in this company, nor do we have the ability to exert significant influence over the operating and financial policies of this investee company. Property and equipment, patents and product rights are depreciated or amortized on a straight-line basis over their useful lives, which we determine based upon our estimate of the period of time over which each asset will generate revenues. In August 2005, we recorded a $1.5 million intangible asset related to a payment under a license agreement to certain patents related to the Hepatitis C Virus. We recorded an additional $3.0 million related to this license in 2006. Management’s intent in executing this license is to provide for various alternatives for use, including uses in the international market that would not require additional research and development efforts or regulatory approvals. This $4.5 million asset was capitalized based on management’s estimate of the cash flows to be received from future product sales in these international markets. A similar analysis of estimated future cash flows will be prepared upon payment of additional license fees under this agreement, or upon changes in circumstances, to determine the appropriate accounting treatment for payments under this license agreement. An impairment of long-lived or intangible assets could occur whenever events or changes in circumstances indicate that the net book value of these assets may not be recoverable. Events which could trigger an asset impairment include significant underperformance relative to expected historical or projected future operating results, significant changes in the manner of our use of an asset or in our overall business strategy, significant negative industry or economic trends, shortening of product life-cycles or changes in technology, and negative financial performance of the nonaffiliated investee company. If we believe impairment of an asset has occurred, we measure the amount of such impairment by comparing the net book value of the affected assets to the fair value of these assets, which is generally determined based upon the present value of the expected cash flows associated with the use of these assets. If the net book value exceeds the fair value of the impaired assets, we would incur an impairment expense equal to this difference. In June 2005, we recorded a $196,000 provision for loss on our UPlink^® fixed assets as a result of our inability to reach an agreement to transfer these assets to our distribution partner or determine an alternative outlet for these assets. We currently believe the future cash flows to be received from all other long-lived and intangible assets will exceed their book value and, as such, we have not recognized any additional impairment losses through December 31, 2006. Any unanticipated significant impairment in the future, however, could have a material adverse impact to our balance sheet and future operating results.

Deferred Tax Assets.    At December 31, 2006, we had federal NOL carryforwards of $53.0 million. The net deferred tax asset associated with these NOLs and other temporary differences was $23.5 million at December 31, 2006. In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible or the NOLs and credit carryforwards can be utilized. We consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.

Our ability to use our NOL carryforwards to offset future federal income tax obligations, could be limited by changes in the ownership of our stock. Internal Revenue Code (“IRC”) Section 382 contains provisions that limit the amount of federal NOL carryforwards that can be used in any given year in the event of specified occurrences, including significant ownership changes. In the fourth quarter of 2005, the Company completed an analysis, with the assistance of independent tax specialists, to determine if any IRC Section 382 ownership changes have occurred that would limit the amount of NOLs that could be utilized to offset future taxable income. As a result of this analysis, the Company concluded that prior period ownership changes may impose a limitation on the amount of NOLs that can be utilized in a given year. The Company does not believe, however, that this limitation will impair our future ability to utilize NOLs to offset our forecasted taxable income or to realize the related deferred tax asset.

Prior to December 31, 2005, a valuation allowance had been established for the full amount of the deferred tax asset created by these carryforwards and other items. Based on our 2005 results and our projections for future taxable income over the periods in which the deferred tax assets are deductible or the NOLs and credit carryforwards can be utilized, we believe a significant portion of the deferred tax asset was realizable at

54

December 31, 2005. As such, we recorded the estimated net realizable value of the deferred tax asset at December 31, 2005 and have begun providing for income taxes at a rate equal to our combined federal and state effective rates. Subsequent revisions to the estimated net realizable value of the deferred tax asset could cause our provision for income taxes to vary significantly from period to period.

Contingencies.    In the ordinary course of business, we have entered into various contractual relationships with strategic corporate partners, customers, distributors, research laboratories and universities, licensors, licensees, suppliers, vendors and other parties. As such, we could be subject to litigation, claims or assessments arising from any or all of these relationships. We account for contingencies such as these in accordance with SFAS No. 5, “Accounting for Contingencies.” SFAS No. 5 requires us to record an estimated loss contingency when information available prior to issuance of our financial statements indicates that it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Accounting for contingencies arising from contractual or legal proceedings requires that we use our best judgment when estimating an accrual related to such contingencies. As additional information becomes known, our accrual for a loss contingency could fluctuate, thereby creating variability in our results of operations from period to period. Likewise, an actual loss arising from a loss contingency which significantly exceeds the amount accrued for in our financial statements could have a material adverse impact on our operating results for the period in which such actual loss becomes known.

ITEM 7A.     Quantitative and Qualitative Disclosures About Market Risk.

We do not hold any amounts of derivative financial instruments or derivative commodity instruments and, accordingly, we have no material derivative risk to report under this Item.

A significant portion of our assets is comprised of certificates of deposit, commercial paper, U.S. government and agency obligations, and U.S. corporate bonds. All such instruments are classified as available-for-sale securities. The primary objective of our investment activities is to preserve principal while maximizing the related income without significantly increasing risk. Even so, some of the securities in which we invest may be subject to market risk. Market risk is the risk that a change in prevailing interest rates may cause the fair value of an investment to fluctuate. As interest rates increase, the fair value of a debt instrument would be expected to decrease. Correspondingly, if interest rates decrease the fair value of a debt instrument would be expected to increase. To minimize market risk, we have the ability to hold such debt instruments to maturity, at which time the debt instrument would be redeemed at its stated or face value. We also typically invest in the shorter end of the maturity spectrum. As such, we do not believe that we have a material exposure to market risk.

At December 31, 2006, approximately $10.5 million of the Company’s long-term debt bears interest at a variable or floating rate tied to either the United States prime rate or the London Interbank Offered Rate. A one percentage point increase in these interest rates would cost the Company approximately $105,000 in additional interest expense.

As of December 31, 2006, we did not have any foreign currency exchange contracts or purchase currency options to hedge local currency cash flows. We have operations in The Netherlands, which are subject to foreign currency fluctuations. As currency rates change, translation of revenues and expenses for these operations from euros to U.S. dollars affects year-to-year comparability of operating results. Sales denominated in a foreign currency represented approximately $135,000 of our total revenues for the year ended December 31, 2006. We do not expect the risk of foreign currency fluctuations to be material in the near future.

ITEM 8.    Financial Statements and Supplementary Data.

Information with respect to this Item is contained in our Financial Statements included in Item 15 of this Annual Report on Form 10-K.

55

ITEM 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

Not applicable.

ITEM 9A.    Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures.

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of December 31, 2006. Based on that evaluation, the Company’s management, including such officers, concluded that the Company’s disclosure controls and procedures are adequate and effective to ensure that information required to be disclosed by the Company in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure and is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission.

(b) Management’s Report on Internal Control Over Financial Reporting.

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a(f) and 15d-15(f) under the Securities Exchange Act of 1934. Under the supervision and with the participation of the Company’s management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework, our management concluded that our internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles as of December 31, 2006.

Our management’s assessment of the effectiveness of our internal control over financial reporting as of December 31, 2006 has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their report, which is included below.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

(c) Changes in Internal Control Over Financial Reporting.

There was no change in the Company’s internal control over financial reporting identified in connection with the evaluation referred to in paragraph (a) above that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

(d) Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

OraSure Technologies, Inc.:

We have audited management’s assessment, included in the accompanying Management’s Report on Internal Control over Financial Reporting, that OraSure Technologies, Inc. maintained effective internal control over financial reporting as of December 31, 2006, based on criteria established in Internal Control—Integrated

56

Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). OraSure Technologies, Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, management’s assessment that OraSure Technologies, Inc. maintained effective internal control over financial reporting as of December 31, 2006, is fairly stated, in all material respects, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Also, in our opinion, OraSure Technologies, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2006, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the balance sheets of OraSure Technologies, Inc. as of December 31, 2006 and 2005, and the related statements of operations, stockholders’ equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2006, and our report dated March 16, 2007 expressed an unqualified opinion on those financial statements.

/s/ KPMG LLP

Philadelphia, Pennsylvania

March 16, 2007

ITEM 9B.    Other Information.

Not applicable.

57

PART III

We have omitted from Part III the information that will appear in our Definitive Proxy Statement for our 2007 Annual Meeting of Stockholders (the “Proxy Statement”), which will be filed within 120 days after the end of our fiscal year pursuant to Regulation 14A.

ITEM 10.    Directors, Executive Officers and Corporate Governance.

Certain information required by this Item is incorporated by reference to the information under the captions, “Corporate Governance—Committees of the Board—Audit Committee,” “Election of Directors,” “Executive Officers,” and “Section 16(a) Beneficial Ownership Reporting Compliance,” in the Proxy Statement.

Our Board of Directors has adopted a Code of Business Conduct and Ethics that applies to our principal executive officer, principal financial officer and principal accounting officer, as well as to the members of our Board of Directors and our other officers and employees. This Code of Business Conduct and Ethics is available on our website at www.orasure.com. We intend to satisfy the amendment and waiver disclosure requirements under applicable securities regulations by posting any amendments of, or waivers to, the Code of Business Conduct and Ethics on our website.

ITEM 11.    Executive Compensation.

The information required by this Item is incorporated by reference to the information under the caption, “Executive Compensation,” in the Proxy Statement.

ITEM 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item with respect to the securities ownership of certain beneficial owners and management, and equity compensation plan information, is incorporated by reference to the information under the captions, “Principal Stockholders” and “Equity Compensation Plan Information,” respectively, in the Proxy Statement.

ITEM 13.    Certain Relationships and Related Transactions, and Director Independence.

The information required by this Item is incorporated by reference to the information under the captions, “Transactions with Related Persons” and “Corporate Governance—Director Independence,” in the Proxy Statement.

ITEM 14.    Principal Accountant Fees and Services.

The information required by this Item is incorporated by reference to the information under the caption, “Audit Fees; Audit-Related Fees; Tax Fees; All Other Fees,” in the Proxy Statement.

58

PART IV

ITEM 15.    Exhibits and Financial Statement Schedules.

(a)(1) and (a)(2). Financial Statements and Schedules.    For a list of the Financial Statements filed herewith, see the Index to Financial Statements following the signature page to this Annual Report. No schedules are included with the Financial Statements because the required information is inapplicable or is presented in the Financial Statements or related notes thereto.

(a)(3). Exhibits.    See Index to Exhibits following the Financial Statements in this Annual Report.

59

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 16, 2007.

ORASURE TECHNOLOGIES, INC.
By:	/s/ DOUGLAS A. MICHELS
	Douglas A. Michels
	President and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed on March 16, 2007, by the following persons on behalf of the Registrant and in the capacities indicated.

SIGNATURE	TITLE
/s/  DOUGLAS A. MICHELS Douglas A. Michels	President, Chief Executive Officer and Director (Principal Executive Officer)
/s/  RONALD H. SPAIR Ronald H. Spair	Chief Operating Officer, Chief Financial Officer and Director (Principal Financial Officer)
/s/  MARK L. KUNA Mark L. Kuna	Senior Vice President, Finance and Controller (Principal Accounting Officer)
*MICHAEL CELANO Michael Celano	Director
*JACK GOLDSTEIN, PH.D. Jack Goldstein, Ph.D.	Director
Frank G. Hausmann	Director
*RONNY B. LANCASTER Ronny B. Lancaster	Director
*CHARLES W. PATRICK Charles W. Patrick	Director
*ROGER L. PRINGLE Roger L. Pringle	Director
*DOUGLAS G. WATSON Douglas G. Watson	Director

*By:	/s/  JACK E. JERRETT
	Jack E. Jerrett (Attorney-in-Fact)

60

INDEX TO FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm	F-2
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Stockholders’ Equity and Comprehensive Income (Loss)	F-5
Statements of Cash Flows	F-6
Notes to the Financial Statements	F-7

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors and Stockholders

OraSure Technologies, Inc.:

We have audited the accompanying balance sheets of OraSure Technologies, Inc. as of December 31, 2006 and 2005, and the related statements of operations, stockholders’ equity and comprehensive income (loss), and cash flows for each of the years in the three-year period ended December 31, 2006. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of OraSure Technologies, Inc. as of December 31, 2006 and 2005, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2006, in conformity with U.S. generally accepted accounting principles.

As discussed in Note 2 to the financial statements, effective January 1, 2006, the Company adopted the fair value method of accounting for stock-based compensation as required by Statement of Financial Accounting Standards No. 123R, Share-Based Payment.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of OraSure Technologies, Inc.’s internal control over financial reporting as of December 31, 2006, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated March 16, 2007 expressed an unqualified opinion on management’s assessment of, and the effective operation of, internal control over financial reporting.

/s/ KPMG LLP

Philadelphia, Pennsylvania

March 16, 2007

F-2

ORASURE TECHNOLOGIES, INC.

BALANCE SHEETS

	December 31,
	2006			2005
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	19,949,821		$	32,826,740
Short-term investments		71,051,482			44,793,046
Accounts receivable, net of allowance for doubtful accounts of $200,094 and $278,066		10,357,287			11,602,127
Inventories		5,534,567			4,128,029
Deferred income taxes		3,675,785			6,503,946
Prepaid expenses and other		1,989,882			1,553,545
Total current assets		112,558,824			101,407,433
PROPERTY AND EQUIPMENT, net		17,374,718			5,815,233
PATENTS AND PRODUCT RIGHTS, net		6,328,344			2,879,958
DEFERRED INCOME TAXES		19,845,789			20,204,352
OTHER ASSETS		457,788			440,227
	$	156,565,463		$	130,747,203
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Current portion of long-term debt	$	608,595		$	456,541
Accounts payable		3,311,968			2,546,621
Accrued expenses and other		12,659,149			7,733,941
Total current liabilities		16,579,712			10,737,103
LONG-TERM DEBT		10,030,541			884,021
OTHER LIABILITIES		451,235			207,037
COMMITMENTS AND CONTINGENCIES (Note 11)
STOCKHOLDERS’ EQUITY:
Preferred stock, par value $0.000001; 25,000,000 shares authorized, none issued		—			—
Common stock, par value $0.000001; 120,000,000 shares authorized, 45,994,752 and 45,775,625 shares issued and outstanding		46			46
Additional paid-in capital		228,069,433			226,218,469
Deferred compensation		—			(3,334,792	)
Accumulated other comprehensive loss		(151,197	)		(282,825	)
Accumulated deficit		(98,414,307	)		(103,681,856	)
Total stockholders’ equity		129,503,975			118,919,042
	$	156,565,463		$	130,747,203

The accompanying notes are an integral part of these statements.

F-3

ORASURE TECHNOLOGIES, INC.

STATEMENTS OF OPERATIONS

	For the year ended December 31,
	2006			2005			2004
REVENUES:
Product	$	67,830,561		$	69,066,152		$	53,604,124
Licensing and product development		324,359			300,040			404,140
		68,154,920			69,366,192			54,008,264
COST OF PRODUCTS SOLD		24,756,195			27,973,907			22,143,190
Gross profit		43,398,725			41,392,285			31,865,074
OPERATING EXPENSES:
Research and development		8,647,484			5,269,083			6,062,275
Sales and marketing		15,921,467			16,060,413			15,154,174
General and administrative		13,367,111			12,490,074			12,005,309
		37,936,062			33,819,570			33,221,758
Operating income (loss)		5,462,663			7,572,715			(1,356,684	)
INTEREST EXPENSE		(404,680	)		(96,632	)		(133,652	)
INTEREST INCOME		4,097,860			2,185,486			983,841
FOREIGN CURRENCY GAIN (LOSS)		(94,390	)		57,329			(53,147	)
Income (loss) before income taxes		9,061,453			9,718,898			(559,642	)
INCOME TAX PROVISION (BENEFIT)		3,793,904			(17,729,189	)		—
NET INCOME (LOSS)	$	5,267,549		$	27,448,087		$	(559,642	)
EARNINGS (LOSS) PER SHARE
BASIC	$	0.11		$	0.61		$	(0.01	)
DILUTED	$	0.11		$	0.59		$	(0.01	)
SHARES USED IN COMPUTING EARNINGS (LOSS) PER SHARE
BASIC		45,909,990			45,109,580			44,463,861
DILUTED		46,580,266			46,146,612			44,463,861

The accompanying notes are an integral part of these statements.

F-4

ORASURE TECHNOLOGIES, INC.

STATEMENTS OF STOCKHOLDERS’ EQUITY AND COMPREHENSIVE INCOME (LOSS)

For the years ended December 31, 2006, 2005 and 2004

	Common Stock				Additional Paid-in Capital			Deferred Compensation			Accumulated Other Comprehensive Loss			Accumulated Deficit			Total
	Shares		Amount
Balance at January 1, 2004	44,260,931		$	44	$	204,867,765		$	(614,515	)	$	(173,704	)	$	(130,570,301	)	$	73,509,289
Common stock issued upon exercise of options	370,800			1		1,904,160			—			—			—			1,904,161
Restricted stock grants to employees	—			—		3,176,150			(3,176,150	)		—			—			—
Amortization of deferred compensation expense	—			—		—			874,162			—			—			874,162
Comprehensive loss:
Net loss	—			—		—			—			—			(559,642	)		(559,642	)
Currency translation adjustment	—			—		—			—			(12,983	)		—			(12,983	)
Net unrealized loss on marketable securities	—			—		—			—			(137,982	)		—			(137,982	)
Total comprehensive loss																		(710,607	)
Balance at December 31, 2004	44,631,731			45		209,948,075			(2,916,503	)		(324,669	)		(131,129,943	)		75,577,005
Common stock issued upon exercise of options	1,009,794			1		6,067,868			—			—			—			6,067,869
Compensation expense for stock option grants	—			—		123,916			—			—			—			123,916
Vesting of restricted stock	197,180			—		—			—			—			—			—
Restricted stock grants to employees	—			—		1,918,343			(1,918,343	)		—			—			—
Purchase and retirement of treasury shares	(63,080	)		—		(601,347	)		—			—			—			(601,347	)
Amortization of deferred compensation expense	—			—		—			1,500,054			—			—			1,500,054
Deferred taxes related to stock options	—			—		8,761,614			—			—			—			8,761,614
Comprehensive income:
Net income	—			—		—			—			—			27,448,087			27,448,087
Currency translation adjustment	—			—		—			—			(39,095	)		—			(39,095	)
Unrealized gain on marketable securities, net of tax provision of $26,268	—			—		—			—			80,939			—			80,939
Total comprehensive income																		27,489,931
Balance at December 31, 2005	45,775,625			46		226,218,469			(3,334,792	)		(282,825	)		(103,681,856	)		118,919,042
Reclassification of deferred compensation	—			—		(3,334,792	)		3,334,792			—			—			—
Reclassification of liability-classified awards	—			—		(230,659	)		—			—			—			(230,659	)
Common stock issued upon exercise of options	85,013			—		457,334			—			—			—			457,334
Vesting of restricted stock	199,633			—		—			—			—			—			—
Purchase and retirement of treasury shares	(65,519	)		—		(631,509	)		—			—			—			(631,509	)
Compensation cost for restricted stock	—			—		1,969,178						—			—			1,969,178
Compensation cost for stock option grants	—			—		3,621,412			—			—			—			3,621,412
Comprehensive income:
Net income	—			—		—			—			—			5,267,549			5,267,549
Currency translation adjustment	—			—		—			—			6,787			—			6,787
Unrealized gain on marketable securities, net of tax provisions of $72,979	—			—		—			—			124,841			—			124,841
Total comprehensive income																		5,399,177
Balance at December 31, 2006	45,994,752		$	46	$	228,069,433		$	—		$	(151,197	)	$	(98,414,307	)	$	129,503,975

The accompanying notes are an integral part of these statements

F-5

ORASURE TECHNOLOGIES, INC.

STATEMENTS OF CASH FLOWS

	For the year ended December 31,
	2006			2005			2004
OPERATING ACTIVITIES:
Net income (loss)	$	5,267,549		$	27,448,087		$	(559,642	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income taxes		3,113,745			(18,165,068	)		—
Stock-based compensation		5,590,590			1,623,970			874,162
Depreciation and amortization		1,923,275			2,346,861			2,487,121
Acquired in-process technology		1,000,000			—			—
Provision for loss on property and equipment, net		—			196,011			4,339
Provision for excess and obsolete inventories		750,542			2,062,855			839,130
Changes in assets and liabilities:
Accounts receivable		1,250,552			(4,553,469	)		1,159,881
Inventories		(2,156,302	)		(1,240,049	)		(1,787,590	)
Prepaid expenses and other		(452,502	)		(360,945	)		(272,265	)
Accounts payable		465,344			457,543			(1,066,064	)
Accrued expenses and other liabilities		133,011			576,540			1,759,144
Net cash provided by operating activities		16,885,804			10,392,336			3,438,216
INVESTING ACTIVITIES:
Purchases of property and equipment		(12,643,266	)		(2,048,167	)		(912,144	)
Proceeds from the sale of property and equipment		—			—			66,427
Purchase of patents, product rights, or acquired in-process technology		(200,000	)		(1,800,000	)		(600,000	)
Purchases of short-term investments		(91,494,215	)		(54,071,801	)		(65,638,600	)
Proceeds from maturities and redemptions of short-term investments		65,433,600			65,935,674			42,226,980
(Increase) decrease in other assets		—			(24,801	)		80,160
Net cash (used in) provided by investing activities		(38,903,881	)		7,990,905			(24,777,177	)
FINANCING ACTIVITIES:
Borrowings of long-term debt		10,000,000			—			—
Repayments of long-term debt		(701,426	)		(1,116,129	)		(1,126,186	)
Proceeds from issuance of common stock		457,334			6,067,869			1,904,161
Purchase and retirement of common stock		(631,509	)		(601,347	)		—
Net cash provided by financing activities		9,124,399			4,350,393			777,975
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		16,759			(28,102	)		(12,983	)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS		(12,876,919	)		22,705,532			(20,573,969	)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR		32,826,740			10,121,208			30,695,177
CASH AND CASH EQUIVALENTS, END OF YEAR	$	19,949,821		$	32,826,740		$	10,121,208

The accompanying notes are an integral part of these statements.

F-6

ORASURE TECHNOLOGIES, INC.

NOTES TO THE FINANCIAL STATEMENTS

1. THE COMPANY:

We develop, manufacture and market oral specimen collection devices using our proprietary oral fluid technologies, diagnostic products including in vitro diagnostic tests, and other medical devices. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. One of our products is also sold in the over-the-counter or consumer retail markets in the United States, Canada, Europe and Mexico.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

We consider all highly liquid investments with a purchased maturity of ninety days or less to be cash equivalents. As of December 31, 2006 and 2005, cash equivalents consisted of commercial paper, U.S. government agency obligations, state and local government agency obligations, corporate bonds, and certificates of deposit.

Short-term Investments

We consider all short-term investments to be available-for-sale securities, in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 115, “Accounting for Certain Investments in Debt and Equity Securities.” These securities are comprised of certificates of deposits, commercial paper, U.S. government and agency obligations, state and local government agency obligations, and corporate bonds, all with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses reported in stockholders’ equity as a component of accumulated other comprehensive loss. There were no securities held as of December 31, 2006 in a continuous unrealized loss position for twelve or more months.

F-7

The following is a summary of our available-for-sale securities at December 31, 2006 and 2005:

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
December 31, 2006
Certificates of deposit	$	800,000	$	—	$	—		$	800,000
Commercial paper		28,079,352		165,064		—			28,244,416
Government and agency bonds		3,331,455		—		(4,618	)		3,326,837
Corporate bonds		38,713,921		2,264		(35,956	)		38,680,229
Total available-for-sale securities	$	70,924,728	$	167,328	$	(40,574	)	$	71,051,482
December 31, 2005
Certificates of deposit	$	10,385,000	$	—	$	(464	)	$	10,384,536
Commercial paper		1,984,999		—		(1,059	)		1,983,940
Government and agency bonds		18,544,871		—		(43,851	)		18,501,020
State and local government agency obligations		75,000		—		—			75,000
Corporate bonds		13,874,242		1,261		(26,953	)		13,848,550
Total available-for-sale securities	$	44,864,112	$	1,261	$	(72,327	)	$	44,793,046
At December 31, 2006, maturities of our available-for-sale securities were as follows:
Less than one year	$	67,851,766	$	165,064	$	(40,574	)	$	67,976,256
One to two years		3,072,962		2,264		—			3,075,226
Total available-for-sale securities	$	70,924,728	$	167,328	$	(40,574	)	$	71,051,482

Supplemental Cash Flow Information

In 2006, 2005, and 2004, we paid interest of $350,535, $99,728, and $137,112, respectively.

In 2006 and 2005, we paid federal and state income taxes of $695,765 and $170,000, respectively. No income tax payments were made in 2004.

For 2006, 2005, and 2004, we recorded through the statement of operations a reduction in our allowance for doubtful accounts of $61,950, $71,962, and $10,360, respectively. We had write-offs/(recoveries) of $16,022, $(4,771), and $3,541 against the allowance for doubtful accounts in 2006, 2005, and 2004, respectively.

For 2006, 2005, and 2004, we recorded accruals for purchases of property and equipment of $346,258, $57,923, and $72,394, respectively.

In 2006, we recorded a $4,000,000 accrual related to two licensing agreements. In 2004, we recorded a $300,000 accrual related to a new license agreement.

Accounts Receivable

Accounts receivable have been reduced by an allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as the balances become past due, the financial condition of our customers and our historical experience related to write-offs. If not reserved through these specific examination procedures, our policy is to reserve for uncollectible accounts by applying fixed percentages to the aging categories of accounts receivable.

F-8

Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis, and include the cost of raw materials, labor and overhead. The majority of our inventories are subject to expiration dating. We continually evaluate quantities on hand and the carrying value of our inventories to determine the need for reserves for excess and obsolete inventories, based primarily on the estimated forecast of product sales. When factors indicate that impairment has occurred, either a reserve is established against the inventories’ carrying value or the inventories are completely written off, as in the case of lapsing expiration dates. In addition to reserving for these items identified through specific identification procedures, we also reserve for unidentified scrap or spoilage under a fixed-formula methodology. We currently buy a portion of our cryosurgical product line from a foreign vendor, with such purchases payable in Euros. Changes in the exchange rate of the Euro will impact our product cost.

Property and Equipment

Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over 20-40 years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over three to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the statement of operations.

Patents and Product Rights

Patents and product rights consist of costs associated with the acquisition of patents, licenses and product distribution rights. Patents and product rights are amortized using the straight-line method over their estimated useful lives of three to ten years.

Other Assets

Included in other assets is a $337,253 investment, representing a 7.7% ownership interest in a privately-held nonaffiliated company. We do not have a controlling interest in this company, nor do we have an ownership or voting interest which allows us to exert significant influence over the operating and financial policies of this investee company. Accordingly, we have accounted for this investment using the cost method of accounting. In January, 2007, this privately-held nonaffiliated company was sold, and we received approximately $1,750,000 for our ownership interest.

Impairment of Long-Lived Assets

In accordance with SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived Assets,” if indicators of impairment exist, we assess the recoverability of the affected long-lived assets, which include property and equipment and patents and product rights, by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows from the use and eventual disposition of the asset. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the asset. During 2005, we recorded a $196,011 impairment on certain equipment because its carrying value exceeded the future cash flows to be received from those assets. We believe the future cash flows to be received from our long-lived assets will exceed the assets’ carrying value, and accordingly we have not recognized any additional impairment losses through December 31, 2006.

F-9

Revenue Recognition

We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. We do not grant price protection or product return rights to our customers, except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

Up-front licensing fees are deferred and recognized ratably over the related license period. Product development revenues are recognized over the period in which the related product development efforts are performed. Amounts received prior to the performance of product development efforts are recorded as deferred revenues. Grant revenue is recognized as the related work is performed and costs are incurred. We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold.

Significant Customer Concentration

During 2006, Quest Diagnostics, including its wholly-owned subsidiary, LabOne, Inc. (“Quest”), and Abbott Laboratories (“Abbott”) accounted for 14 percent and 10 percent of our total revenues, respectively.

Additionally, four customers each accounted for more than 10 percent of our accounts receivable at December 31, 2006. Prestige Brands Holdings, Inc. (“Prestige”), Quest, SSL International plc, and Abbott accounted for 12 percent, 11 percent, 10 percent and 11 percent, respectively, of our accounts receivable at December 31, 2006.

During 2005 and 2004, two of our customers accounted for more than 10 percent of our total revenues. Prestige accounted for 17% and 25% of total revenues for 2005 and 2004, respectively. Quest accounted for 13% and 14% of our total revenues for 2005 and 2004, respectively.

At December 31, 2005, Prestige and SSL International plc accounted for 15% and 20% of our accounts receivable, respectively.

Research and Development

Research and development costs are charged to expense as incurred.

Advertising Expenses

Advertising costs are charged to expense as incurred. During 2006, 2005, and 2004, we incurred $805,936, $2,232,945, and $3,512,037, respectively, in advertising expenses. Included in advertising expenses for 2006, 2005 and 2004 were $539,856, $1,820,022 and $2,883,145, respectively, in reimbursement for marketing expenses incurred for the Compound W^® Freeze Off^® product.

Stock-Based Compensation

Prior to 2006, we accounted for stock-based compensation to employees and directors using the intrinsic value method in accordance with Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations. Under APB Opinion No. 25, no stock-based compensation expense was recognized for stock options granted to employees or directors, as the exercise price was equal to the market price of our common stock on the date of grant. We account for stock-based compensation to nonemployees using the fair value method in accordance with SFAS No. 123 (revised 2004), (“SFAS No. 123R”), “Share-Based Payment,” and Emerging Issues Task Force (“EITF”) Issue No. 96-18, “Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.”

F-10

Effective January 1, 2006, we adopted SFAS No. 123R, which eliminated the ability to account for stock-based compensation under APB Opinion No. 25 and requires us to recognize compensation expense based on the fair value of our stock-based awards. We elected the modified prospective transition method as permitted by SFAS No. 123R. Accordingly, results from prior periods have not been restated. Under this transition method, stock-based compensation expense for the year ended December 31, 2006 includes:

(a) compensation expense for all stock-based awards granted prior to January 1, 2006, but not yet vested, based on the grant date fair value previously estimated in accordance with the original provisions of SFAS No. 123, “Accounting for Stock-Based Compensation,” and

(b) compensation expense for all stock-based awards granted, modified or settled subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS No. 123R.

Upon the adoption of SFAS No. 123R, our deferred compensation balance of $3,334,792 was reclassified against additional paid-in capital. Consistent with our past practice under the disclosure requirements of SFAS No. 123, we have elected to recognize compensation expense for stock option awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.

Pursuant to the disclosure requirements of SFAS No. 123, the table below illustrates the effect on net income (loss) and earnings (loss) per share had compensation expense for our stock-based awards been determined based upon the fair value of the awards at the date of grant for the years ended December 31, 2005 and 2004:

	Year ended December 31,
	2005			2004
Net income (loss):
As reported	$	27,448,087		$	(559,642	)
Add: stock-based employee compensation expense included in net income (loss), net of tax		945,634			874,162
Deduct: total stock-based employee compensation expense determined under the fair value-based method for all awards, net of tax		(3,004,813	)		(5,921,957	)
Pro forma	$	25,388,908		$	(5,607,437	)
Earnings (loss) per share:
Basic
As reported	$	0.61		$	(0.01	)
Pro forma	$	0.56		$	(0.13	)
Diluted
As reported	$	0.59		$	(0.01	)
Pro forma	$	0.55		$	(0.13	)

Income Taxes

We follow the asset and liability method for accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax basis of assets and liabilities, and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates that are expected to apply to taxable income in the years in which those temporary differences and operating loss and credit

F-11

carryforwards are expected to be recovered, settled or utilized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Foreign Currency Translation

Pursuant to SFAS No. 52, “Foreign Currency Translation,” the assets and liabilities of our foreign operations are translated from Euros into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Earnings (Loss) Per Share

We have presented basic and diluted earnings (loss) per share pursuant to SFAS No. 128, “Earnings per Share.” In accordance with SFAS No. 128, basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed in a manner similar to basic earnings per share except that the weighted average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, warrants and unvested restricted stock. The number of incremental shares is calculated by assuming that outstanding stock options and warrants were exercised and unvested restricted shares were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market prices during the reporting period.

The computations of basic and diluted earnings (loss) per share are as follows:

	Year ended December 31,
	2006		2005		2004
Net income (loss)	$	5,267,549	$	27,448,087	$	(559,642	)
Weighted average shares of common stock outstanding:
Basic		45,909,990		45,109,580		44,463,861
Dilutive effect of stock options, warrants and restricted shares		670,276		1,037,032		—
Diluted		46,580,266		46,146,612		44,463,861
Earnings (loss) per share:
Basic	$	0.11	$	0.61	$	(0.01	)
Diluted	$	0.11	$	0.59	$	(0.01	)

For the years ended December 31, 2006, 2005, and 2004, outstanding common stock options, warrants and unvested restricted stock representing 1,308,809, 1,069,181, and 5,479,504 shares, respectively, were excluded from the computation of diluted earnings (loss) per share as their inclusion would have been anti-dilutive.

Other Comprehensive Income (Loss)

We follow SFAS No. 130, “Reporting Comprehensive Income.” This statement requires the classification of items of other comprehensive income (loss) by their nature and disclosure of the accumulated balance of other comprehensive income (loss), separately from accumulated deficit and additional paid-in capital, in the stockholders’ equity section of our balance sheet.

Fair Value of Financial Instruments

As of December 31, 2006, the carrying values of cash and cash equivalents, short-term investments, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on

F-12

their short-term nature. In addition, we believe the carrying value of our debt instruments, which do not have readily ascertainable market values, approximate their fair values, given that the interest rates on outstanding borrowings approximate market rates.

Recent Accounting Pronouncements

In July 2006, the Financial Accounting Standards Board (“FASB”) issued FASB Interpretation (“FIN”) No. 48, “Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No. 109,” which clarifies what criteria must be met prior to recognition of the financial statement benefit of a position taken in a tax return. FIN No. 48 will require companies to include additional qualitative and quantitative disclosures within their financial statements. The disclosures will include potential tax benefits from positions recognized for tax return purposes but not recognized for financial reporting purposes, as well as a tabular presentation of significant changes in such benefits during each period. The disclosures will also include a discussion of the nature of uncertainties, factors that could cause a change, and an estimated range of reasonably possible changes in tax uncertainties. FIN No. 48 will require a company to recognize a financial statement benefit for a position taken for tax return purposes when it will be more-likely-than-not that the position will be sustained. FIN No. 48 is effective for fiscal years beginning after December 15, 2006. We are currently assessing the impact FIN No. 48 will have on our financial statements.

In September 2006, the United States Securities and Exchange Commission issued Staff Accounting Bulletin No. 108 (“SAB No. 108”) “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements.” SAB No. 108 requires companies to evaluate the materiality of identified unadjusted errors using both the income statement approach and the balance sheet approach. In the initial year of adoption, if a company determines that an adjustment to prior year financial statements is required under either approach, SAB No. 108 allows for a one-time cumulative-effect adjustment to beginning retained earnings. SAB No. 108 is effective for interim periods of the first fiscal year ending after November 15, 2006. The adoption of SAB No. 108 did not have any impact on our financial statements.

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements.” This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years. We are currently assessing the impact, if any, that SFAS No. 157 will have on our financial statements.

In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115.” SFAS No. 159 permits entities to elect to measure many financial instruments and certain other items at fair value. Unrealized gains and losses on items for which the fair value option has been elected will be recognized in earnings at each subsequent reporting date. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007. We are currently assessing the impact SFAS No. 159 will have on our financial statements.

3. INVENTORIES:

	December 31,
	2006		2005
Raw materials	$	3,868,301	$	2,625,889
Work in process		533,470		718,804
Finished goods		1,132,796		783,336
	$	5,534,567	$	4,128,029

In 2005, we recorded a $1,288,655 provision on our UPlink^® inventory as a result of the inability to determine an alternative use for this product and the termination of an agreement with our distribution partner.

F-13

4. PROPERTY AND EQUIPMENT:

	December 31,
	2006			2005
Land	$	1,117,788		$	—
Buildings and improvements		13,454,065			4,895,253
Machinery and equipment		8,623,415			7,855,947
Computer equipment		1,577,073			2,052,741
Furniture and fixtures		781,103			847,512
Construction in progress		3,672,005			1,966,125
		29,225,449			17,617,578
Less—Accumulated depreciation		(11,850,731	)		(11,802,345	)
	$	17,374,718		$	5,815,233

On June 30, 2006, we exercised purchase options contained in the commercial leases for two of our facilities located in Bethlehem, Pennsylvania and acquired both facilities for an aggregate purchase price of approximately $9,100,000, including settlement costs. As a result of these purchases, the leases for these facilities, which required minimum annual rental payments of $1,051,000, were terminated.

Depreciation expense was $1,371,400, $1,573,852, and $1,739,733 for 2006, 2005, and 2004, respectively. In addition, we retired or disposed of $1,323,014 of fully depreciated assets during 2006. No gain or loss was recognized on these disposals.

5. PATENTS, PRODUCT RIGHTS AND ACQUIRED IN-PROCESS TECHNOLOGY:

Patents product rights and licenses were as follows:

	December 31,
	2006			2005
HIV-related	$	1,900,000		$	1,900,000
HCV-related		4,500,000			1,500,000
Lateral flow-related		1,500,000			500,000
Cryosurgery-related		2,548,620			2,548,620
		10,488,620			6,448,620
Less accumulated amortization		(4,120,276	)		(3,568,662	)
	$	6,328,344		$	2,879,958

Amortization expense for 2006, 2005, and 2004 was $551,614, $700,377, and $705,808, respectively. Amortization expense for each of the five succeeding fiscal years is estimated at $1,066,565 for 2007, $896,619 for 2008, $789,515 for 2009, $789,515 for 2010, and $789,515 for 2011.

In June 1998, we acquired the patents and exclusive worldwide distribution rights to our cryosurgical product line. The purchase price of $2,548,620, including transaction costs, has been recorded as patents and product rights and is being amortized using the straight-line method over an estimated useful life of ten years. In connection with this acquisition, we also entered into a product purchase agreement with the manufacturer of the cryosurgical product line, with a current term extending through 2008.

In June 2004, we entered into a sublicense agreement with a third party, pursuant to which we have been granted a limited, worldwide, non-exclusive sublicense to certain HIV-2 patents held by such party. The agreement required us to pay the third party a one-time non-refundable license fee of $900,000, which was

F-14

recorded as patent and product rights on our balance sheet and is being amortized through June 30, 2014. This agreement also contained an option to expand the application of this sublicense to other immunoassay platforms, in addition to our OraQuick^® platform. In June 2006, we exercised this option, which requires us to pay the third party a non-refundable license fee of $600,000, of which $200,000 was paid in July 2006. Two remaining contractually obligated payments of $200,000 each are due in July 2007 and 2008. As of December 31, 2006, $200,000 of this obligation is included in accrued expenses, with the remaining $200,000 included in other liabilities. We have recognized this $600,000 license fee as acquired in-process technology, which is included in research and development expense in our statement of operations, because other immunoassay platforms for the detection of HIV-2 will require additional research and development efforts and subsequent regulatory approvals.

In August 2005, we entered into a license agreement with third parties, pursuant to which we have been granted a limited, personal, non-transferable, non-exclusive license related to certain Hepatitis C Virus (“HCV”) patents held by such parties. The agreement required us to pay the third parties a one-time non-refundable license fee of $1,500,000, which was paid in August 2005. In December 2006, an additional milestone payment of $3,000,000 was due and is included in accrued expenses as of December 31, 2006. We may also be required to pay additional license fees of up to $5,500,000, upon the achievement of specific development and/or commercial milestones.

Management’s intent in executing the HCV license agreement is to provide for various alternatives for use of the licensed patents. Some of these uses require additional research and development efforts and regulatory approvals, while others, specifically in the international market, do not require additional research and development efforts or regulatory approvals. Based on management’s estimate of the cash flows to be received from future product sales in international markets, we capitalized both the $1,500,000 and $3,000,000 license fees in the accompanying balance sheet. We are amortizing these amounts to cost of products sold on a straight-line basis over ten years, which represents management’s estimate of the remaining useful life of the licensed patents.

Under the terms of the HCV license agreement, we are also obligated to pay royalties based on our net sales of certain products, which incorporate the technology covered by the licensed patents. Royalties under the license agreement vary based upon the geographical territory where the product is sold. No sales have been made under the terms of this license agreement through December 31, 2006.

In December 2006, we amended a license agreement with third parties, pursuant to which we have been granted a limited, non-exclusive license to certain lateral flow technology patents held by such parties. The amendment provides for the renewal of our license to certain lateral flow patents held by these parties, the expansion of these patents to future product applications to be developed by our Company, and the settlement of prior royalty obligations arising prior to the amendment date. It requires us to pay the third parties a one-time non-refundable fee of $1,750,000. We allocated the $1,750,000 fee based upon the relative fair values of the items contained in the agreement. Accordingly, at December 31, 2006, we capitalized $1,000,000 as patent and product rights and will amortize this amount through December 2011. Of the remaining $750,000, we recognized $400,000 as acquired in-process technology as such amount was allocated to royalties for future product applications that will require additional research and development efforts and regulatory approvals. The remaining $350,000 was recorded as a reduction of the accrued prior royalty obligations, which resulted in the reversal of $738,983 of royalty expense during 2006. The $1,750,000 fee is included in accrued expenses at December 31, 2006.

F-15

6. ACCRUED EXPENSES AND OTHER:

	December 31,
	2006		2005
Payroll and related benefits	$	2,117,630	$	2,510,240
Deferred revenue		1,877,546		1,302,791
Professional fees		681,850		487,712
Royalties		2,813,102		1,925,679
Advertising		201,509		757,906
License fees		4,200,000		—
Laboratory testing fees		155,996		210,604
Other		611,516		539,009
	$	12,659,149	$	7,733,941

At December 31, 2006, accrued payroll and related benefits decreased primarily as a result of a decrease in annual bonuses. Deferred revenue includes customer prepayments of $1,727,546 and $1,012,891 at December 31, 2006 and 2005, respectively. Professional fees at December 31, 2006 increased primarily as a result of legal fees related to current litigation. Accrued royalties and advertising expenses at December 31, 2006 and 2005 are primarily related to our OraQuick^® and Freeze Off^® products, respectively. License fees at December 31, 2006 are related to the sublicense agreements, which we entered into in December 2006, as discussed in Note 5.

7. CREDIT FACILITIES:

On June 27, 2006, we executed an amendment to our existing $11,900,000 credit facility (the “Credit Facility”) with Comerica Bank (“Comerica”). This amendment permitted us to borrow up to an additional $15,000,000 in advances in order to fund the purchase and future expansion of two leased facilities in Bethlehem, Pennsylvania. The original Credit Facility was comprised of an $887,000 mortgage loan, a $3,000,000 term loan, a $4,000,000 non-revolving line of credit for the purchase of both capital equipment and software, and a $4,000,000 revolving working capital line of credit. On June 29, 2006, we borrowed $10,000,000 under the terms of this Credit Facility, as amended, and purchased our two Bethlehem facilities. We can borrow the remaining $5,000,000 at any time before June 30, 2007. At our option, interest on outstanding borrowings is payable monthly at either a fixed rate equal to the five-year U.S. Treasury Note rate plus 1.03% to 1.73%, or a variable rate equal to the 30, 180, or 360-day LIBOR rate plus 0.55% to 1.25%. In each case, the interest rate is determined at the date of the advance and is based upon the amount of cash and cash equivalents we invest and retain at Comerica Securities, Inc. We also can choose the fixed rate option, without penalty, at the expiration of a previously elected LIBOR period. Principal is repayable in periodic installments, based upon the rate option that we elect, with the remaining balance of unpaid principal due on June 27, 2011. This amendment also extended the maturity date of our $4,000,000 revolving working capital line of credit to June 29, 2007. All other terms of the Credit Facility, as previously amended, remain in effect, except for our financial covenant related to liquidity, which was modified to require a minimum liquidity, as defined by Comerica, of not less than $25,000,000, of which at least $15,000,000 must be held by Comerica or its affiliates.

As of December 31, 2006, we had no outstanding borrowings under the $3,000,000 term loan, the $4,000,000 non-revolving line of credit, or the $4,000,000 revolving working capital line of credit.

At December 31, 2006, interest on the new $10,000,000 borrowing is payable monthly, at the 360-day LIBOR rate plus 0.9%, or 6.1894%. Principal is repayable in installments, due at the end of each LIBOR rate period, based upon a twenty-year amortization schedule and the number of months in the expiring LIBOR rate period. Accordingly, on December 27, 2007, we will be required to make a $500,000 principal repayment and the interest rate on this loan will reset.

F-16

All borrowings under the Credit Facility are collateralized by a first priority security interest in all of our assets, including present and future accounts receivable, chattel paper, contracts and contract rights, equipment and accessories, general intangibles, investments, instruments, inventories, and a mortgage on our three facilities in Bethlehem, Pennsylvania. Borrowings under the revolving working capital line of credit are limited to commercially standard percentages of accounts receivable. The Credit Facility contains certain covenants that set forth minimum requirements for our quick ratio, liquidity, and tangible net worth. We were in full compliance with all covenants at December 31, 2006. The Credit Facility also restricts our ability to pay dividends, to make certain investments, to incur additional indebtedness, to sell or otherwise dispose of a substantial portion of assets, and to merge or consolidate operations with an unaffiliated entity, without the consent of Comerica.

8. LONG-TERM DEBT:

	December 31,
	2006			2005
Note payable to bank, interest payable monthly at the 360-day LIBOR rate plus 0.9%, (6.1894% at December 31, 2006), principal payments due at the end of each LIBOR rate period through June 2011, at which time the remaining unpaid principal balance is payable, secured by a first priority security interest in all of our assets.	$	9,750,000		$	—
Mortgage loan payable to bank, interest at an annual floating rate equal to the bank’s prime rate (8.25% at December 31, 2006), fixed monthly installments of principal and interest of $7,426 through September 2007, at which time the interest rate and fixed monthly repayment amount is reset for the remaining sixty monthly installments, secured by our building.		689,442			722,233
Notes payable to bank, matured in 2006.		—			311,210
Note payable to bank, interest at an annual floating rate equal to the bank’s prime rate (8.25% at December 31, 2006), monthly principal installments of $2,144, plus interest, through June 2007, secured by certain equipment		12,863			38,590
Note payable to bank, interest at an annual floating rate equal to the bank’s prime rate (8.25% at December 31, 2006), monthly principal installments of $2,264, plus interest, through March 2007, secured by certain equipment.		6,793			33,963
Note payable to Pennsylvania Industrial Development Authority, interest at 2%, monthly installments of principal and interest of $4,893 through March 2010, secured by a second lien on our building.		180,038			234,566
		10,639,136			1,340,562
Less—Current portion		(608,595	)		(456,541	)
	$	10,030,541		$	884,021

Long-term debt maturities as of December 31, 2006 are as follows:

2007	$	608,595
2008		593,087
2009		597,346
2010		552,670
2011		7,796,730
Thereafter		490,708
	$	10,639,136

Certain of these notes payable require, among other items, the maintenance of certain financial covenants. We were in compliance with these covenants as of December 31, 2006.

F-17

9. INCOME TAXES:

The components of the provision (benefit) for income taxes for the years ended December 31, 2006, 2005 and 2004 are as follows:

	2006		2005			2004
Current
Federal	$	251,074	$	224,153		$	—
State		429,085		211,726			—
		680,159		435,879			—
Deferred
Federal		2,976,992		3,285,740			(123,009	)
State		136,753		495,298			(18,823	)
		3,113,745		3,781,038			(141,832	)
Change in valuation allowance		—		(21,946,106	)		141,832
		3,113,745		(18,165,068	)		—
Total provision (benefit)	$	3,793,904	$	(17,729,189	)	$	—

A reconciliation of the statutory United States federal tax rate to our effective tax rate for the year ended December 31, is as follows:

	2006		2005		2004
Statutory U.S. federal tax rate—expense (benefit)	34.0	%	34.0	%	(34.0	)%
State income taxes, net of federal benefit	4.1		4.8		(2.2	)
Nondeductible expenses and other	3.8		4.6		10.9
Net change in valuation allowance, federal and state	—		(225.8	)	25.3
Effective tax rate	41.9	%	(182.4	)%	—	%

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting purposes and tax purposes, and net operating loss and tax credit carryforwards. Significant components of our total deferred tax asset as of December 31, 2006 and 2005 are as follows:

	2006		2005
Net operating loss carryforwards	$	18,019,056	$	22,827,988
Inventory		1,315,262		1,165,890
Capitalized research and development costs		552,740		665,353
Accruals and reserves currently not deductible		573,819		579,584
Patent costs		764,311		579,347
Depreciation and amortization		472,586		391,677
Stock-based compensation		1,418,655		359,573
Alternative minimum tax credit carryforwards		405,145		138,886
Total deferred tax asset	$	23,521,574	$	26,708,298

F-18

In assessing the realizability of our deferred tax asset, we follow the guidance contained within SFAS No. 109, “Accounting for Income Taxes,” which requires that deferred income tax assets be reduced by a valuation allowance, if after considering all relevant positive and negative evidence, it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The realization of the gross deferred tax assets is dependent on several factors, including the generation of sufficient taxable income prior to the expiration of the net operating loss (“NOL”) carry forwards. We conclude that it is more likely than not that we will generate sufficient taxable income to recognize the deferred tax assets. Our federal NOL carryforwards expire as follows:

Year of Expiration	NOLs
2008	$	596,830
2009		7,053,000
2010		795,394
2011		7,731,587
2017-2021		30,428,371
2022-2025		6,383,686
	$	52,988,868

The Tax Reform Act of 1986 contains provisions that limit the annual amount of NOLs available to be used in any given year in the event of a significant change in ownership. On September 29, 2000, two separate companies, STC Technologies, Inc. and Epitope, Inc. merged to form our Company. A significant change in ownership, as defined by Section 382 of the Internal Revenue Code, occurred in connection with this merger. As such, the utilization of NOLs generated prior to September 29, 2000 is limited to approximately $13,700,000 per year. We do not believe that this limitation will have a material adverse impact on the utilization of our NOL carryforwards.

At the end of 2005, we concluded that it was more likely than not that the majority of our deferred tax asset would be recovered. Accordingly, we reduced our valuation allowance by approximately $26,700,000. Included in the 2005 reduction of the valuation allowance was approximately $8,500,000 related to prior years’ tax benefits associated with the exercise of employee stock options. This amount was recognized as an increase to additional paid-in capital in 2005. A tax benefit of approximately $245,000 associated with employee exercises of non-qualified stock options and disqualifying dispositions of stock acquired with incentive stock options during the year ended December 31, 2005 was also recorded as additional paid-in capital during 2005.

10. STOCKHOLDERS’ EQUITY:

Stock-based Awards

We grant stock-based awards under the OraSure Technologies, Inc. 2000 Stock Award Plan, as amended and restated (the “2000 Plan”). The 2000 Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the 2000 Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards.

Under the terms of the 2000 Plan, qualified incentive stock options for shares of our common stock may be granted to eligible employees, including our officers. To date, options generally have been granted with ten-year exercise periods and an exercise price not less than the fair market value on the date of grant. Options generally vest over four years, with one quarter of the options vesting one year after grant and the remainder vesting on a monthly basis over the next three years. The 2000 Plan also provides that nonqualified options may be granted at a price not less than 75 percent of the fair market value of a share of common stock on the date of grant. The option term and vesting schedule of such awards may either be unlimited or have a specified period in which to vest and be exercised.

F-19

As of December 31, 2006, 2,749,391 shares were available for future grants under the 2000 Plan.

The fair value of each stock option was estimated on the date of the grant using the Black-Scholes option-pricing model using the following weighted-average assumptions:

	Year Ended December 31,
Black-Scholes Option Valuation Assumptions	2006		2005		2004
Risk-free interest rate(1)	4.53	%	3.72	%	3.21	%
Expected dividend yield	—		—		—
Expected stock price volatility(2)	56	%	58	%	65	%
Expected life of stock options (in years)(3)	5		4		5

(1) Based on the Treasury Securities constant maturity interest rate whose term is consistent with the expected life of our stock options.

(2) Expected stock price volatility is based upon historical experience.

(3) Expected life of stock options is based upon historical experience.

The weighted-average grant date fair value of stock options granted during the years ended December 31, 2006, 2005 and 2004 was $4.85, $3.17 and $4.60, respectively.

Amounts recognized in the financial statements related to stock options were as follows:

	Year Ended December 31, 2006
Total compensation cost during the year	$	3,621,412
Amounts capitalized into inventory and property and equipment during the year		(468,754	)
Amounts recognized in cost of products sold for amounts previously capitalized		264,038
Amounts charged against income, before income tax benefit	$	3,416,696
Amount of related income tax benefit	$	842,239

As a result of adopting SFAS No. 123R, the Company’s income before income taxes and net income for the year ended December 31, 2006 were $3,416,696 and $2,574,457 lower, respectively, than if it had continued to account for share-based compensation under APB Opinion No. 25. Basic and diluted earnings per share for the year ended December 31, 2006 would have been $0.06 per share higher if the Company had not adopted SFAS No. 123R.

As a result of modifying the vesting provisions of two grants made to former members of the Company’s Board of Directors, the Company recognized $123,916 in compensation cost related to these modifications in the year ended December 31, 2005.

The aggregate intrinsic value of options (the amount by which the market price of the stock on the date of exercise exceeded the exercise price) exercised during the years ended December 31, 2006, 2005 and 2004 was $332,261, $4,338,143, and $1,326,796, respectively.

F-20

The following table summarizes the stock option activity under the 2000 Plan:

	Options		Weighted-Average Exercise Price Per Share		Weighted-Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding on January 1, 2004	3,935,463		$	6.42
Granted	1,629,891			8.07
Exercised	(370,800	)		5.14
Forfeited	(320,050	)		7.89
Outstanding on December 31, 2004	4,874,504			6.98
Granted	778,572			6.60
Exercised	(1,009,794	)		6.01
Forfeited	(426,497	)		7.55
Outstanding on December 31, 2005	4,216,785			7.08
Granted	801,900			9.22
Exercised	(85,013	)		5.38
Forfeited	(145,254	)		7.99
Balance, December 31, 2006	4,788,418		$	7.44	7.57	$	4,409,463
Vested or expected to vest as of December 31, 2006	4,638,197		$	7.44	7.57	$	4,271,130
Exercisable on December 31, 2006	3,536,575		$	7.12	7.23	$	4,366,963

As of December 31, 2006, there was $4,637,882 of unrecognized compensation expense related to unvested option awards that is expected to be recognized over a weighted-average period of 1.7 years.

Net cash proceeds from the exercise of stock options were $457,334, $6,067,869 and $1,904,161 for the years ended December 31, 2006, 2005 and 2004, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises for these periods.

The following table summarizes information about stock options outstanding at December 31, 2006:

Options outstanding					Options exercisable
Range of exercise prices	Number outstanding	Weighted- average remaining life, in years	Weighted- average exercise price		Number exercisable	Weighted- average exercise price
$ 0.80–$5.60	858,895	11.91	$	4.75	679,406	$	4.53
$ 5.76–$6.84	486,953	5.23		5.96	480,160		5.96
$6.87	63,333	5.39		6.87	63,333		6.87
$6.96	509,452	6.08		6.96	501,251		6.96
$ 6.98–$7.77	863,943	5.91		7.49	669,359		7.42
$ 7.90–$8.18	106,000	8.23		8.05	32,603		8.03
$8.20	711,448	7.04		8.20	563,156		8.20
$ 8.36–$9.56	818,184	8.55		9.26	230,643		9.18
$ 9.78–$12.23	365,210	5.54		10.57	311,664		10.63
$12.69	5,000	4.68		12.69	5,000		12.69
	4,788,418	7.57	$	7.44	3,536,575	$	7.12

F-21

The 2000 Plan also permits us to grant restricted shares of our common stock to eligible employees, including officers. Generally, these shares are nontransferable and are subject to three-year vesting requirements or forfeiture, as determined by the Compensation Committee of our Board of Directors. The market value of these shares at the date of grant is recognized on a straight-line basis over the period during which the restrictions lapse. Compensation cost of $1,969,178, $1,500,054 and $874,162 related to restricted shares was recognized during the years ended December 31, 2006, 2005 and 2004, respectively.

The following table summarizes restricted stock award activity under the 2000 Plan:

	Shares		Weighted-Average Grant Date Fair Value
Issued and unvested, January 1, 2004	75,000		$	8.68
Granted	410,000			7.75
Vested	—			—
Forfeited	—			—
Issued and unvested, December 31, 2004	485,000			7.89
Granted	332,188			6.00
Vested	(197,180	)		9.26
Forfeited	(13,563	)		5.60
Issued and unvested, December 31, 2005	606,445			6.90
Granted	465,313			9.16
Vested	(199,633	)		6.99
Forfeited	(65,071	)		7.56
Issued and unvested, December 31, 2006	807,054		$	8.13
Issued and expected to vest, December 31, 2006	802,242		$	8.08

As of December 31, 2006, there was $5,136,029 of unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 3.7 years.

In connection with the vesting of restricted shares during the years ended December 31, 2006 and 2005, we purchased and immediately retired 65,519 and 63,080 shares with aggregate values of $631,509 and $601,347, respectively, in satisfaction of minimum tax withholding obligations. No shares were purchased and retired during the year ended December 31, 2004.

SFAS No. 123R addresses the accounting for awards issued as part of share-based payment arrangements in exchange for employee services. Certain of the Company’s share-based payment arrangements are outside the scope of SFAS No. 123R and are subject to EITF Issue No. 00-19, “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock,” which requires that vested stock options held by certain nonemployee consultants be accounted for as liability-classified awards. The fair value of these vested and unexercised awards was estimated using the Black-Scholes option pricing model and $109,080 was reclassified from equity to other liabilities as of January 1, 2006. An additional $121,579 was reclassified for options that vested during 2006. The fair value of these awards are remeasured at each financial reporting date until the awards are settled or expire. As of December 31, 2006, $228,475 was included in other liabilities for stock options to acquire 63,000 shares of common stock which remained unexercised.

Common Stock Warrants

As of December 31, 2006, warrants to purchase 120,000 shares of common stock at $6.13 per share were outstanding. These warrants were issued on September 30, 1998 and expire on September 30, 2008.

F-22

11. COMMITMENTS AND CONTINGENCIES:

Sublicense Agreement

In June 2004, we entered into a sublicense agreement with a third party, pursuant to which we have been granted a limited, worldwide, non-exclusive sublicense to certain HIV-2 patents held by such party. Under the terms of this sublicense agreement, we are obligated to pay royalties based on a percentage of our net sales of certain products, which incorporate the technology covered by the licensed patents. Future minimum payments under this agreement are as follows:

2007	$	500,000
2008		500,000
2009		500,000
2010		500,000
2011		500,000
Thereafter		3,291,667
	$	5,791,667

Royalties from our commercial sale of products covered by the sublicense can be credited against these minimum royalty obligations.

License Agreement

In August 2005, we entered into a license agreement with third parties, pursuant to which we have been granted a limited, personal, non-transferable, non-exclusive license related to certain HCV patents held by such parties. Under the terms of the HCV license agreement, we are also obligated to pay royalties based on our net sales of certain products which incorporate the technology covered by the licensed patents. Royalties under the license agreement vary based upon the geographical territory where the product is sold. No minimum payments are required under this agreement in 2007 or thereafter. We may, however, be required to pay additional license fees of up to $5,500,000, upon the achievement of specific development and/or commercial milestones.

Leases

We lease office and warehouse facilities under operating lease agreements. Future payments required under these non-cancelable leases are as follows:

2007	$	81,866
2008		68,480
2009		11,413
	$	161,759

Rent expense for 2006, 2005 and 2004 was $624,479, $1,146,697, and $1,690,858, respectively.

Purchase Commitments

As of December 31, 2006, we had outstanding non-cancelable purchase commitments in the amount of $5,349,799, of which $3,749,692, $198,340 and $1,401,767 are related to inventory, capital expenditures, and other goods or services, respectively.

F-23

Employment Agreements

Under terms of employment agreements with certain executive officers, extending through 2008, we are required to pay each individual a base salary for continuing employment with our Company. The agreements require payments of $1,804,625 and $724,800 in 2007 and 2008, respectively.

Litigation

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcome of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

12. RETIREMENT PLANS:

Substantially all employees of the Company are eligible to participate in the OraSure Technologies, Inc. 401(k) Plan (the “401(k) Plan”). The 401(k) Plan permits voluntary employee contributions to be excluded from an employee’s current taxable income under provisions of Internal Revenue Code Section 401(k) and the regulations thereunder. The 401(k) Plan also provides for us to match employee contributions up to $4,000 per year. Contributions to the 401(k) Plan, net of forfeitures, were $397,970, $361,629, and $330,552 in 2006, 2005, and 2004, respectively.

13. GEOGRAPHIC INFORMATION:

Based on guidance in SFAS No. 131, “Disclosures about Segments of an Enterprise and Related Information,” we believe we operate within one reportable segment. Our products are sold principally in the United States and Europe. Segmentation of operating income and identifiable assets is not applicable since our revenues outside the United States are export sales, and we do not have significant operating assets outside the United States.

The following table represents total revenues by geographic area, based on the location of the customer (amounts in thousands):

	2006		2005		2004
United States	$	56,780	$	59,859	$	47,843
Europe		9,521		7,868		4,318
Other regions		1,854		1,639		1,847
	$	68,155	$	69,366	$	54,008

F-24

14. QUARTERLY DATA (Unaudited):

The following tables summarize the quarterly results of operations for each of the quarters in 2006 and 2005. These quarterly results are unaudited, but in the opinion of management, have been prepared on the same basis as our audited financial information and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the information set forth herein (all amounts in thousands, except per share amounts).

	2006 Results
	Three months ended								Year ended December 31, 2006
	March 31, 2006		June 30, 2006		September 30, 2006		December 31, 2006
Revenues	$	15,217	$	17,564	$	17,639	$	17,735	$	68,155
Costs and expenses		14,331		16,261		15,160		16,940		62,692
Operating income		886		1,303		2,479		795		5,463
Other income (expense), net		791		896		920		992		3,599
Income before income taxes		1,677		2,199		3,399		1,787		9,062
Income tax provision		777		991		1,265		761		3,794
Net income	$	900	$	1,208	$	2,134	$	1,026	$	5,268
Earnings per share(1)
Basic	$	0.02	$	0.03	$	0.05	$	0.02	$	0.11
Diluted	$	0.02	$	0.03	$	0.05	$	0.02	$	0.11

	2005 Results
	Three months ended									Year ended December 31, 2005
	March 31, 2005		June 30, 2005		September 30, 2005		December 31, 2005
Revenues	$	15,828	$	17,430	$	18,077	$	18,031		$	69,366
Costs and expenses		14,613		16,468		14,863		15,849			61,793
Operating Income		1,215		962		3,214		2,182			7,573
Other income (expense), net		346		481		594		725			2,146
Income before income taxes		1,561		1,443		3,808		2,907			9,719
Income taxes (benefit)		—		—		—		(17,729	)		(17,729	)
Net income	$	1,561	$	1,443	$	3,808	$	20,636		$	27,448
Earnings per share(1)
Basic	$	0.03	$	0.03	$	0.08	$	0.45		$	0.61
Diluted	$	0.03	$	0.03	$	0.08	$	0.44		$	0.59

(1) The summation of the quarterly amounts may not equal the year-end amounts due to the use of weighted-average shares for each period.

F-25

INDEX TO EXHIBITS

Exhibit Number	Exhibit
3.1.1	Certificate of Incorporation of OraSure Technologies, Inc. is incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-4 (No. 333-39210), filed June 14, 2000.
3.1.2	Certificate of Amendment to Certificate of Incorporation dated May 23, 2000 is incorporated by reference to Exhibit 3.1.1 to the Company’s Registration Statement on Form S-4 (No. 333-39210), filed June 14, 2000.
3.1.3	Certificate of Designation of Series A Preferred Stock of OraSure Technologies (filed as Exhibit A to the Rights Agreement referred to in Exhibit 4.1).
3.2	Amended and Restated Bylaws of OraSure Technologies, effective as of February 4, 2003, are incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2002.
4.1	Rights Agreement, dated as of May 6, 2000, between OraSure Technologies, Inc. and ChaseMellon Shareholder Service, L.L.C. (now called Mellon Investor Services LLC), as Rights Agent, is incorporated by reference to Exhibit 4.2 to Amendment No. 1 to the Company’s Registration Statement on Form S-4 (No. 333-39210), filed August 8, 2000.
10.1	Form of Indemnification Agreement (and list of parties to such agreement) is incorporated by reference to Exhibit 10.1 to Amendment No. 3 to the Company’s Registration Statement on Form S-4 (No. 333-39210), filed August 30, 2000.*
10.2	Employment Agreement, dated as of June 22, 2004, between OraSure Technologies, Inc. and Douglas A. Michels, is incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.*
10.3	Employment Agreement, dated as of July 1, 2004, between OraSure Technologies, Inc. and Ronald H. Spair, is incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.*
10.4	Employment Agreement, dated September 23, 2005, between OraSure Technologies, Inc. and Stephen R. Lee, Ph.D., is incorporated herein by reference to Exhibit 99 to the Company’s Current Report on Form 8-K filed September 28, 2005.*
10.5	Employment Agreement, dated as of July 1, 2004, between OraSure Technologies, Inc. and P. Michael Formica, is incorporated by reference to Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.*
10.6	Employment Agreement, dated as of July 1, 2004, between OraSure Technologies, Inc. and Joseph E. Zack, is incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.*
10.7	Employment Agreement, dated as of July 1, 2004, between OraSure Technologies, Inc. and Jack E. Jerrett, is incorporated by reference to Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.*
10.8	Employment Agreement, dated as of October 2, 2006, between Mark L. Kuna and OraSure Technologies, Inc., is incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K filed October 5, 2006.*
10.9	Description of Nonemployee Director Compensation Policy, as amended as of November 15, 2005, is incorporated by reference to Exhibit 10.8 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005.*
10.10	Amended and Restated Epitope, Inc. 1991 Stock Award Plan is incorporated by reference to Exhibit 10.9 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2002.*

Exhibit Number	Exhibit
10.11	OraSure Technologies, Inc. Employee Incentive and Non-Qualified Stock Option Plan, as amended and restated effective September 29, 2000, is incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2000.*
10.12	OraSure Technologies, Inc. 2000 Stock Award Plan, as amended and restated effective as of May 16, 2006, is incorporated by reference to Exhibit 10 to the Company’s Current Report on Form 8-K filed May 18, 2006.*
10.13	Form of Restricted Share Grant Agreement is incorporated by reference to Exhibit 10.2.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.*
10.14	Incentive Stock Option General Terms and Conditions (Officers and Employees) is incorporated by reference to Exhibit 10.12 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004.*
10.15	Nonqualified Stock Option Award General Terms and Conditions (Officers and Employees) is incorporated by reference to Exhibit 10.13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004.*
10.16	Nonqualified Stock Option Award General Terms and Conditions (Non-Employee Directors) is incorporated by reference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004.*
10.17	Description of the OraSure Technologies, Inc. 2007 Management Incentive Plan is incorporated by reference to Item 5.02 to the Company’s Current Report on Form 8-K filed February 8, 2007.*
10.18	Description of the OraSure Technologies, Inc. 2006 Self-Funding Management Incentive Plan is incorporated by reference to Exhibit 10.17 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2005.*
10.19	Description of the OraSure Technologies, Inc. Management Stock Award Guidelines dated January 26, 2005 is incorporated by reference to Exhibit 10.16 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004.*
10.20	Description of the OraSure Technologies, Inc. 2007 Stock Guidelines is incorporated by reference to Item 5.02 to the Company’s Current Report on Form 8-K filed February 8, 2007.*
10.21	Distribution Agreement, dated as of April 24, 2003, between OraSure Technologies, Inc. and Medtech Holdings, Inc., is incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2004.
10.22	Amendment No. 1 to Distribution Agreement, dated as of February 10, 2006, among OraSure Technologies, Inc., Medtech Holdings, Inc., Medtech Products, Inc. (as assignee of Medtech Holdings, Inc.) and Prestige Brands Holdings, Inc., as guarantor, is incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2006.
10.23	Distribution Agreement, dated as of June 1, 2005, between OraSure Technologies, Inc. and SSL International plc, is incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2005.
10.24	Loan and Security Agreement, dated as of September 10, 2002, between Comerica Bank—California and OraSure Technologies, Inc., is incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2002.
10.25	First Amendment to Loan and Security Agreement, dated as of May 23, 2003, between OraSure Technologies, Inc. and Comerica Bank – California, is incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003.

Exhibit Number	Exhibit
10.26	Second Amendment to Loan and Security Agreement, dated as of September 12, 2003, between OraSure Technologies, Inc. and Comerica Bank, is incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, dated September 17, 2003.
10.27	Third Amendment to Loan and Security Agreement, dated as of April 21, 2005, between OraSure Technologies, Inc. and Comerica Bank, is incorporated by reference to Exhibit 10 to the Company’s Current Report on Form 8-K filed April 27, 2005.
10.28	Fourth Amendment to Loan and Security Agreement, dated as of June 27, 2006, between OraSure Technologies, Inc. and Comerica Bank, is incorporated by reference to Exhibit 10 to the Company’s Current Report on Form 8-K filed June 30, 2006.
10.29	Supply and Distribution Agreement, dated as of February 11, 2005, between Abbott Laboratories and OraSure Technologies, Inc.**
10.30	Amendment No. 1 to Supply and Distribution Agreement, dated as of July 21, 2005, between Abbott Laboratories and OraSure Technologies, Inc.**
23	Consent of KPMG LLP, Independent Registered Public Accounting Firm.
24	Powers of Attorney.
31.1	Certification of Douglas A. Michels required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.2	Certification of Ronald H. Spair required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32.1	Certification of Douglas A. Michels required by Rule 13a-14(b) or Rule 15a-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Ronald H. Spair required by Rule 13a-14(b) or Rule 15a-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

* Management contract or compensatory plan or arrangement.

** Portions of this exhibit were omitted pursuant to an application for confidential treatment and filed separately with the Securities and Exchange Commission.

EX-10.29

Exhibit 10.29

Execution Copy

Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 406 under the Securities Act of 1933. Such omissions are designated as ***.

SUPPLY AND DISTRIBUTION AGREEMENT

THIS SUPPLY AND DISTRIBUTION AGREEMENT (this “Agreement”) is made and entered into as of this 11th day of February 2005 (“Effective Date”), by and between Abbott Laboratories, an Illinois corporation with principal offices at 100 Abbott Park Road, Abbott Park, IL, 60064-3500 (“Abbott”), and OraSure Technologies, Inc., a Delaware corporation with principal offices at 220 East First Street, Bethlehem, Pennsylvania 18015 (“OraSure”).

BACKGROUND

WHEREAS, OraSure manufactures a rapid, point-of-care in vitro diagnostic product for the detection of HIV-1 and HIV-2 antibodies, which test is sold under the trade name, OraQuick® ADVANCE^™ Rapid HIV-1/2 Antibody Test;

WHEREAS, Abbott is in the business of manufacturing and selling in vitro diagnostic products as well as other healthcare products; and

WHEREAS, the parties desire to appoint Abbott as distributor for OraSure’s new OraQuick® ADVANCE^™ Rapid HIV-1/2 Antibody Test in certain segments in the United States.

NOW, THEREFORE, in consideration of the foregoing, and of the mutual promises and covenants contained in this Agreement, OraSure and Abbott, intending to be legally bound, hereby set forth their agreement in its entirety, as follows:

ARTICLE 1 - DEFINITIONS

For the purposes of this Agreement, the following terms will have the respective meanings set forth below:

1.1 “Abbott Complaint” shall have the meaning set forth in Section 6.6.

1.2 “Abbott Net Sales” shall mean, with respect to any month or Quarterly Period, the gross amount invoiced by Abbott or its Affiliates for OraQuick® ADVANCE^™ Devices sold by Abbott or its Affiliates to unaffiliated third parties (a distributor, sub-distributor or agent of Abbott or any of its Affiliates who is not an Affiliate of Abbott or any of its Affiliates, shall be considered such an unaffiliated third party) during such month or Quarterly Period, less (i) trade, cash and quantity discounts and rebates allowed and taken by the unaffiliated third party, (ii) amounts repaid, credited or allowed and taken by the unaffiliated third party on account of returned or rejected OraQuick® ADVANCE^™ Devices, recalls, billing errors, or retroactive price

reductions or price reductions imposed by governmental authorities, (iii) tariffs, duties, excises and taxes included in the amount charged to the unaffiliated third party, and (iv) freight, insurance and other transportation and shipping costs included in the amount charged to the unaffiliated third party. In the event an OraQuick® ADVANCE^™ Device is sold with any other products or services of Abbott, Abbott shall separately itemize and individually price such OraQuick® ADVANCE^™ Device on the invoice to the customer and such itemized price shall be used to calculate Abbott Net Sales that includes the sale of such OraQuick® ADVANCE^™ Device. In no event shall the same OraQuick® ADVANCE^™ Device be included in Abbott’s Net Sales more than once.

1.3 “Abbott Trademarks” shall have the meaning set forth in Section 9.1.

1.4 “Affiliate” shall mean, when used with reference to a party, any individual or entity directly or indirectly controlling, controlled by or under common control with such party. For purposes of this Agreement, “control” (including correlative meanings “controlling,” “controlled by,” or “under common control with”) means: (a) the direct or indirect ownership, in the aggregate, of more than fifty percent (50%) of the outstanding voting securities of an entity; or (b) the right or power, directly or indirectly, to direct or cause the direction of the policy decisions of an entity, whether by ownership of voting securities, contract or otherwise.

1.5 “Approved Facility” shall mean an FDA-approved site for the Manufacture of the Products. Such term includes all of the equipment, machinery and facilities of OraSure at such location that are used in Manufacturing the Products.

1.6 “Competing Product” shall have the meaning set forth in Section 3.2.

1.7 “Confidential Information” shall mean all information disclosed hereunder in writing, orally, visually or through some other media, which is identified as confidential at the time of disclosure, except any portion thereof which (i) is known to the recipient at the time of the disclosure free of any restriction as to its use or disclosure, as evidenced by its written records; (ii) is disclosed to the recipient by a third person lawfully in possession of such information and not under an obligation of nondisclosure to the disclosing party; (iii) is or becomes patented, published or otherwise part of the public domain through no fault of the recipient; or (iv) is developed by or for the recipient independently of Confidential Information disclosed hereunder, as evidenced by the recipient's written records.

1.8 “Contract Year” shall mean, for the first Contract Year, the twelve (12) month period beginning on the Effective Date and ending on December 31, 2005, and for all subsequent Contract Years, the twelve (12) month period beginning on each January 1 thereafter.

1.9 “Contractual Minimum” shall have the meaning set forth in Section 2.1.5.

1.10 “FDA” shall mean the United States Food and Drug Administration, or any successor entity thereto.

1.11 “GSA” shall mean the U.S. General Services Administration, or any successor entity thereto.

2

1.12 “HIV-1” shall mean the Human Immunodeficiency Virus, Type 1.

1.13 “HIV-2” shall mean the Human Immunodeficiency Virus, Type 2.

1.14 “HIV-1/2” shall mean both HIV-1 and HIV-2.

1.15 “Hospital” shall mean any of the approximate 5,000 acute care institutions in the Territory that (i) are licensed and operated as hospitals, (ii) are accredited as a hospital by the Joint Commission on Accreditation of Health Care Organizations or the Bureau of Hospitals of the American Osteopathic Association and, in each case, are certified as a hospital provider under Medicare, (iii) provide for the care and treatment of resident in-patients for a variety of medical conditions, both surgical and non-surgical, and (iv) provide treatment under the supervision of a staff of physicians with twenty four (24)-hour a day nursing care and internal laboratory services. The term “Hospital” shall not include any affiliated clinic or treatment center or physician office or physician practice unless that clinic, treatment center, physician office or physician practice is wholly-owned by an institution described in the first sentence of this definition.

1.16 “Hospital Adjustment Number” shall have the meaning set forth in Section 8.2.2.

1.17 “Hospital Baseline” shall mean, with respect to a particular month or Quarterly Period, an amount equal to the difference between (a) the product of the aggregate number of OraQuick® ADVANCE^™ Devices sold by Abbott or its Affiliates in the Hospital Segment and U.S. Government Hospital Segment during such month or Quarterly Period multiplied by the Transfer Price for such OraQuick® ADVANCE^™ Devices, minus (b) the product of the aggregate number of OraQuick® ADVANCE^™ Devices sold by Abbott or its Affiliates in the U.S. Government Hospital Segment during such month or Quarterly Period multiplied by the OraSure FSS Baseline for such month or Quarterly Period.

1.18 “Hospital Segment” shall mean the segment for rapid, point-of-care testing of Whole Blood or Oral Fluid samples for HIV-1 and HIV-2 solely in the Territory by Hospitals located in the Territory; provided that the Hospital Segment shall not include any Hospitals included in the U.S. Government Hospital Segment.

1.19 “Improved Product” shall mean any and all modifications, improvements, additions, alterations, or refinements to a Product, whether patented or unpatented, (i) that relate solely to the detection of antibodies to HIV-1 or HIV-2, (ii) are subject to a Regulatory Approval that permits the Product, as so modified or improved, to be marketed and sold in the Segments in the Territory and (iii) that OraSure has the right to market in the Territory; provided that a New Product shall not constitute an Improved Product.

1.20 “Manufacture”, “Manufactured” or “Manufacturing” shall mean the manufacture, assembly, labeling, packaging, handling, quality control, and storing of the Products in accordance with applicable law.

1.21 “Negotiation Period” shall have the meaning set forth in Section 2.4.

3

1.22 “New Product” shall mean any device, which OraSure has the right to market in the Territory, that is subject to an approval of the FDA that permits the device to be marketed and sold in the Territory for the rapid, point-of-care detection of (a) any one or more diseases or conditions, other than HIV-1 and HIV-2, in any specimen type or (b) HIV-1 and/or HIV-2 plus any one or more diseases or conditions in any specimen type. An OraQuick® Combo Product shall be deemed to be a New Product.

1.23 “New Product Notice” shall have the meaning set forth in Section 2.4.

1.24 “Oral Fluid” shall mean mucosal transudate, saliva, or other fluids extracted from the human oral cavity.

1.25 “OraQuick® ADVANCE^™ Controls” shall mean the positive and negative controls that are developed, manufactured, marketed and sold by OraSure or any of its Affiliates solely for use with the OraQuick® ADVANCE^™ Devices to confirm the ability of a person to properly use an OraQuick® ADVANCE^™ Device and interpret any resulting test results.

1.26 “OraQuick® ADVANCE^™ Control Specifications” shall mean all product specifications on the package inserts and product labeling for the OraQuick® ADVANCE^™ Controls.

1.27 “OraQuick® ADVANCE^™ Device” shall mean the collection and testing device that (i) is developed, manufactured, marketed, sold or otherwise distributed under the trademark OraQuick® ADVANCE^™ by OraSure or any of its Affiliates or designees for the purpose of detecting both HIV-1 and HIV-2 in Whole Blood and Oral Fluid, and (ii) meets the OraQuick® ADVANCE^™ Device Specifications; provided that an OraQuick® ADVANCE^™ Device shall not include any device that is a New Product or has claimed indications that permit marketing and sale under a Regulatory Approval only with respect to the detection of HIV-1 in any specimen type.

1.28 “OraQuick® ADVANCE^™ Device Specifications” shall mean all product specifications on the package inserts and package labeling for the OraQuick® ADVANCE^™ Device.

1.29 “OraQuick® ADVANCE^™ Control Warranty Period” shall have the meaning set forth in Section 10.1.2.

1.30 “OraQuick® ADVANCE^™ Device Warranty Period” shall have the meaning set forth in Section 10.1.1.

1.31 “OraQuick® Combo Product” shall have the meaning set forth in Section 2.4.

1.32 “OraSure FSS” shall mean the Federal Supply Schedule Contract effective October 1, 2004 and numbered V797P-5755X that OraSure has filed with the GSA and which lists the Products as available for sale pursuant to the GSA Federal Supply Service, as such Federal Supply Schedule Contract may be amended or modified from time to time by OraSure. In the event that the OraSure FSS is amended or modified, OraSure shall provide written notice to Abbott of such amendment or modification as soon as practicable thereafter.

4

1.33 “OraSure FSS Baseline” shall mean, with respect to a particular month or Quarterly Period, an amount equal to (i) the Transfer Price minus (ii) *** of the unit price for OraQuick® ADVANCE^™ Devices set forth on the OraSure FSS in effect for such month or Quarterly Period; provided that the OraSure FSS Baseline shall not be less than zero.

1.34 “OraSure Trademarks” shall have the meaning set forth in Section 9.1.

1.35 “Person” shall mean an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, government, governmental agency, authority or instrumentality, or any other form of entity not specifically listed in this Agreement.

1.36 “Physicians’ Office Segment” shall mean the market for rapid, point-of-care testing of Whole Blood and/or Oral Fluid for HIV-1 and HIV-2 solely in the Territory by general practitioners, internists, obstetricians, gynecologists, pediatricians and other licensed physicians located within the Territory; provided that the Physicians’ Office Segment shall not include any such physicians in offices or practices that are wholly-owned by any Hospital or that practice in the Public Health Segment.

1.37 “PO/RL Adjustment Number” shall have the meaning set forth in Section 8.2.3.

1.38 “PO/RL Baseline” shall mean, with respect to a particular month or Quarterly Period, an amount equal to the product of (a) the aggregate number of OraQuick® ADVANCE^™ Devices sold by Abbott or its Affiliates in the Physicians’ Office Segment and Reference Lab Segment during such month or Quarterly Period, multiplied by (b) the Transfer Price for such OraQuick® ADVANCE^™ Devices.

1.39 “Products” shall mean the OraQuick® ADVANCE^™ Controls and the OraQuick® ADVANCE^™ Devices.

1.40 “Promote,” “Promotion” or “Promotional” shall mean those activities undertaken by a party to encourage sales of Products, including but not limited to, journal advertising, broadcast advertising, direct mail programs, detailing, customer meetings, convention and trade show exhibits, Product presentations, symposia and other forms of advertising, promotion and sales support.

1.41 “Public Health Segment” shall mean the market for rapid, point-of-care testing of any specimen type for HIV-1 and HIV-2 by community-based organizations, AIDS service organizations, county public health departments, correctional and criminal justice departments (including county, state, and federal drug courts, probation centers, departments of correction, detention centers, jails and prisons), substance abuse clinics, sexually transmitted disease clinics, substance abuse centers, student health centers and clinics, abortion clinics, family planning clinics, planned parenthood clinics, and any other similar organization or entity, in each case located within the Territory; provided that the Public Health Segment shall not include any clinic or treatment center that is within the definition of Hospital.

1.42 “Purchase Order” shall have the meaning set forth in Section 7.1.

5

1.43 “QSRs” shall mean current Quality Systems Regulations for the methods to be used in, and the facilities and controls to be used for, the Manufacture, processing, packing, labeling and storage of diagnostic products, all as set forth in 21 CFR 820, including all amendments and supplements thereto throughout the Term of this Agreement.

1.44 “Quarterly Period” means each successive period of three (3) months beginning on the Effective Date.

1.45 “Reference Lab Segment” shall mean the market for rapid, point-of-care testing of any specimen type for HIV-1 and HIV-2 by commercial reference laboratories where such tests are performed solely by and within such laboratories for outside customers and such tests are not resold or otherwise distributed by such laboratories. Examples of such laboratories include Quest Diagnostics and Labcorp.

1.46 “Regulatory Approvals” shall mean the technical, medical and scientific licenses, registrations, authorizations and/or approvals of the Products (including the prerequisite manufacturing approvals or authorizations, marketing authorization based upon such approvals and labeling approvals related thereto) that are required by the FDA for the Manufacture at the Approved Facility and the distribution, marketing, storage, transportation, use, and sale of the Products in the Segments in the Territory, as such Regulatory Approvals are amended or supplemented from time to time.

1.47 “Revenue-Based Amount” shall have the meaning set forth in Section 8.2 of this Agreement.

1.48 “Segments” shall mean the Hospital Segment, the Physicians’ Office Segment, the U.S. Government Hospital Segment and the Reference Lab Segment.

1.49 “Senior Executive” means, with respect to OraSure, the Chief Executive Officer of OraSure, and with respect to Abbott, the Vice President, U.S. Sales Organization for the Diagnostics Division of Abbott.

1.50 “Senior Manager” means, with respect to OraSure, the Executive Vice President, Marketing and Sales and Vice President, Sales of OraSure, and with respect to Abbott, the Director of U.S. Sales for the Diagnostics Division of Abbott.

1.51 “Sublicense” shall have the meaning set forth in Section 13.2.6.

1.52 “Territory” shall mean the United States and its geographic territories or possessions.

1.53 “Transfer Price” shall mean the price payable by Abbott for the Products, as determined in accordance with Exhibit 1.53.

1.54 “U.S. Government Hospital Segment” shall mean the market for rapid, point-of-care testing of Whole Blood and/or Oral Fluid for HIV-1 and HIV-2 solely in the continental United States by Hospitals (including Veterans Administration and United States Military Hospitals) that (i) are owned and operated by the United States government, (ii) purchase

6

product (including the Products) and services under the U.S. General Services Administration Federal Supply Service and (iii) are permanently located in the continental United States.

1.55 “Whole Blood” shall mean blood specimen collected from humans by venous or capillary puncture, plasma or serum.

ARTICLE 2 - APPOINTMENT

2.1 Appointments; Subdistributors.

2.1.1 Exclusive Appointment - Hospital Segment and Reference Lab Segment. In accordance with the terms and subject to the conditions and limitations of this Agreement, OraSure appoints Abbott, and Abbott accepts appointment, as the exclusive marketer and distributor of the Products during the Term in the Hospital Segment and Reference Lab Segment, with the right to commercially distribute the Products on an exclusive basis to customers solely in the Hospital Segment and Reference Lab Segment, including all activities ancillary thereto (including, without limitation, warehousing, order entry, shipping, billing and collection, promotional, advertising, marketing and sales activities). Subject to Section 2.1.5, the grant of exclusive rights to Abbott under this Section 2.1.1 means that, for so long as Abbott’s rights under this Section 2.1.1 with respect to the Hospital Segment and Reference Lab Segment remain exclusive, OraSure may not promote, market and sell the Products, directly or indirectly, to customers in the Hospital Segment or Reference Lab Segment, except that OraSure shall be permitted to engage in promotional, advertising, marketing and sales support activities pursuant to or as permitted by Article 5.

2.1.2 Non-Exclusive Appointment – Physicians’ Office Segment. In accordance with the terms and subject to the conditions and limitations of this Agreement, OraSure appoints Abbott, and Abbott accepts appointment, as the non-exclusive marketer and distributor of Products during the Term in the Physicians’ Office Segment, with the right to commercially distribute the Products on a non-exclusive basis to customers solely in the Physicians’ Office Segment, including all activities ancillary thereto (including, without limitation, warehousing, order entry, shipping, billing and collection, promotional, advertising, marketing and sales activities). The grant of non-exclusive rights to Abbott under this Section 2.1.2 means that OraSure shall be permitted to promote, market and sell Products, directly or indirectly, to customers in the Physicians’ Office Segment, including engaging in all activities ancillary thereto (including, without limitation, warehousing, order entry, shipping, billing and collection, promotional, advertising, marketing and sales activities). The parties agree to meet after the end of each Contract Year to review the level of Abbott’s sales of Product into the Physicians’ Office Segment and penetration of that Segment by Abbott to determine if such sales and penetration are sufficient to warrant converting Abbott’s non-exclusive appointment for the Physicians’ Office Segment to an exclusive appointment. Each party shall determine whether to agree to such conversion in its sole discretion.

2.1.3 Exclusive Appointment – U.S. Government Hospital Segment.

7

(a) In accordance with the terms and subject to the conditions and limitations of this Agreement, OraSure appoints Abbott, and Abbott accepts appointment, as the exclusive marketer and distributor of the Products during the Term in the U.S. Government Hospital Segment, with the right to commercially distribute the Products on an exclusive basis to customers solely in the U.S. Government Hospital Segment, including all activities ancillary thereto (including, without limitation, warehousing, order entry, shipping, billing and collection, promotional, advertising, marketing and sales activities). Subject to Section 2.1.5, the grant of exclusive rights to Abbott under this Section 2.1.3 means that, for so long as Abbott’s rights under this Section 2.1.3 with respect to the U.S. Government Hospital Segment remain exclusive, OraSure may not promote, market and sell the Products, directly or indirectly, to customers in the U.S. Government Hospital Segment, except that OraSure shall be permitted to engage in promotional, advertising, marketing and sales support activities pursuant to or as permitted by this Section 2.1.3 and Article 5.

(b) All sales of Product by Abbott to the U.S. Government Hospital Segment shall be made by Abbott pursuant to and in compliance with the terms and conditions of the then current OraSure FSS and in compliance with all applicable laws and regulations relating to the OraSure FSS. OraSure agrees to cooperate with Abbott in Abbott’s provision of services, compliance with the OraSure FSS, compliance with applicable laws and regulations relating to the OraSure FSS and Abbott’s provision of services thereunder. Abbott shall not list or otherwise offer the Products on a Federal Supply Schedule filed by Abbott or any of its Affiliates. In the event the OraSure FSS is modified, expires or is terminated and such action materially and adversely affects Abbott’s ability to meet the Contractual Minimums, then the parties shall negotiate in good faith reasonable reductions to the Contractual Minimums to reflect such action and the quantity of OraQuick® ADVANCE^™ Devices sold by Abbott in the U.S. Government Hospital Segment during the most recent twelve (12) month period.

(c) It is expected that customers in the U.S. Government Hospital Segment will remit payment for the Products directly to Abbott. If, however, OraSure receives payment from a customer in the U.S. Government Hospital Segment with respect to the sale of Products to such customer, OraSure will receive such payment in trust for Abbott and either (i) pay Abbott the entire amount of the payment received, or (ii) credit Abbott the entire amount of the payment received against another Abbott payment.

(d) OraSure shall be responsible for, at OraSure’s cost, adding Abbott as a distributor under the OraSure FSS in the U.S. Government Hospital Segment. In addition, OraSure acknowledges and agrees that it is responsible for the IFF payment related to the OraSure FSS. Abbott agrees that it shall comply with the obligations of a distributor under the then current OraSure FSS, including without limitation the clause entitled, “G-FSS-913 Contractor’s Billing Responsibilities,” as such clause may be amended from time to time.

2.1.4 Sub-distributors. Abbott may appoint sub-distributors or agents solely in the Physicians’ Office Segment and in no other Segment; provided, however, that (i) each such sub-distributor or agent agrees in writing to comply with Abbott’s obligations under this Agreement that are applicable to the distribution of the Products and (ii) Abbott’s use of sub-distributors or agents does not relieve Abbott of any of its obligations under this Agreement.

8

2.1.5 Conditions to Exclusivity. In order to maintain its exclusive appointment under Sections 2.1.1 and 2.1.3, Abbott must purchase the following number of OraQuick® ADVANCE^™ Devices in respect of each of the following Contract Years, such that OraSure may invoice Abbott and delivery to Abbott must occur for the specified number of OraQuick® ADVANCE^™ Devices during the applicable Contract Year: (a) at least *** OraQuick® ADVANCE^™ Devices during the first Contract Year (so long as Abbott is not prevented from launching the Products in one or more of the Segments by May 1, 2005 solely as a result of a failure by OraSure to supply Product ordered by Abbott in accordance with this Agreement); (b) at least *** OraQuick® ADVANCE^™ Devices during the second Contract Year, and (c) at least *** OraQuick® ADVANCE^™ Devices during the third Contract Year (each a “Contractual Minimum”). The Contractual Minimums shall be equitably adjusted in the event OraSure fails to supply Product as provided in Section 7.7 or is unable to supply Product with a shelf life of at least seven (7) months as provided in Section 10.5. The Contractual Minimums for any Contract Year following the Initial Term shall be determined pursuant to Section 13.1. In the event that Abbott does not meet its Contractual Minimum for any Contract Year, then OraSure’s sole and exclusive remedy shall be to convert Abbott’s appointment under Section 2.1.1 to non-exclusive and to terminate Abbott’s exclusive appointment under Section 2.1.3. OraSure shall exercise its right to convert or terminate under this Section 2.1.5 by giving Abbott written notice thereof. If OraSure exercises any of its rights under this Section 2.1.5 to convert or terminate an appointment under this Agreement, OraSure shall have the right to promote, market, sell and distribute the Products, directly or indirectly through one or more distributors, sub-distributors or agents, in the Segment in which Abbott’s appointment has been converted or terminated, including engaging in all activities ancillary thereto (including, without limitation, warehousing, order entry, shipping, billing and collection, promotional, advertising, marketing and sales activities). Once an appointment is converted to non-exclusive or terminated under this Agreement it may not be restored to an exclusive appointment by any means including, without limitation, Abbott taking delivery of an additional quantity of OraQuick® ADVANCE^™ Devices in a subsequent Contract Year that would satisfy the Contractual Minimum for such Contract Year. Without limiting the generality of the foregoing, a failure to meet any required Contractual Minimum may not be cured by issuance of a Purchase Order during a Contract Year calling for delivery in a subsequent Contract Year or taking delivery of OraQuick® ADVANCE^™ Devices in a subsequent Contract Year equal to or greater than the aggregate of the number of units of OraQuick® ADVANCE^™ Devices that Abbott failed to order and take delivery during a prior Contract Year in order to satisfy the applicable Contractual Minimum plus the Contractual Minimum for such subsequent Contract Year. The number of units of OraQuick® ADVANCE^™ Devices in excess of the Contractual Minimum for a given Contract Year that Abbott orders and takes delivery during the Contract Year shall not be credited to the Contractual Minimum for any subsequent Contract Year.

2.1.6 Favored Nation Pricing. If, during the Term, OraSure exercises its right under Section 2.1.5 to convert Abbott’s appointment under this Agreement with respect to the Hospital Segment to non-exclusive as a result of Abbott failing to meet the Contractual Minimum for any Contract Year, OraSure agrees that, for Purchase Orders delivered by Abbott after such conversion, the Transfer Price for Products purchased under such Purchase Orders shall not be higher than *** of the lowest price charged by OraSure or its Affiliates to any third party (other than Affiliates of OraSure) purchasing substantially similar volumes of the same Products for sale or distribution in the Hospital Segment in the Territory. In addition, with

9

respect to the Physicians’ Office Segment, OraSure shall not provide Products to any other distributor to the Physicians’ Office Segment at a transfer price which is less than *** of the Transfer Price.

2.2 Restrictions. Abbott shall not, directly or indirectly, promote, market, sell or otherwise distribute or provide (or arrange any sale, distribution or provision of) the Products outside of the Hospital Segment, Physicians’ Office Segment, U.S. Government Hospital Segment, Reference Lab Segment or the Territory. Abbott further agrees not to sell the Products to customers whom Abbott knows has resold or distributed or facilitated the resale or distribution of the Products outside the Hospital Segment, Physicians’ Office Segment, U.S. Government Hospital Segment, Reference Lab Segment or the Territory in violation of this Agreement or to customers that Abbott knows intend to take such action. For so long as Abbott’s appointment in any Segment under this Agreement is exclusive, if Products sold by OraSure to a distributor are being resold inside such Segment, then, upon written notice by Abbott of such occurrence, OraSure shall pursue any contractual remedies it may have against such distributor, such remedy to be determined by OraSure’s election in OraSure’s sole discretion, to prevent such resale or distribution, including discontinuation of sales of Products to such distributor, until such time as such distributor discontinues selling Products in the applicable Segment. If Products sold by Abbott to a distributor are being resold outside the Physicians’ Office Segment or outside the Territory, then upon written notice by OraSure of such occurrence, Abbott shall pursue any contractual remedies it may have against such distributor, such remedy to be determined by Abbott’s election in Abbott’s sole discretion, to prevent such resale or distribution including discontinuing of sales of Products to such distributor or person until such time as such distributor or person discontinues selling Products outside the Physicians’ Office or Territory, as the case may be. The parties shall each designate a representative who will have quarterly meetings with the other party’s representative to try to resolve any issues that may arise related to Product being sold outside of either party’s designated Segments.

2.3 Non-Assertion. During the Term and any additional period contemplated by Section 13.3.3, OraSure covenants that it will not enforce any patent rights owned or licensed by OraSure against Abbott, its Affiliates or its customers in respect of the marketing, distribution, sale, and use of the Products in the Segments in the Territory purchased by Abbott in accordance with this Agreement.

2.4 New Product. Except as provided in this Section 2.4, if OraSure develops a New Product and desires to distribute the New Product in the Territory, OraSure shall have no obligation to offer Abbott the right to distribute, market, promote, sell and/or represent the New Product and Abbott shall have no distribution rights with respect to such New Product. Notwithstanding the foregoing sentence, if OraSure develops and desires to distribute a New Product which consists solely of a device using OraSure’s OraQuick® platform for the rapid, point of care detection of both HIV-1 and HIV-2 as well as one or more other infectious diseases or conditions on the same device (an “OraQuick® Combo Product”), OraSure shall provide Abbott with written notice thereof (“New Product Notice”). Abbott shall have a right of first negotiation with respect to the distribution of such OraQuick® Combo Product in the Segments in the Territory for a ninety (90) day period commencing on the date it receives the New Product Notice (the “Negotiation Period”), subject to the terms and conditions set forth in this Section 2.4. During the Negotiation Period, the parties shall negotiate in good faith regarding the terms

10

and conditions of a distribution agreement with respect to such OraQuick® Combo Product. If following the end of the Negotiation Period, the parties have not executed and delivered a mutually agreeable form of distribution agreement providing for the distribution by Abbott of such OraQuick® Combo Product in the Segments in the Territory, (i) Abbott’s right of first negotiation with respect to such OraQuick® Combo Product shall terminate (provided that Abbott shall have a continuing first right of negotiation with respect to any different OraQuick® Combo Products developed in the future, in accordance with the procedures set forth in this Section 2.4) and (ii) OraSure shall be free to distribute the OraQuick® Combo Product, directly or indirectly through one or more agents or subdistributors, in any market or territory including the Segments in the Territory, provided that any such distribution arrangement with a third party entered into by OraSure or its Affiliates within twelve (12) months of the expiration of the Negotiation Period shall be on terms which, when taken as a whole, using reasonable judgment, are not materially more favorable to such third party than those terms offered by OraSure to Abbott during the Negotiation Period.

2.5 Improved Product. If OraSure develops an Improved Product and desires to distribute, have distributed, market, have marketed, promote, have promoted or sell or have sold such Improved Product in the Territory, Abbott shall have the same rights to the Improved Product as it has to the Products under this Agreement, and such Improved Product shall be deemed to be a “Product” hereunder and may be supplied by OraSure in lieu of the original Product supplied hereunder. Nothing in this Agreement shall obligate OraSure to develop or seek FDA approval of an Improved Product, including without limitation an Improved Product that has indications or claims that are different than those approved by the FDA for the Products or reflected in the Regulatory Approvals as of the Effective Date.

2.6 OTC Approval. It is possible that OraSure may seek to obtain FDA approval for the marketing and sale of a device for the rapid, point-of-care detection of HIV-1 and/or HIV-2 in the retail or over-the-counter market segment in the Territory. Abbott shall have no rights with respect to the marketing, promotion, distribution, representation and/or sale of such a device in the retail or over-the-counter market segment in the Territory, and no adjustments shall be made to this Agreement in connection with OraSure seeking or obtaining any such FDA approval or OraSure directly or indirectly marketing, promoting, distributing and/or selling such a device in the retail or over-the-counter market segment in the Territory.

2.7 Sales to CDC, Etc. Nothing in this Agreement shall preclude OraSure from marketing, promoting, selling or distributing Products to the Centers for Disease Control and Prevention (“CDC”), the Substance Abuse and Mental Health Services Administration (“SAMHSA”) or other government agencies, including without limitation state or county public health departments. OraSure shall exercise commercially reasonable efforts to prevent the CDC, SAMHSA and such other governmental agencies from reselling any Product into the Hospital Segment or U.S. Government Hospital Segment; provided that in the event the CDC, SAMHSA or such other governmental agency donates or otherwise provides or uses any Product in Hospitals for clinical studies or other purposes, such action shall not constitute a breach of this Agreement by OraSure, or entitle Abbott to any adjustments to this Agreement except as provided below. So long as Abbott’s appointments under Sections 2.1.1 and 2.1.3 have not been converted to non-exclusive or terminated within sixty (60) days following the end of each Contract Year, or, if such appointments are converted or terminated, such conversion or

11

termination was reasonably caused by such reselling or donating by the CDC, SAMHSA or other such governmental agencies, the parties shall meet to discuss the quantity of OraQuick® ADVANCE^™ Devices sold by OraSure to the CDC, SAMHSA or other governmental agencies that are shown by reasonable documentation to have been sold or distributed by the CDC, SAMHSA or such agency into the Hospital Segment or U.S. Government Hospital Segment during such Contract Year other than for purposes of a clinical or non-clinical study or research (the “Subject Quantity”). If the Subject Quantity is greater than ten percent (10%) of the Contractual Minimum for the preceding Contract Year, the parties shall negotiate in good faith an appropriate adjustment to the Contractual Minimum for the next Contract Year, taking into account whether the same or different Subject Quantity is reasonably expected during such next Contract Year.

2.8 Records; Audit. Abbott and OraSure each shall keep records sufficient, in accordance with generally accepted accounting principles in the United States, to permit verification of the determination of the Subject Quantity made under Section 2.7, above, and any other information required by Section 2.7, and as may be required to confirm that each such party is marketing and selling Product within the segments permitted under this Agreement. Such records shall be maintained and made available for examination in accordance with this Section 2.8 for at least two (2) years after the close of the applicable Quarterly Period to which they relate. Abbott and OraSure each shall permit such records to be examined during normal business hours by independent third party public accountants designated by the other party and reasonably acceptable to the party being audited. Such accountants shall report to the party requesting the audit only the amount by which the Subject Quantity in respect of the audited period was overstated or understated and the amount of Product being sold by either party which is not in compliance with this Agreement, and the basis for such determination, and shall make such report simultaneously available to both OraSure and Abbott. Such accountants shall also agree to keep any information they obtain during an audit and the results of their audit confidential pursuant to the terms of a confidentiality agreement with the party being audited, which agreement shall be in form and substance reasonably satisfactory to the party being audited. Any dispute regarding the Subject Quantity or regarding whether a party is marketing or selling Products in a segment which is not in compliance with this Agreement, shall be brought to the Oversight Committee for resolution and, if not resolved, shall be handled pursuant to Section 5.13.

2.9 Transition. The parties acknowledge that, prior to the Effective Date, OraSure entered into commitments to sell Products into the Hospital Segment. OraSure shall, subject to the proviso set forth at the end of this sentence, (a) cease selling Products directly into the Hospital Segment and (b) use commercially reasonable efforts to terminate or transfer to Abbott its existing contractual commitments to sell Products to that Segment; provided that in no event shall OraSure be required to breach any contract that it made prior to the Effective Date with respect to the sale or distribution of the Product into the Hospital Segment (including the sale and supply of Products pursuant to purchase orders issued and accepted after the Effective Date under such contracts).

12

ARTICLE 3 - OBLIGATIONS OF ABBOTT.

3.1 Level of Effort. Abbott shall use commercially reasonable efforts to market and promote the Products in the Hospital Segment, Physicians’ Office Segment and U.S. Government Hospital Segment.

3.2 Competition. During the Term, Abbott shall not, directly or indirectly (including without limitation through Affiliates or other third parties or business arrangements), develop, import, manufacture, market, promote, distribute or sell any rapid, point-of-care test for detecting HIV-1 or HIV-2 (including a test that can detect HIV-1 and/or HIV-2 as well as one or more other diseases or conditions) that competes or would compete with the OraQuick® ADVANCE^™ Device in the Territory (a “Competing Product”), provided that such prohibition shall not include any product sold or supplied by OraSure to Abbott. If any provision of this Section 3.2 shall be held unenforceable because of scope, duration or area of its applicability, it shall be deemed modified to the extent necessary to make it enforceable, while preserving its intent, In the event Abbott fails to comply with this Section 3.2, OraSure’s sole remedy shall be to terminate this Agreement in accordance with Section 13.2.2.

3.3 Staffing. Abbott shall provide sufficient staffing in order to meet its obligations under this Agreement to promote, market, sell and distribute the Products for use in the Hospital Segment, Physicians’ Office Segment and U.S. Government Hospital Segment.

3.4 Compliance with Laws. Abbott shall comply with all applicable treaties, laws, rules, regulations and Regulatory Approvals within the Territory in connection with its promotion, marketing and/or sale of the Products and performance of its obligations under this Agreement.

3.5 Records. Abbott shall maintain accurate and complete records of its sales of the Products including an auditable method of determining the particular Segment (i.e., Hospital Segment, Physicians’ Office Segment, U.S. Government Hospital Segment and Reference Lab Segment) into which a particular unit of the Products is distributed or sold by Abbott. The records shall include but not be limited to the quantity of Product sold in units by region and Segment (and by individual customers in the Hospital Segment and U.S. Government Hospital Segment) in a manner sufficient for OraSure to allocate sales to their sales personnel. In addition, Abbott shall maintain accurate and complete records of all customer complaints or inquiries it receives with respect to the Products and any responses or investigations related to such complaints or inquiries. Abbott shall maintain such records for at least three (3) years from the date of sale or such longer period as may be required by applicable law or regulation. Abbott shall comply with all applicable record-keeping requirements imposed by the FDA in the Territory. At OraSure’s expense, Abbott shall cooperate with OraSure in OraSure’s communication and correspondence with the FDA, including providing information required by OraSure to respond to or prepare filings with the FDA, provided that any Confidential Information provided by Abbott shall be maintained by OraSure in accordance with Article 12. Other than as required under this Section 3.5, for the purposes of complying with an FDA audit or investigation, as contemplated under Article 5 (including providing reports under Section 5.12), or complying with the audit requirements in Section 8.2, Abbott shall not be obligated to disclose the records required by this Section 3.5 to OraSure.

13

ARTICLE 4 - OBLIGATIONS OF ORASURE.

4.1 Regulatory Approvals. OraSure shall use commercially reasonable efforts to obtain and maintain all requisite Regulatory Approvals in the Territory. All such Regulatory Approvals shall be owned by OraSure or its nominee. OraSure shall bear all costs related to obtaining and maintaining all Regulatory Approvals.

4.2 Compliance with Laws. OraSure shall comply with all applicable treaties, laws, rules, regulations and Regulatory Approvals within the Territory in connection with its Manufacture of the Products and performance of its obligations under this Agreement.

4.3 Approved Vendor. Abbott shall only accept a Product that was manufactured at a facility that has passed an Abbott supplier quality audit for qualification as an “Approved Vendor”. Abbott may perform annual quality audits pursuant to this Section 4.3 and Section 6.3. The scope of any quality audit permitted hereunder shall be subject to approval by OraSure and Abbott, which shall not be unreasonably withheld. The parties acknowledge that Abbott has recently performed such an audit at OraSure’s Bethlehem, Pennsylvania facilities, but not specifically for the Products, and that at the time of such audit, OraSure was found to be an Approved Vendor. Abbott shall also be entitled to perform a quality audit at OraSure’s Bethlehem, Pennsylvania facility (not to exceed one (1) week in duration) within thirty (30) days after the execution of this Agreement and at each relocated Approved Facility at which OraSure will Manufacture the Products no later than thirty (30) days after receipt of OraSure’s notice to Abbott of the relocation of the Approved Facility. Any audits permitted under this Section 4.3 shall otherwise be performed in accordance with Section 6.3. Within thirty (30) days after the completion of each quality audit performed after the date of this Agreement, Abbott shall inform OraSure in writing of the results of such audit. If OraSure does not pass any audit and the reasons for such failure can be remedied within a reasonable period of time (which shall not be less than sixty (60) days), then Abbott shall provide OraSure with a list of proposed remedial action items and a proposed commercially reasonable timeframe within which to accomplish such action items. If (i) OraSure does not pass such audit and the reasons for such failure cannot be remedied within a reasonable period of time, (ii) OraSure fails or elects not to complete any remedial actions suggested by Abbott, or (iii) the parties are unable to agree on the appropriate scope of the audit, then Abbott’s sole and exclusive remedy shall be to terminate this Agreement in accordance with the provisions of Section 13.2.3. Notwithstanding the foregoing, in no event shall OraSure be required to meet quality requirements more stringent than those required under any Regulatory Approvals applicable to the Manufacture of the Products in the Territory, and OraSure shall not be required to disclose or make available to Abbott any of OraSure’s proprietary technology, know-how, trade secrets, processes, methods or raw materials relating to the Products or otherwise.

4.4 Manufacturing Changes. OraSure shall notify Abbott in writing of any changes in its manufacturing process which could potentially affect the safety or efficiency or materially affect the fit, form or function of the Products, including but not limited to any changes that affect written quality plans for production or written quality procedures respecting same, as well as any changes outside the validated level or procedure, in manufacturing procedures, component

14

part or raw materials vendors, manufacturing sites or batch sizes. Upon the request of Abbott, OraSure shall provide to Abbott representative samples of such changed Products in reasonable quantities. In the event such manufacturing change has an impact on any Regulatory Approvals, OraSure shall be responsible for and bear the costs of any amendment, notification or resubmission required with respect to such Regulatory Approvals as a result of such manufacturing change.

ARTICLE 5 – PRODUCT COMMERCIALIZATION.

5.1 Joint Promotion. The parties hereby agree to jointly Promote the Products in the Segments in the Territory, as provided in this Article 5.

5.2 Oversight Committee. In order to effect the objectives of this Article 5, the parties agree to establish an oversight committee which shall operate as provided below (“Oversight Committee”).

5.2.1 Composition. The Oversight Committee shall consist of the sales and marketing managers and such other relevant personnel (as needed) from each party as each party shall appoint from time to time. The Oversight Committee shall have two (2) co-chairpersons, one designated by each of OraSure and Abbott. Each party shall confirm to the other in writing its representatives to serve on the Oversight Committee.

5.2.2 Meetings. The Oversight Committee shall, at a minimum, meet once each calendar quarter, and as otherwise mutually agreed by the parties. Meetings may be held in person, by telephone, or by video conference call, and the location of each meeting shall alternate between sites selected by each of the parties’ respective co-chairperson, unless otherwise agreed. Additional participants may be invited by any representative to attend meetings where appropriate.

5.2.3 Decision-Making. All decisions by the Oversight Committee shall be made by vote of the co-chairpersons, with each co-chairperson having one vote, and all decisions shall be by unanimous consent of the co-chairpersons. The parties shall cause their respective representatives on the Oversight Committee to use diligent efforts, acting in good faith, to resolve all matters presented to them as expeditiously as possible. Each party shall be responsible for expenses incurred by its employees and representatives in attending or otherwise participating in Oversight Committee meetings and activities. To the extent the Oversight Committee is unable to resolve any matter or dispute which should arise, the procedures set forth in Section 5.13, shall be followed.

5.2.4 Duties and Responsibilities. The Oversight Committee will be responsible for all Promotional activities as set forth herein, including but not limited to, the following:

(a) Determine the general Marketing Plan as provided in Section 5.3, including general positioning, sales and marketing strategies for the Hospital Segment and U.S. Government Hospital Segment;

15

(b) Develop advertising material and strategies and other sales and Promotional materials for use by the Abbott sales representatives for the Products, design packaging for the Products (subject to Article 9), and plan and oversee educational and professional symposia, trade shows and other similar activities and speaker and activity programs for the Products in the Territory;

(c) Develop and implement a publication strategy for the Products, targeted at the Segments;

(d) Coordinate and develop Product presentations and Product exhibits and booths for use at medical or trade show meetings and Promotional events;

(e) Schedule periodic joint meetings for the Abbott and OraSure sales forces and marketing representatives; and Provide updates to each party’s management regarding the Oversight Committee’s activities and progress against the Marketing Plan.

5.3 Marketing Plan. The Oversight Committee shall develop a marketing plan (each, a “Marketing Plan”) for each Contract Year during the Term, consistent with the terms of this Agreement, applicable law and the Regulatory Approvals. The Oversight Committee shall review the Marketing Plan during each quarterly period and make any modifications or updates deemed necessary by the Oversight Committee based on such review. OraSure shall be permitted to engage in Promotion, marketing and sales support activities, as provided in this Agreement and the Marketing Plan or as otherwise approved by the Oversight Committee. The Marketing Plan will describe the plan for promoting, marketing, advertising and selling the Products in the Segments in the Territory, including: (a) general strategies for the marketing of the Products (including positioning, sales and marketing strategies for the Hospital Segment and U.S. Government Hospital Segment) and allocation of responsibilities for marketing activities; (b) each party’s training activities; (c) sales and marketing forecasts for the Products; (d) advertising, public relations, and other Promotional programs, including professional symposia, speaker and activity programs and trade shows to be used in the Promotion of the Products in the Segments; and (e) such other matters related to the Promotion of the Products as the Oversight Committee shall determine. The parties may from time to time add to or modify the scope of the Marketing Plan and responsibilities and duties of the Oversight Committee by setting forth such additions or modifications in a written instrument agreed to by both parties.

5.4 Training. OraSure shall provide initial Product training for Abbott’s sales force in accordance with OraSure’s existing training programs at such time. Such initial training shall occur on not more than three occasions, at such times and locations as may be mutually agreed by the parties. OraSure shall be permitted to attend and participate in Abbott’s annual sales meetings and other meetings of Abbott’s sales force; provided that such participation shall be limited to those portions of the meetings dealing with the Segments for which Abbott maintains an exclusive appointment hereunder and for which no proprietary or confidential information will be disclosed. OraSure shall provide additional ongoing sales and Product training for Abbott sales representatives, or assist Abbott in providing such training, as may be mutually agreed by the parties. Abbott shall be responsible for the costs of the foregoing training and sales meetings

16

including production of training materials, except that OraSure shall be responsible for its lodging and transportation costs of attending such training meetings.

5.5 Promotional Materials. The Abbott sales forces will only use promotional, advertising, marketing, communication and educational materials, including all written, graphic, electronic, audio and video pieces, general advertisements, direct mail, internet postings, broadcast advertisements and sales aids relating to the Products that have been approved by the Oversight Committee for Promotion in the Segments in the Territory (“Promotional Materials”), and shall only conduct Promotional activities for the Products, which in each case have been approved in the Marketing Plan or otherwise by the Oversight Committee and comply with the Regulatory Approvals. At substantially the same time that any Promotional Materials and any Product-related communication is sent in hard copy, electronically, by voice mail or otherwise by Abbott to its sales force, Abbott will provide OraSure with copies of all such materials. All Promotional activities conducted by the Abbott sales force shall be consistent with the Promotional Materials so approved, the then-current Marketing Plan, applicable law and the Regulatory Approvals. Unless and until Promotional Materials are approved by the Oversight Committee for publication or other general dissemination, each party shall maintain them in confidence pursuant to the terms of Article 12; provided that nothing herein shall preclude OraSure from using Promotional Materials that it develops for promotional activities and sales in the Physicians’ Office Segment or any other segment in which OraSure is permitted to Promote, distribute or sell Products.

5.6 Samples and Free Product. The parties, through the Oversight Committee, shall determine whether it is necessary and appropriate to undertake a sampling program for the Products or to otherwise make available “free Product” to customers within the Segments. If a sampling or “free Product” program is adopted within the Segments, Abbott shall be solely responsible for accounting for the Product used in such program and shall make such records available to OraSure.

5.7 Medical Inquiries. The Oversight Committee will provide Abbott with information and materials appropriate to allow its medical and sales professionals, as appropriate, to respond to those medical questions or inquiries from medical and paramedical professions relating to any Promotional Materials. Any medical questions or inquiries that do not relate to Promotional Materials will be forwarded to OraSure for the appropriate response to those questions or inquiries. Abbott will only use the materials provided by the Oversight Committee, which shall be consistent with the relevant FDA-approved Product labeling and applicable Regulatory Approvals, when answering questions and inquiries under this Section 5.7.

5.8. Trade Shows, Meetings, Symposia and Marketing Activities. It is generally agreed that Product presentations, exhibits and booths at meetings and symposia, including trade shows related to or including the Segments, will be a joint Abbott and OraSure activity under the Marketing Plan and that the costs thereof shall be borne by Abbott, except for OraSure’s out-of-pocket expenses of attending such meetings and symposia. To the extent that Abbott sponsors an exhibit or booth and intends to Promote the Products at such event, space for promoting the Products will be provided in accordance with the Marketing Plan and OraSure shall be permitted to send a representative to such exhibit or booth. To the extent not included within the

17

Marketing Plan, OraSure, at its sole expense, shall have the right to make Product presentations and have its own exhibits and booths that feature the Products, provided that any such presentations, exhibits and booths are consistent with the Marketing Plan to the extent directed at any of the Segments.

5.9 Abbott Sales Force. Abbott shall maintain a sales force in the Territory comprised of sales representatives who are adequately trained to Promote the Products in the Segments in the Territory. Nothing in this Agreement shall be construed to provide that any employees or agents of Abbott are employees or agents of OraSure or subject to OraSure’s direction and control. Abbott shall have sole authority over the terms and conditions of its employees’ and agents’ employment, and shall select, engage and discharge its employees and agents in its sole discretion. Abbott agrees that the sales of the Products in the Hospital Segment and U.S. Government Hospital Segment may constitute an element in the variable compensation of Abbott’s sales representatives for such Segments, as determined by Abbott.

5.10 OraSure Sales Force. OraSure may, at its option, maintain a sales force in order to provide Promotional and sales support for the Abbott sales force, for the purpose of Promoting and selling the Products into the Segments in the Territory. The OraSure sales force may perform those functions specifically set forth in the Marketing Plan and may include customer meetings and co-traveling with Abbott sales representatives, training and other support. OraSure may directly solicit sales in the Hospital Segment, U.S. Government Hospital Segment and Reference Lab Segment so long as such activity is coordinated with Abbott and all such sales are referred to Abbott for handling in accordance with this Agreement.

5.11 Responsibility for Expenses. Except as otherwise specifically provided herein, Abbott shall be solely responsible for all sales and Promotional expenses related to the Segments, including without limitation, expenses incurred for sales aids, training programs and materials, collateral materials, exhibits, trade shows and conventions, direct mail programs, broadcast advertisements, journal advertisements, peer influence/symposia, public relations, and sampling and “free Product”, and screening programs.

5.12 Sales Reports. Notwithstanding anything to the contrary contained in this Agreement, Abbott shall deliver to OraSure by the tenth (10^th) day of each month a general summary of Abbott Net Sales by Segment for the preceding month and by the fifteenth (15^th) day of each Quarterly Period during the Term a report in form mutually agreed by the parties, setting forth the Abbott Net Sales, broken down by Segments and geographic territory within the Territory (including solely with respect to the Hospital Segment and U.S. Government Hospital Segment the quantity of Product sold in units by region and individual customers in a manner sufficient for OraSure to allocate sales to their sales personnel.) for the preceding Quarterly Period and on a Contract Year-to-date basis.

5.13 Deadlocks. If for any reason the Oversight Committee cannot resolve any matter properly referred or presented to it, either party may refer the matter to the Senior Managers for resolution. If after discussing the matter in good faith and attempting to find a mutually satisfactory resolution to the issue, the Senior Managers fail to come to consensus within thirty (30) days of the date on which the matter is referred to the Senior Managers, either party may

18

refer the matter to the Senior Executives for resolution. If after discussing the matter in good faith and attempting to find a mutually satisfactory resolution to the issue, the Senior Executives fail to come to consensus within thirty (30) days of the date on which the matter is referred to the Senior Executives, the provisions of Section 14.13 shall apply for resolution of the matter. It is the parties’ intention to exercise diligent efforts to resolve all matters without resorting to Section 14.13, if possible.

ARTICLE 6 - QUALITY ASSURANCE.

6.1 Facility Compliance. OraSure shall maintain the Approved Facility and shall conduct all Manufacturing in compliance with all applicable laws, rules, regulations and Regulatory Approvals, including QSRs, at all times during the Term of this Agreement. OraSure shall be responsible for all costs and expenses related to the compliance of the Approved Facility with such laws, rules and regulations. OraSure shall notify Abbott at least thirty (30) days prior to any relocation of the Approved Facility. In the event a relocation of the Approved Facility has an impact on any Regulatory Approvals, OraSure shall be responsible for and bear the costs of any amendment, notification or resubmission required with respect to such Regulatory Approvals as a result of such relocation of the Approved Facility.

6.2 Quality Control. OraSure shall maintain a quality control program consistent with QSRs and other applicable laws or regulations. In addition, OraSure will test and release Products in accordance with its quality control program. Each shipment of Products from OraSure to Abbott shall be accompanied by a certificate of compliance from OraSure’s quality assurance department indicating that the Products, as sampled pursuant to OraSure’s quality control program, have passed the quality control parameters developed by OraSure. OraSure shall notify Abbott as soon as practicable after OraSure becomes aware of any material design or manufacturing problems with respect to the Products and subsequently OraSure and Abbott shall meet to discuss solutions to any such problems.

6.3 Audit Rights. Abbott shall have the right, upon thirty (30) days’ prior written notice to OraSure, to conduct during normal business hours a quality assurance audit (subject to Section 4.3) and inspection of OraSure’s records and production facilities relating to OraSure’s compliance with the terms of this Agreement, including with respect to the Manufacture of Products, and to perform follow-up audits as reasonably necessary. The duration of such audits shall not exceed three (3) days and such audits shall be performed by no more than three (3) auditors. Notwithstanding the foregoing, in no event shall Abbott be entitled to conduct more than one (1) audit in any Calendar Year, whether such audit occurs under Section 4.3 or this Section 6.3, unless significant compliance issues are discovered during such audit in which case Abbott shall be entitled to conduct reasonable follow up audits in accordance with this Section 6.3. At OraSure’s request, Abbott shall provide OraSure with a written summary of the results of any audit conducted under this Section 6.3. Notwithstanding the foregoing, Abbott shall have the right at any time during the Term of this Agreement, upon reasonable prior written notice to OraSure, to conduct any audits specifically mandated by the FDA or to respond to specific questions from the FDA, to the extent such audits relate to the Products or Manufacture thereof.

19

Visits by Abbott to OraSure’s production facilities may involve the transfer of Confidential Information, and any such Confidential Information shall be subject to the terms of Article 12 hereof. The results of such audits and any information obtained during such audits shall be considered Confidential Information of the party disclosing such Confidential Information and shall not be disclosed by the receiving party to third persons, including but not limited to the FDA, except in accordance with Article 12.

If Abbott utilizes auditors that are not employees of Abbott, each of such auditors shall execute a non-disclosure agreement, with confidentiality terms at least as stringent as those set forth herein which protect the Confidential Information of OraSure, and Abbott shall provide OraSure with written representation that such auditors have executed such non-disclosure agreement.

6.4 Recalls. In the event OraSure shall be required (or shall voluntarily decide) to initiate a recall, withdrawal or field correction of, or field alert report with respect to, the Products, whether or not such recall, withdrawal, field correction or field report has been requested or ordered by the FDA, OraSure shall notify Abbott, and Abbott shall fully cooperate with OraSure, at OraSure’s expense, to implement the same. OraSure shall make all contacts with the FDA and shall be responsible for coordinating all of the necessary activities in connection with any such recall, withdrawal, field correction or field alert report, and subject to Section 12.1 and 12.4, OraSure shall make all statements to the media, including press releases and interviews for publication or broadcast. Abbott agrees to make no statement to the media, except to refer the media to OraSure for comment, unless otherwise required by law, and in any such event, Abbott shall cooperate with OraSure and obtain OraSure’s prior approval on the content of any such statement. OraSure shall indemnify Abbott against all reasonable and necessary costs and expenses that Abbott may incur as a result of any recall, withdrawal, field correction or field alert, except to the extent it is the direct result of any fault or omission attributable to Abbott, its Affiliates or permitted subdistributors or agents. Abbott shall indemnify OraSure against all reasonable and necessary costs and expenses that OraSure may incur as a result of any recall, withdrawal, field correction or field alert to the extent that it is the direct result of any fault or omission attributable to Abbott, its Affiliates or permitted subdistributors or agents. In no event shall either party have liability to the other for lost profits.

6.5 Adverse Experience. Any adverse experience information obtained by Abbott shall be reported to OraSure, by telephone or by facsimile within three (3) business days after Abbott’s initial receipt of any such information: provided, however, any report of a serious adverse event or any report of a death shall be reported to OraSure by telephone within twenty-four (24) hours after Abbott’s receipt of the information and by facsimile within forty-eight (48) hours after Abbott’s receipt of the information. Reports under this Section 6.5 shall be sent to OraSure’s Vice President, Regulatory Affairs and Quality.

6.6 Customer Support and Complaints. OraSure shall also provide and maintain, at its own expense, adequate support services and a staff properly trained in all aspects of the Products to provide Abbott with such levels of customer service and technical support throughout the Term that are commercially reasonable in light of the then current and reasonably

20

anticipated sales volumes of the Products under this Agreement. Such customer service and technical support will be available Monday through Friday during the hours of 8 a.m. to 5 p.m. Eastern Time by dialing a toll-free telephone number established by OraSure. In the event that Abbott receives any customer complaint regarding Products covered by this Agreement, Abbott shall give OraSure written notice of the complaint as soon as practicable and in no event later than ten (10) days after Abbott’s receipt of the complaint, which notice shall include a copy of any written correspondence of the customer and Abbott and a written summary of any oral communications in respect of such complaint. OraSure shall commence the investigation and evaluation of customer complaints received on Products sold to customers by Abbott as soon as practicable but in no event later than ten (10) days after OraSure’s receipt of Abbott’s written notice of any such complaint. OraSure shall use commercially reasonable efforts to close any customer complaint evaluation and investigation as soon a practicable and, if practicable, in no event later than thirty (30) days after OraSure’s receipt of the complaint or notice of the complaint. OraSure shall handle all follow-up of and correction regarding Product complaints directly with the customer unless otherwise stated herein or otherwise agreed between the parties. At Abbott’s reasonable request, OraSure shall provide Abbott reasonable access to customer complaint evaluations and closed records relating thereto with respect to any Product sold to Abbott hereunder. Notwithstanding the foregoing, Abbott will be responsible for investigating and evaluating, and will bear all costs of evaluation, investigation and closure of, any customer complaint to the extent such complaint results from any cause or event arising from factors that are attributable solely to Abbott or its Affiliates, sub-distributors or agents (such complaint, an “Abbott Complaint”). Abbott promptly shall provide notice to OraSure of each Abbott Complaint and, at OraSure’s reasonable request, Abbott shall provide OraSure reasonable access to Abbott Complaint evaluations and closed records relating thereto. Unless otherwise agreed by the parties, Abbott shall handle all follow-up of and correction regarding Abbott Complaints directly with the applicable customers. As necessary, Abbott shall handle all follow-up and correction regarding Abbott Complaints directly with the FDA. Notwithstanding the foregoing, the parties shall cooperate in communicating with any customer concerning a complaint (including an Abbott Complaint), and both Abbott and OraSure shall be permitted to communicate with such customer (so long as it advises the other party in writing of such communication and any response from the customer) to the extent required to meet applicable legal or regulatory requirements or the requirements of this Agreement.

6.7 Retention of Samples. OraSure shall retain a sufficient quantity of each batch of the Products to allow investigation of complaints and confirmation of product shelf life. OraSure shall maintain samples of each batch of the Products in a suitable storage facility until at least six (6) months after the end of the assigned shelf life of such batch, or such longer period as may be required under applicable law, regulation or rule. All such samples shall be available for inspection by Abbott or a third party chosen by Abbott at its sole discretion, including but not limited to any Affiliate of Abbott, upon reasonable notice.

6.8 Batch Failures. OraSure shall notify Abbott as soon as practicable and in no event later than five (5) business days after discovery of any batch failure that could result in OraSure’s inability to meet Abbott’s requested delivery dates. OraSure shall notify Abbott as soon as practicable and in no event later than three (3) business days after any failure of a released batch of Products distributed to Abbott.

21

6.9 Notification of Inspections. OraSure agrees to notify Abbott of any action by the FDA in regard to the Products or OraSure’s Manufacturing activities that could materially affect OraSure’s ability to perform its obligations hereunder.

ARTICLE 7 - ORDERING AND DELIVERY.

7.1 Generally. Abbott may order units of the Products by issuing binding purchase orders (each, a “Purchase Order”) to OraSure pursuant to the terms of this Agreement. Each Purchase Order or any acknowledgment thereof, whether printed, stamped, typed, or written, shall be governed by the terms of this Agreement and none of the provisions of such Purchase Order or acknowledgment shall be applicable except those specifying quantity ordered, delivery dates, special shipping instructions and invoice information.

7.2 Acceptance or Rejection of Purchase Orders. OraSure shall indicate its acceptance or rejection of each Purchase Order within ten (10) business days after receipt; provided that OraSure may reject a Purchase Order, in whole or in part, only if: (a) the Purchase Order fails to comply with the terms and conditions of this Agreement; (b) the delivery date is less than ninety (90) days from the date of OraSure’s receipt of such Purchase Order; or (c) the volume under the Purchase Order and all other accepted Purchase Orders covering the applicable monthly period exceeds the volume set forth in Abbott’s then-current forecast (delivered pursuant to Section 7.3) by more than fifty percent (50%). If requested by Abbott, following Abbott’s receipt of OraSure’s rejection notice under clause (c) above, OraSure will use commercially reasonable efforts to deliver the excess volume of the Products specified in the rejected Purchase Order, but OraSure’s failure to so deliver the excess volume shall not be a breach of this Agreement. OraSure shall use commercially reasonable efforts to fill Abbott’s orders for the Products. In no event shall OraSure be liable to any third party for OraSure’s failure to deliver the Products to Abbott by any delivery date set forth in any Purchase Order.

7.3 Forecasts. Within thirty (30) days after the Effective Date, Abbott shall issue to OraSure Abbott’s written forecast of Abbott’s anticipated monthly requirements for the Products during the next twelve (12) calendar month period. Thereafter, Abbott shall provide to OraSure monthly a rolling twelve (12) month forecast of requirements of Products to be supplied by OraSure. The first three (3) months of such forecast shall be binding on Abbott and may not be cancelled or rescheduled without prior written agreement of OraSure. The remaining nine (9) months of such forecast shall be used by OraSure for planning purposes only and shall not be considered firm orders.

7.4 Shipment. OraSure shall ship Products FCA (Incoterms 2000) the Approved Facility. OraSure shall be deemed to have delivered the Products and title and risk of loss shall pass to Abbott at the time such Products are loaded onto a carrier designated by Abbott. Abbott shall be responsible for all shipping and insurance costs. OraSure shall ensure that the Products are suitably packed in bulk for shipment in OraSure standard containers. OraSure shall provide to Abbott, in advance of each shipment, all necessary information relating to such shipment, including without limitation, the identity of the carrier, flight number or similar information, scheduled arrival time and package identification number. All shipments under this Agreement shall be made to a single centralized shipping destination identified by Abbott in writing after the date of this Agreement, and each shipment hereunder shall contain not less than 5,000

22

OraQuick® ADVANCE^™ Devices. All Products purchased hereunder shall be purchased in OraSure’s standard type and size boxes, which for purposes of the OraQuick® ADVANCE^™ Devices shall contain either 25 or 100 OraQuick® ADVANCE^™ Devices.

7.5 Inspection by Abbott. Within thirty (30) days after receipt of the Products, Abbott shall check whether there is any shortage and whether the Products are in compliance with the warranties stated in Article 10. If Abbott finds any shortage, Abbott shall notify OraSure within thirty (30) days of receipt of the Products and Abbott’s sole remedy shall be prompt shipment by OraSure of additional Products so that Abbott receives the proper quantity. If Abbott finds any noncompliance with the warranties stated in Article 10, then Abbott shall follow the procedures indicated in Article 10.

7.6 Safety Stock. Within thirty (30) days after the first delivery of Products to Abbott, OraSure shall maintain at least a six (6) month safety stock of the critical components (including, but not limited to, antigens and nitrocellulose) for the Products, based on the most recent forecast provided by Abbott pursuant to Section 7.3. OraSure shall rotate the safety stock with each new manufacturing lot.

7.7 Failure to Supply.

7.7.1 Abbott Remedies. If, during any Contract Year, OraSure is unable for any reason to supply at least ninety percent (90%) of the quantities of Products, in accordance with the terms and conditions of this Agreement ordered by binding Purchase Order that complies with the terms of Article 7 (which quantities shall not include any excess quantities contemplated by Section 7.2 (c)), and such failure continues for at least sixty (60) days after the delivery date set forth in such Purchase Order, then Abbott may elect either of the following: (i) to adjust the Contractual Minimums specified for such Contract Year under Section 2.1.5 or (ii) to obtain a supply of a replacement rapid, point of care diagnostic test for HIV-1 and HIV-2 (a “Replacement Product”) from a third party (a “Third Party Supplier”) in an amount equal to the quantity of Product OraSure is unable to supply. Abbott shall notify OraSure in writing of its election no later than thirty (30) days after the end of the sixty (60) day period specified above, after which Abbott shall no longer be entitled to exercise any remedy in connection with such failure to supply.

7.7.2 Adjustment of Minimums. If Abbott elects to adjust the Contractual Minimums as permitted in Section 7.7.1, the Contractual Minimum for the Contract Year in which the failure to supply occurred shall equal (x) three hundred sixty five (365) (or the actual number of days in such Contract Year) minus the number of days after the applicable delivery date the failure to supply continued, multiplied by (y) the quotient of the unadjusted Contractual Minimum for such Contract Year divided by three hundred sixty five (365) (or the actual number of days in such Contract Year).

7.7.3 Third Party Supplier. If Abbott exercises its right to have a Third Party Supplier manufacture and supply a Replacement Product pursuant to Section 7.7.1 and thereafter during the Term OraSure desires to resume supplying Abbott with the Product (whether by OraSure, through another source or otherwise), then OraSure shall notify Abbott of such desire. Abbott shall then resume purchasing Product exclusively from OraSure for the remainder of the

23

Term of this Agreement as soon as OraSure demonstrates to Abbott’s reasonable satisfaction that OraSure (whether by OraSure, another source or otherwise) is capable of re-establishing a satisfactory supply of Product; provided that Abbott shall not be required to cancel any contract with a Third Party Supplier or a purchase orders for Replacement Product with a Third Party Supplier that were issued in accordance with the forecasts required by Section 7.3 to the Third Party Supplier prior to the date that OraSure gave Abbott notice of its desire to resume supply. Abbott agrees that it will not enter into any contracts with Third Party Suppliers in accordance with this Section under which Abbott cannot terminate its purchase commitments for Product within six (6) months from the date such contracts are executed. If OraSure is capable of re-establishing a supply of Product and Abbott does not resume purchasing Product exclusively from OraSure for any reason including a contractual commitment to a Third Party Supplier, then OraSure shall be permitted to directly or indirectly market, distribute and sell Products into the Hospital Segment and the U.S. Government Hospital Segment, notwithstanding Abbott’s exclusive appointment to such Segments, until Abbott resumes purchasing Product exclusively from OraSure; provided that OraSure shall redirect any customers it obtains in the Hospital Segment and U.S. Government Hospital Segment to Abbott once Abbott resumes purchasing Product exclusively from OraSure, and any sales by OraSure to such customers shall be credited against the Contractual Minimums for the Contract Year in which such sales occur. Any action by OraSure pursuant to the preceding sentence shall not constitute a waiver of OraSure’s available remedies in the event Abbott fails to resume purchasing Product exclusively from OraSure in accordance with this Section 7.7.3.

7.7.4 Nondiscrimination. In the event OraSure is unable to supply all Product ordered by Abbott hereunder (other than excess quantities of Product contemplated by Section 7.2 (c)), OraSure shall distribute available Product to Abbott on a pro-rata basis with OraSure’s other customers based upon each customer’s (including Abbott’s) aggregate purchases for the prior twelve (12) months.

ARTICLE 8 - COMPENSATION.

8.1 Transfer Price.

8.1.1 Transfer Prices. Abbott shall pay OraSure the applicable per unit Transfer Price as set forth in Exhibit _1.53 for Products ordered under this Agreement. The Transfer Price payable by Abbott hereunder may be adjusted by OraSure in accordance with Exhibit 1.50. The Transfer Prices are based on the assumption that OraSure will package individual OraQuick® ADVANCE^™ Devices and OraQuick® ADVANCE^™ Controls in its standard type and size boxes. If Abbott desires to purchase Products packaged in non-standard type or size boxes, the parties shall meet to discuss an appropriate allocation of costs and adjustments to the applicable Transfer Prices.

8.1.2 Taxes. The Transfer Prices for the Products are exclusive of all sales, use, excise, ad valorem, value added and other similar taxes (other than taxes assessed on OraSure’s income), which shall be paid solely by Abbott. Abbott shall provide OraSure with a valid resale

24

certificate for all purchases that are exempt from sales tax. In addition, Abbott shall be solely responsible for paying any import, customs and other fees or governmental charges.

8.1.3 Other Charges. OraSure reserves the right to charge Abbott a commercially reasonable fee for: (i) any change or cancellation by Abbott of an accepted Purchase Order; and (ii) any order that requires any special shipping or handling. Abbott shall be solely responsible for freight, shipping and insurance charges relating to Products purchased hereunder.

8.1.4 Payment. Abbott shall pay all amounts due under Section 8.1 of this Agreement no later than thirty (30) days after receipt of an invoice from OraSure and delivery of the quantity of Products in covered by such invoice.

8.2 Revenue-Based Amount.

8.2.1 Revenue-Based Amounts. The parties shall be obligated to pay separate revenue-based amounts in respect of each Quarterly Period based on Abbott Net Sales during such Quarterly Period to the Hospital Segment and U.S. Government Hospital Segment, on the one hand, and to the Physicians’ Office Segment and Reference Lab Segment, on the other, in accordance with this Section 8.2 (each a “Revenue-Based Amount”). At the end of each month, Abbott shall report to OraSure the number of OraQuick® ADVANCE^™ Devices sold and the Abbott Net Sales generated from such sales in each Segment and at the end of each Quarterly Period Abbott shall report to OraSure the number of OraQuick® ADVANCE^™ Devices sold in each of the Segments during such Quarterly Period, including a breakout of the number of OraQuick® ADVANCE^™ Devices sold by Segment (and with respect to the Hospital Segment and U.S. Government Hospital Segment a breakout by specific customer and region in a manner sufficient for OraSure to allocate sales to their sales personnel) and the Abbott Net Sales generated from such sales.

8.2.2 Revenue-Based Amount for Hospitals. If an amount equal to *** of Abbott Net Sales in the Hospital Segment and U.S. Government Hospital Segment for a Quarterly Period (such amount being the “Hospital Adjustment Number”) exceeds the Hospital Baseline for such Quarterly Period, then Abbott shall pay OraSure a Revenue-Based Amount equal to the excess of the Hospital Adjustment Number over the product of (a) the total number of OraQuick® ADVANCE^™ Devices sold in the Hospital Segment and U.S. Government Hospital Segment during such Quarterly Period, multiplied by (b) the Transfer Price for such Products. If, however, the Hospital Adjustment Number for the Quarterly Period is less than the Hospital Baseline for the Quarterly Period, then OraSure shall pay Abbott, in the form of a credit against amounts due to OraSure under this Agreement, an amount equal to the difference of (x) the product of the Transfer Price for the OraQuick® ADVANCE^™ Device multiplied by the total number of OraQuick® ADVANCE^™ Devices sold in the Hospital Segment during the Quarterly Period minus (y) the Hospital Baseline for the Quarterly Period.

8.2.3 Revenue-Based Amount for Physicians’ Offices and Reference Labs. In addition to the amount payable to Abbott pursuant to Section 8.2.2, if an amount equal to *** of Abbott Net Sales in the Physicians’ Office Segment and Reference Lab Segment in a Quarterly Period (such amount being the “PO/RL Adjustment Number”) exceeds the PO/RL Baseline for

25

such Quarterly Period, then Abbott shall pay OraSure a Revenue-Based Amount equal to the excess of the PO/RL Adjustment Number for such Quarterly Period over the PO/RL Baseline.

8.2.4 Change in Transfer Price. Whenever a reference is made to the Transfer Price in making a calculation required to apply this Section 8.2 and the Transfer Price changed during the month or Quarterly Period or the units sold into the Segment during the month or Quarterly Period had different Transfer Prices, the Transfer Price applicable to the units sold during the Quarterly Period shall be determined using a first in, first out methodology.

8.2.5 Reporting. Abbott shall deliver the report required under Section 8.2.1 to OraSure no later than ten (10) days after the end of each month and fifteen (15) days after the end of each Quarterly Period, which report shall include all the information specified in Section 8.2.1 and a calculation of Abbott Net Sales, the Hospital Adjustment Number, the PO/RL Adjustment Number, the Hospital Baseline, the PO/RL Baseline and the Revenue-Based Amounts for the applicable month and Quarterly Period. If a payment is due to Abbott under this Section 8.2, the payment shall be included with the report for the Quarterly Period. If an amount is due from OraSure to Abbott under Section 8.2.2, Abbott shall submit an invoice with the report for the Quarterly Period in the amount due under Section 8.2.2 to Abbott and OraSure shall issue the credit in the amount shown on the invoice no later than thirty (30) days after receipt thereof unless it disputes the invoice in good faith.

8.2.6 Records; Audit. Abbott shall keep records sufficient, in accordance with generally accepted accounting principles in the United States, to permit verification of the determinations made under this Section 8.2, the calculations of Abbott Net Sales, the Hospital Adjustment Number, the PO/RL Adjustment Number, the Hospital Baseline, the PO/RL Baseline, any Revenue-Based Amounts and any other information required by Section 8.2.1. Such records shall be maintained and made available for examination in accordance with this Section 8 for at least two (2) years after the close of the applicable Quarterly Period. Abbott shall permit such records to be examined during normal business hours by independent third party public accountants designated by OraSure and reasonably acceptable to Abbott. Such accountants shall report to OraSure only the amount by which a Revenue-Based Amount due under this Section 8.2. in respect of the audited period was overpaid or underpaid and the basis for such determination, and shall make such report simultaneously available to both OraSure and Abbott. In the event an examination of Abbott’s records reveals that a Revenue-Based Amount paid to OraSure was less than the amount required to be paid to OraSure under Section 8.2.1 in respect of the audited period, Abbott shall promptly pay the amount of such underpayment. In the event that such underpayment amounts to five percent (5%) or more of the total correct amount of the Revenue-Based Amount, Abbott shall also reimburse OraSure for all reasonable out-of-pocket costs of the examination to a maximum amount of twenty thousand dollars ($20,000.00) and Abbott shall pay to OraSure interest at a rate per annum equal to the lesser of one-half percent (0.5%) per month or such lower rate as may be required by applicable law from the date on which the Revenue-Based Amount for the audited period was due. In the event an examination of Abbott’s records reveals that a Revenue-Based Amount paid to OraSure was more than the amount required to be paid to OraSure under this Section 8.2. in respect of the audited period, OraSure shall credit the amount of the overpayment against amounts otherwise due to OraSure under this Agreement.

26

ARTICLE 9 –INTELLECTUAL PROPERTY

9.1 Branding. OraSure shall label the Products using the trademarks of both OraSure and Abbott and the trade dress of OraSure, in accordance with this Section 9.1. The individual OraQuick® ADVANCE^™ Devices, the laminated packages containing individual OraQuick® ADVANCE^™ Devices, and the individual OraQuick® ADVANCE^™ Controls shall be labeled solely with OraSure’s trademarks, trade names, logos and trade dress (the “OraSure Trademarks”) as determined by OraSure in its sole discretion. The boxes in which packages containing individual OraQuick® ADVANCE^™ Devices and OraQuick® ADVANCE^™ Controls are packaged (the “OraQuick® Boxes”) shall be labeled with the OraSure Trademarks and with Abbott’s trademarks and tradenames (the “Abbott Trademarks”) identified from time to time by Abbott. Abbott shall provide OraSure with at least sixty (60) days advance notice of the Abbott Trademarks or any changes in the Abbott Trademarks proposed by Abbott for labeling on OraQuick® Boxes. Subject to Article 5, the parties shall cooperate in the design of the labeling for OraQuick® Boxes and the final labeling design shall be subject to approval by both parties, which shall not be unreasonably withheld, conditioned or delayed. Abbott shall reimburse OraSure for OraSure's actual out-of-pocket costs of making any label changes on the OraQuick® Boxes resulting from Abbott’s modifications to the Abbott Trademarks proposed for such labeling; provided, however, that in no event shall Abbott be required to reimburse OraSure for more than three (3) months production requirements, as set forth in Abbott’s most recent forecast provided pursuant to Section 7.3, for such labels, unless purchase of such excess items had previously been authorized in writing by Abbott. Abbott hereby consents to OraSure’s use of the Abbott Trademarks on labeling for the OraQuick® Boxes in accordance with this Section 9.1. The pricing set forth in this Agreement for Products assumes that the same label and packaging, including OraSure’s standard type and size boxes, will be used for all Products supplied to Abbott under this Agreement and if this assumption is proved incorrect, the parties shall meet to discuss a reasonable allocation of costs.

9.2 Promotional Materials. OraSure hereby consents to the use by Abbott of the OraSure Trademarks on promotional materials for the purpose of promoting, marketing and selling the Products in the Segments in the Territory. No promotional materials bearing the OraSure Trademarks may be used without OraSure’s prior written approval, which shall not be unreasonably withheld, conditioned or delayed by more than fourteen (14) days after receipt of Abbott’s request for approval.

9.3 No Other Rights; Allocation of Goodwill. Except for the rights herein, neither party shall acquire any right, title, or interest in any trademark, trade name, logo or trade dress, copyright, patent, or any other intellectual property rights of the other party by reason of this Agreement. Abbott acknowledges and agrees that all use of any of the OraSure Trademarks and all of the goodwill associated therewith shall inure solely to OraSure’s benefit. OraSure acknowledges and agrees that all use of any of the Abbott Trademarks and all of the goodwill associated therewith shall inure solely to Abbott’s benefit.

27

9.4 Effect of Termination. Upon termination of this Agreement both parties shall immediately cease all use of the other party’s trademarks, trade names, logos and trade dress, except such use as is necessary to complete Manufacturing and sale of Products under open Purchase Orders at the time of termination or to sell off inventory as permitted under Section 13.3.3.

ARTICLE 10 –PRODUCT WARRANTIES.

10.1 Limited Product Warranty.

10.1.1 Limited Warranty for OraQuick® ADVANCE^™ Devices. OraSure warrants to Abbott that: (a) each OraQuick® ADVANCE^™ Device, when delivered, will conform to the specifications set forth in the OraQuick® ADVANCE^™ Device Specifications for the OraQuick® ADVANCE^™ Device; and (b) each OraQuick® ADVANCE^™ Device shall be free from defects in materials, workmanship, packaging or labeling for a period equal to its stated shelf life (the “OraQuick® ADVANCE^™ Device Warranty Period”).

10.1.2 Limited Warranty for OraQuick® ADVANCE^™ Controls. OraSure warrants to Abbott that: (a) each OraQuick® ADVANCE^™ Control, when delivered, will conform to the specifications set forth in the OraQuick® ADVANCE^™ Control Specifications for the OraQuick® ADVANCE^™ Control; and (b) each OraQuick® ADVANCE^™ Control shall be free from defects in materials, workmanship, packaging or labeling for a period equal to its stated shelf life (the “OraQuick® ADVANCE^™ Control Warranty Period”).

10.2 OraSure Disclaimer. THE EXPRESS LIMITED WARRANTIES FOR ORAQUICK® ADVANCE^™ DEVICES AND ORAQUICK® ADVANCE^™ CONTROLS SET FORTH IN SECTION 10.1 AND THE ADDITIONAL REPRESENTATIONS AND WARRANTIES SET FORTH IN SECTION 11.1 AND SECTION 14.16 ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES, WHETHER EXPRESS OR IMPLIED. ORASURE HEREBY DISCLAIMS ANY AND ALL OTHER REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESSED OR IMPLIED, WHETHER ARISING FROM A COURSE OF DEALING OR USAGE OF TRADE, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT.

10.3 Warranty Claim Procedure. Unless otherwise agreed by OraSure, to make a warranty claim, Abbott shall at Abbott’s expense return the allegedly defective Products, or a representative sample thereof, together with a description of the alleged defect. OraSure shall, promptly after receipt and as required, inspect the alleged defective Products. If such inspection results reasonably confirm that the Products do not conform with the applicable warranty set forth in Section 10.1 and the non-conformance did not arise from misuse, mishandling, storage in a manner inconsistent with labeling, neglect, modification or unusual physical or chemical stress after delivery to the carrier, Abbott shall return any remaining Products in Abbott’s inventory with the same defect at OraSure’s expense, and the sole and exclusive warranty remedies set forth in Section 10.4 shall apply. If such test results fail to confirm the Products’ non-conformance to the applicable warranty set forth in Section 10.1, or if the parties fail to

28

otherwise resolve the dispute, the parties shall submit the affected Products, or a representative sample thereof, along with a reference batch which has previously been shown by Abbott to conform to the applicable warranty set forth in Section 10.1, to a mutually acceptable independent laboratory along with the inspection protocols described in the specifications and mutually agreeable interrogatories to be answered by such laboratory. The determination of the affected Products’ conformance or non-conformance to the applicable warranty set forth in Section 10.1 shall be binding upon the parties. If the laboratory determines that the Products conform to the applicable warranty set forth in Section 10.1, Abbott shall pay all independent laboratory and shipping costs incurred by OraSure, and if such laboratory confirms that the Products do not conform with the applicable warranty set forth in Section 10.1, OraSure shall pay all independent laboratory and shipping costs incurred by Abbott and the sole and the exclusive warranty remedies set forth in Section 10.4 shall apply.

10.4 Abbott’s Warranty Remedies. During the OraQuick® ADVANCE^™ Device Warranty Period and OraQuick® ADVANCE^™ Control Warranty Period, as the case may be, OraSure shall replace, at OraSure’s expense, or at Abbott’s option, refund or credit the purchase price of, any Product that does not comply with the applicable limited warranty set forth in Section 10.1. OraSure’s obligation to replace defective Products or to refund or credit the purchase price paid for such Products pursuant to this Section 10.4 shall not apply to any Products that have been subjected to misuse, mishandling, storage in a manner inconsistent with labeling, neglect, modification or unusual physical or chemical stress after delivery to the carrier. Other than as specifically provided in Sections 6.4 and 11.3.2, this Section 10.4 states Abbott’s sole and exclusive remedy for failure of any Product to comply with the applicable limited warranty set forth in Section 10.1.

10.5 Product Shelf Life. OraSure will use commercially reasonable efforts to supply Abbott with Products that have a remaining shelf life of at least *** from the time of delivery. If OraSure is unable to supply Products with at least such remaining shelf life, OraSure shall notify Abbott of that fact and the parties shall cooperate to facilitate the distribution of the affected Product in accordance with this Agreement. If the parties are unable, after exercising good faith efforts, to complete the distribution of the affected Products by Abbott, Abbott’s sole remedy shall be to adjust the Contractual Minimums, in which case the Contractual Minimum for the Contract Year in which OraSure’s inability occurs shall equal (i) three hundred sixty-five (365) days (or the actual number of days in such Contract Year) minus the number of days after the applicable delivery date during which OraSure’s inability to supply continued, multiplied by (ii) the quotient of the unadjusted Contract Minimum for such Contract Year divided by three hundred sixty-five (365) days (or the actual number of days in such Contract Year.)

ARTICLE 11 - -REPRESENTATIONS AND ADDITIONAL WARRANTIES AND INDEMNIFICATION.

11.1 By OraSure. OraSure represents and warrants to Abbott that: (a) OraSure has full corporate power and authority to enter into and carry out its obligations under this Agreement; (b) this Agreement has been duly executed and delivered by OraSure and constitutes the legal, valid and binding obligation of OraSure enforceable against it in accordance with its

29

terms; (c) the execution, delivery and performance of this Agreement will not conflict with, are not inconsistent with and will not result in any breach of any terms, conditions or provisions of, or constitute (with due notice or lapse of time, or both) a default under any agreement, contract, document or instrument to which OraSure is a party or by which it is otherwise bound; (d) no authorization, consent, approval or similar action of or by any third party is required for or in connection with OraSure’s authorization, execution, delivery or performance of this Agreement; and (e) there are no suits, claims or proceedings pending or (to OraSure’s knowledge) threatened against OraSure or any of its Affiliates in any court or by or before any governmental body or agency with respect to intellectual property incorporated in or used in the development and/or Manufacture of the Products.

11.2 By Abbott. Abbott represents and warrants to OraSure that: (a) Abbott has full corporate power and authority to enter into and carry out its obligations under this Agreement; (b) this Agreement has been duly executed and delivered by Abbott and constitutes the legal, valid and binding obligation of Abbott enforceable against it in accordance with its terms; (c) the execution, delivery and performance of this Agreement will not conflict with, are not inconsistent with and will not result in any breach of any terms, conditions or provisions of, or constitute (with due notice or lapse of time, or both) a default under any agreement, contract, document or instrument to which Abbott is a party or by which it is otherwise bound; and (d) no authorization, consent, approval or similar action of or by any third party is required for or in connection with Abbott’s authorization, execution, delivery or performance of this Agreement.

11.3 Indemnification.

11.3.1 By Abbott. Abbott shall indemnify, defend and hold harmless OraSure, its Affiliates, and the respective directors, officers, employees, agents and representatives of each of the foregoing from and against any and all claims, suits and proceedings by a Person (other than a party to this Agreement or its Affiliates) (individually and collectively, “Claims”), and any and all losses, obligations, damages, deficiencies, costs, penalties, liabilities, assessments, judgments, amounts paid in settlement, fines, and expenses (including court costs and reasonable fees and expenses of attorneys) in respect of any Claims (individually and collectively, “Losses”): (a) arising out of the negligence or willful misconduct of Abbott or its Affiliates, employees, agents or any other person for whose actions Abbott is legally liable; (b) arising out of or in connection with a material breach by Abbott of any of its obligations under this Agreement including any representations or warranties set forth in Sections 11.2 or 14.16; or (c) arising out of any claim that any of the Abbott Trademarks constitutes an infringement or dilution of a third party’s trademark rights in the Territory; provided, however, that Abbott shall have no liability to OraSure for any Claims or Losses to the extent that such Claims or Losses resulted from or arose out of: (i) the negligence or willful misconduct of OraSure or its Affiliates, employees, agents or any person for whose actions OraSure is legally liable; (ii) a material breach by OraSure of any of its obligations under this Agreement including any representations or warranties set forth in Article 10, Section 11.1, Section 12.2 or Section 14.16; or (iii) any occurrence for which OraSure has liability to Abbott pursuant to Section 11.3.2.

11.3.2 By OraSure. OraSure shall indemnify, defend and hold harmless Abbott, its Affiliates, and the respective directors, officers, employees, agents and representatives of each of the foregoing from and against any and all Claims and Losses: (a) related to bodily injury,

30

death and property damage caused by the OraQuick® ADVANCE^™ Device; (b) arising out of the negligence or willful misconduct of OraSure or its Affiliates, employees, agents or any other person for whose actions OraSure is legally liable; (c) arising out of a material breach by OraSure of any of its obligations under this Agreement including any representations or warranties set forth in Sections 11.1, 12.2 or 14.16; (d) arising out of any claim that any of the OraSure Trademarks constitutes an infringement or dilution of a third party’s trademark rights in the Territory; or (e) arising out of a claim that any of the Manufacture, marketing, import, sale or use of the Products infringes upon any patent rights (except patents under which Abbott has a non-royalty right to practice); provided, however, that OraSure shall have no liability to Abbott for any Claims or Losses to the extent that such Claims or Losses resulted from or arose out of: (i) the negligence or willful misconduct of Abbott or its Affiliates, subdistributors, employees, agents or any person for whose actions Abbott is legally liable; (ii) a material breach by Abbott of any of its obligations under this Agreement including any representations or warranties set forth in Section 11.2, Section 12.2 or Section 14.16; or (iii) any occurrence for which Abbott has liability to OraSure pursuant to Section 11.3.1.

11.3.3 Indemnification Procedures. When seeking indemnification under this Agreement, the party seeking indemnification must, as a condition of indemnification, provide the indemnifying party with: (i) prompt notice of the reported or alleged Claim and Loss; (ii) the opportunity to investigate such Claim, control the defense of such Claim, and settle such Claim at its discretion; (iii) all information obtained by the party seeking indemnification relating to the Claim and Loss; and (iv) such additional information and assistance as the indemnifying party may reasonably require to defend or settle such Claim. The indemnifying party shall have the option to assume the other party’s defense in any such Claim with counsel reasonably satisfactory to the other party. No settlement or compromise shall be binding on a party hereto without its prior written consent, which consent shall not be unreasonably withheld.

11.4 Additional Rights for Claims of Infringement. Without limitation of any of the rights and obligations of OraSure and Abbott under Section 11.3 of this Agreement, if a third party asserts or threatens any claim, suit or action asserting that any of the Manufacture, marketing, import, sale or use of the Products infringes upon any patent rights (except patents under which Abbott has a non-royalty right to practice), then OraSure may, at its option (i) procure for Abbott a license to continue selling and distributing the infringing Product, (ii) modify such Product to make it non-infringing, (iii) make an appropriate adjustment to the applicable Transfer Price, acceptable to Abbott, for the infringing Product hereunder to reflect any additional royalties that might become payable by Abbott to such third party, or (iv) if none of the foregoing is commercially practicable, terminate this Agreement in accordance with Section 13.2.4.

ARTICLE 12 -CONFIDENTIALITY AND NON-USE OF INFORMATION.

12.1 Non-Disclosure. Each party will, for the Term of this Agreement and for a period of five (5) years thereafter, (i) keep confidential and not disclose to others, all Confidential Information of the other party, and (ii) not use any of the other party’s Confidential Information for its own direct or indirect benefit, or the direct or indirect benefit of any third party, except

31

that each of Abbott and OraSure may use the other party’s Confidential Information to the extent necessary to perform its duties and obligations, or to enforce such party’s rights, under this Agreement. The foregoing shall not prohibit disclosures: (x) made to the receiving party’s employees, agents or permitted subdistributors who have a “need to know” the other party’s Confidential Information to the extent such disclosure is necessary to perform such party’s duties and obligations, or to enforce such party’s rights, under this Agreement, provided that such sub-distributors, employees or agents agree in writing or are otherwise compelled to comply with the obligations of this Article 12; or (y) compelled to be made by any requirement of law or pursuant to any legal, regulatory or investigative proceeding before any court, or governmental or regulatory authority, agency or commission so long as the party so compelled to make disclosure of Confidential Information of the other party provides prior written notice to such other party so that the other party may seek a protective order or other remedy to protect the confidentiality of the Confidential Information and/or waive the compelled party’s compliance with this Article 11. If such protective order, other remedy or waiver is not obtained by the time the compelled party is required to comply, the compelled party may furnish only that portion of the Confidential Information of the other party that it is legally compelled to disclose and shall request, at the other party’s expense, that such Confidential Information be accorded confidential treatment (if such procedure is available). In the event that a party must disclose the other party’s Confidential Information or the terms of this Agreement pursuant to requirements of the Securities and Exchange Commission (“SEC”), in addition to the other requirements under this Section 12.1, the disclosing party shall pursue confidential treatment of such Confidential Information and, consistent with the rules and practices of the SEC, any competitively sensitive information contained in this Agreement, and the non-disclosing party shall cooperate with the disclosing party in preparing the disclosure and any request for confidential treatment.

12.2 Employees. Each party represents to the other that its employees, sub-distributors, agents and contractors are or will be governed by company regulations or agreements, which prohibit the disclosure of confidential and proprietary information, which may belong to the other party, and that such internal regulations and agreements will enable it to comply with all of the items of this Article 12.

12.3 Remedies. Any breach of the restrictions contained in this Article 12 by either Abbott or OraSure is a breach of this Agreement that may cause irreparable harm to the other party entitling such other party to injunctive relief in addition to all other legal remedies.

12.4 Publicity. Neither party shall use the name of the other party in any publicity, advertising or in any written, verbal or any other form of public disclosure (except as required by applicable law or regulation including any requirements of the SEC) without the express written consent of the other party, which consent shall not be unreasonably conditioned, withheld or delayed. Notwithstanding the foregoing, OraSure and Abbott acknowledge that they are reviewing a draft press release disclosing the fact that this Agreement has been executed and the general nature of the matters covered hereby, and agree that they will use their best efforts to complete the release so that OraSure may issue the release within four (4) business days after the Effective Date.

32

ARTICLE 13 -TERM AND TERMINATION.

13.1 Term.

13.1.1 Initial Term and Renewals. The term of this Agreement shall begin on the Effective Date and, subject to earlier termination pursuant to Section 13.2 or as otherwise set forth herein, terminate upon the last day of the third Contract Year (the “Initial Term”). Thereafter, subject to Section 13.1.2 and the last sentence of this Section 13.1.1, this Agreement shall automatically renew for successive periods of one (1) Contract Year each (each, a “Renewal Term,” and together with the Initial Term, the “Term”) unless this Agreement is otherwise terminated earlier pursuant to the terms hereof. Notwithstanding anything to the contrary in this Section 13.1.1 or 13.1.2, if Abbott has failed to meet the Contractual Minimums in any Contract Year ending on or prior to the end of the Initial Term or any Renewal Term, then this Agreement shall not automatically renew at the end of the Initial Term or Renewal Term, as the case may be.

13.1.2. Conditions to Renewal. The provisions of this Section 13.1.2 shall only apply if Abbott meets the Contractual Minimums for all Contract Years. At least one-hundred eighty (180) days prior to the end of the Initial Term and each Renewal Term (if any), Abbott and OraSure shall meet to discuss the new Contractual Minimum for the next succeeding Renewal Term; provided that any agreement on a new Contractual Minimum shall be at each party’s sole discretion. If the parties reach agreement on the new Contractual Minimum at least one-hundred twenty (120) days prior to the commencement of the next succeeding Renewal Term, and provided Abbott has met the Contractual Minimums for all Contract Years (including the Contract Year in which the parties met to discuss the new Contractual Minimum), this Agreement shall automatically renew for such Renewal Term and the Contractual Minimum agreed to by the parties shall be the Contractual Minimum for such Renewal Term under Section 2.1.5. If the parties fail to agree on a new Contractual Minimum within the time frame set forth above, the Agreement shall not automatically renew without the further agreement of both parties. In the event that the Agreement does not renew because the parties fail to agree to a new Contractual Minimum, Abbott shall, notwithstanding the foregoing and subject to the last sentence of this Section 13.1.2, have the right to renew this Agreement for an additional Renewal Term with a Contractual Minimum equal to *** of the greater of (i) the Contractual Minimum for the last Contract Year prior to renewal and (ii) the number of OraQuick® ADVANCE^™ Devices actually sold to Abbott under this Agreement during the last Contract Year prior to renewal. At the end of each Renewal Term, this Agreement shall terminate or renew in accordance with Sections 13.1.1 and 13.1.2. Notwithstanding the foregoing, if OraSure desires to have Abbott discontinue distributing the Products after Abbott has exercised its right to renew as provided above, Abbott shall not be permitted to renew and this Agreement shall terminate, in which case, OraSure shall pay to Abbott a royalty in quarterly installments over *** commencing immediately after termination of this Agreement equal to *** of the Abbott Net Sales for the last Contract Year prior to termination of this Agreement. In the event that this Agreement is renewed for one or more Renewal Terms, OraSure shall also pay to Abbott an additional royalty in quarterly installments over the *** after termination of the Agreement equal to *** of the Abbott Net Sales for the last Contract Year prior to termination of this Agreement.

33

13.2 Termination.

13.2.1 Termination for Breach. Either party may terminate this Agreement by giving written notice to the other party (a) upon the bankruptcy of or commencement of a voluntary or involuntary insolvency involving the other party, which notice shall be effective immediately; or (b) upon the breach of any representation, warranty, or covenant or any other material provision of this Agreement by the other party, in which case termination shall be effective thirty (30) days after delivery of such notice unless the breach is cured within such thirty (30) days.

13.2.2 Competing Product. If, during the Term, Abbott shall fail to comply with Section 3.2, then OraSure shall have the right to terminate this Agreement immediately by giving written notice thereof to Abbott.

13.2.3 Quality Audit. Subject to the last sentence of Section 4.4, Abbott and OraSure shall each have the right to immediately terminate this Agreement upon written notice to the other if (i) the Approved Facility fails to pass an Abbott supplier quality audit conducted in accordance with the provisions of Section 4.3 and OraSure either elects not to or fails to remedy the reasons for such failure within sixty (60) days following written notice by Abbott of such failure or (ii) the parties are unable to agree on the appropriate scope of a quality audit of an Approved Facility and such failure continues for a period of at least sixty (60) days.

13.2.4 Claims of Infringement. Without limitation of any of the rights and obligations of OraSure and Abbott under Articles 10 and 11 and Section 14.13.2 of this Agreement, if a third party asserts or threatens any claim, suit or action asserting that any of the Manufacture, marketing, import, sale or use of any of the Products infringes upon any patent rights (except patents under which Abbott has a non-royalty right to practice), then either party may, if a commercially reasonable alternative is not feasible, immediately terminate this Agreement upon written notice to the other party.

13.2.5 Force Majeure. In accordance with Section 14.3, a party shall have the right to immediately terminate this Agreement upon written notice to the other if an event of force majeure prohibits the other party’s performance under this Agreement for a period of at least ninety (90) consecutive days.

13.2.6 Termination of Sublicense. OraSure shall have the right to terminate this Agreement upon thirty (30) days prior written notice to Abbott in the event that the Sublicense Agreement, dated as of June 14, 2002 and providing for the license to OraSure by Abbott of certain intellectual property owned by or licensed to Abbott with respect to the Products (the “Sublicense”), between the parties is terminated as a result of a “Change in Control” (as defined in the Sublicense) of OraSure.

13.2.7 Termination Because of Debarment, Etc. In the event that either party is or becomes a Debarred Entity, Excluded Entity or Convicted Entity, then the other party shall have the right to terminate this Agreement immediately upon written notice to the affected party.

34

13.3 Effect of Termination.

13.3.1 Subsisting Obligations. Termination or expiration of this Agreement shall not relieve the parties of any obligation arising prior to the effective date of such termination or expiration and shall not constitute a waiver of any right of the parties under this Agreement as a result of breach or default.

13.3.2 Return of Confidential Information. Upon expiration of this Agreement or its termination by either party, each party, as the other may direct, shall destroy or return to the other promptly all tangible materials provided to it by the other that embody the other’s Confidential Information and shall erase or delete all such Confidential Information embodied in any magnetic, optical or similar medium or stored or maintained on any information storage or retrieval device. Notwithstanding the foregoing, and subject to the provisions set forth in Article 12 of this Agreement, each party may retain one (1) copy of such materials for archival purposes.

13.3.3 Inventory. Following expiration of this Agreement or its lawful termination by either party, Abbott and its permitted subdistributors and agents shall be entitled to continue to sell their existing inventory of the Products in the Segments solely for a period equal to the remaining shelf life for each such Product.

13.3.4 Purchase of Labeling. Following expiration or termination of this Agreement, Abbott shall purchase from OraSure up to three (3) months inventory of any unused labels or OraQuick® Boxes with labels containing any Abbott Trademarks which are then held by OraSure or are in process at any vendor of OraSure, to the extent that such inventory level is consistent with Abbott’s most recent forecast provided under Section 7.3. Such labels shall be purchased by Abbott at OraSure’s fully loaded cost, as evidenced by OraSure’s accounting records prepared in accordance with generally accepted accounting principles as applied in OraSure’s publicly filed financial statements. Payment shall be made by Abbott no later than thirty (30) days after termination or expiration.

13.3.5 Survival. The rights and obligations of the respective parties pursuant to Article 1 (Definitions), Section 6.4 (Recalls), Section 6.5 (Adverse Experience), Section 6.7 (Retention of Samples), Section 8.1 (Transfer Price), Section 8.2 (Payment), Article 9 (Intellectual Property), Article 10 (Product Warranties), Article 11 (Representations and Additional Warranties and Indemnification), Article 12 (Confidentiality and Non-Use of Information), Article 13 (Term and Termination) and Article 14 (General Provisions) shall survive the termination or expiration of this Agreement and shall bind the parties and their legal representatives, successors and permitted assigns. Any other provisions of this Agreement contemplated by their terms to pertain to a period of time following termination or expiration of this Agreement shall survive.

ARTICLE 14 - GENERAL PROVISIONS.

14.1 Currency. All amounts payable under this Agreement shall be paid in U.S. dollars, unless otherwise agreed in writing.

35

14.2 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of laws principles.

14.3 Force Majeure. Notwithstanding anything to the contrary set forth herein, neither party shall be liable in damages, nor shall either party have the right to terminate this Agreement for any delay or default in performing any obligation hereunder, if such delay or default is caused by conditions beyond the reasonable control of the relevant party, including but not limited to, acts of God, new governmental restrictions or regulations, wars or insurrections, terrorism, strikes, fire, floods, work-stoppages, lack of materials, unforeseen occurrences or other occurrences beyond the reasonable control of the affected party; provided, however, that the party so affected shall employ reasonable actions to avoid or to remove such cause of non-performance, and shall continue performance under this Agreement with the utmost dispatch whenever the relevant cause is abated; and further provided that if a party is unable to fulfill any relevant obligation under this Agreement due to any such cause, and this situation continues for a period of ninety (90) consecutive days, then the other party hereto shall have the right to terminate this Agreement immediately upon written notice.

14.4 Assignment. Neither party shall assign this Agreement nor any part thereof without the prior written consent of the other party; provided, however: (i) either party may assign this Agreement, in whole or in part, to any of its Affiliates without such consent; and (ii) either party, without such consent, may assign this Agreement in connection with the transfer or sale of substantially all of its business to which this Agreement pertains or in the event of its merger or consolidation with another company. Any permitted assignee shall assume all obligations of its assignor under this Agreement. No assignment shall relieve any party of responsibility for the performance of any accrued obligation that such party then has hereunder.

14.5 Limitation of Liability. EXCEPT IN RESPECT OF EITHER PARTY’S INDEMNIFICATION OBLIGATIONS FOR THIRD PARTY CLAIMS UNDER SECTION 6.4 AND ARTICLE 11, NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY. THIS LIMITATION WILL APPLY EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

14.6 No Third Party Beneficiaries. Abbott and OraSure intend that only Abbott and OraSure and their permitted assignees will benefit from, and are entitled to enforce the provisions of, this Agreement. No third party beneficiary is intended under this Agreement.

14.7 Modifications; Waiver. No modification to this Agreement shall be effective unless such modification is in a writing signed by a duly authorized representative of each of Abbott and OraSure. No waiver of any rights or breach or default under this Agreement shall be effective unless assented to in writing by the party to be charged with such waiver. The waiver of any breach or default shall not constitute a waiver of any other right, breach or default hereunder or any subsequent breach or default.

14.8 Notices. Any notices under this Agreement shall be given in writing at the address of each party set forth below, or to such other address as either party may substitute by written notice to the other in the manner contemplated in this Section 14.8, and shall be deemed

36

given (a) when personally delivered; (b) if sent by recognized overnight courier service, on the next business day after deposit with such courier, properly addressed and fee prepaid; (c) if sent by U.S. certified mail, return receipt requested, on the fourth (4th) business day after deposit in the U.S. mail, properly addressed and postage prepaid; or (d) if sent by facsimile, upon and after the receipt of a machine-generated report corresponding to the notice given evidencing the proper facsimile number of the receiving party and successful transmission of all pages, provided a copy of such notice is also sent by regular first-class U.S. mail. All notices shall be sent to the attention of respective parties as follows:

To Abbott:	Copy to:
Director, Global Licensing	Divisional Vice President
Abbott Diagnostics Division, D9RK AP6C	Domestic Legal, D322 AP6D
Abbott Laboratories	Abbott Laboratories
100 Abbott Park Road	100 Abbott Park Road
Abbott Park, IL 60064-6094	Abbott Park, IL 60064-6049
Fax: (847) 937-6951	Fax: (847) 938-1206
To OraSure:	Copy to:
Chief Executive Officer	Senior Vice President
OraSure Technologies, Inc.	and General Counsel
220 East First Street	OraSure Technologies, Inc.
Bethlehem, PA 18015	220 East First Street
Fax: 610-882-2275	Bethlehem, PA 18015
	Fax: 610-882-2275

14.9 Descriptive Headings. The headings of the several sections of this Agreement are intended for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

14.10 Severability. If any term or provision of this Agreement shall for any reason be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be invalid, illegal or unenforceable, had never been contained herein.

14.11 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. A facsimile transmission of a signed original shall have the same effect as delivery of the signed original.

14.12 Expenses. Except as otherwise expressly set forth in this Agreement, Abbott and OraSure shall bear their own respective expenses incident to the preparation, negotiation, and execution of this Agreement and to the performance of their respective obligations under this Agreement.

37

14.13 Dispute Resolution.

14.13.1 Alternative Dispute Resolution. Subject to Sections 5.2.3, 5.13, 10.3, 14.13.2 and 14.13.3, any dispute in connection with this Agreement shall be settled by final and binding alternative dispute resolution conducted under the auspices of, and in accordance with, the provisions set forth in Exhibit 14.13.1.

14.13.2 Indemnification for Patent Infringement Claims. Any dispute arising in respect of or related to indemnification obligations under Article 11 for any third party claim, suit or action asserting an infringement of such third party’s patent rights shall be subject to litigation in any court of competent jurisdiction.

14.13.3 Right to Seek Injunctive Relief Preserved. Nothing in the Agreement shall be construed as limiting or precluding either party from bringing any action in any court of competent jurisdiction for injunctive or other equitable relief as such party deems necessary or appropriate to compel the other party to comply with its obligations under Article 12.

14.14 Relationship of the Parties. The relationship of the parties under this Agreement is that of independent contractors. Nothing contained herein is intended or is to be construed so as to constitute the parties as partners or joint venturers or either party as an agent or employee of the other. Neither party has the express or implied right under this Agreement to assume or create any obligation on behalf of or in the name of the other, or to bind the other party to any contract, agreement or undertaking with any third party.

14.15 Entire Agreement. This Agreement constitutes the entire and exclusive agreement and understanding between Abbott and OraSure with respect to the subject matter of this Agreement, and supersedes and cancels all previous negotiations, agreements, and commitments, whether oral or in writing, in respect to the subject matter of this Agreement; provided, however, that the Sublicense (as defined in Section 13.2.6) which provides for the license to OraSure by Abbott of certain intellectual property owned by or licensed to Abbott shall not be deemed to have been superseded or cancelled and shall continue in accordance with its terms.

14.16 Debarment. Each party warrants and represents to the other that it has never been, and is not currently, a Debarred Entity, Excluded Entity or Convicted Entity. Each party further agrees to notify the other as soon as possible if it becomes a Debarred Entity, Excluded Entity or Convicted Entity, or if any Person, performing or rendering services or assistance on its behalf related to this Agreement, is or becomes a Debarred Individual, Debarred Entity, Excluded Individual, Excluded Entity, Convicted Individual or Convicted Entity

14.16.1 A “Debarred Individual” is an individual who has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from providing services in any capacity to a person that has an approved or pending drug product application, or an employer, employee or partner of a Debarred Individual.

14.16.2 “Debarred Entity” is a corporation, partnership or association that has been debarred by the FDA pursuant to 21 U.S.C. §335a (a) or (b) from submitting or assisting in

38

the submission of any abbreviated drug application, or an employee, partner, shareholder, member, subsidiary or affiliate of a Debarred Entity.

14.16.3 An “Excluded Individual” or “Excluded Entity” is (i) an individual or entity, as applicable, who has been excluded, debarred, suspended or is otherwise ineligible to participate in federal health care programs such as Medicare or Medicaid by the Office of the Inspector General (OIG/HHS) of the U.S. Department of Health and Human Services, or (ii) is an individual or entity, as applicable, who has been excluded debarred, suspended or is otherwise ineligible to participate in federal procurement and non-procurement programs, including those produced by the GSA.

14.16.4 A “Convicted Individual” or “Convicted Entity” is an individual or entity, as applicable, who has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. §1320a – 7(a), but has not yet been excluded, debarred, suspended or otherwise declared ineligible.

14.16.5 In the event any Person performing or rendering services or assistance related to this Agreement on behalf of a party is or becomes a Debarred Individual, Debarred Entity, Excluded Individual, Excluded Entity, Convicted Individual or Convicted Entity, then the affected party shall immediately cause such Person to cease any services or assistance relating to the activities undertaken by such party under this Agreement. In the event either party is or becomes a Debarred Entity, Excluded Entity or Convicted Entity, then the other party shall have the right to terminate this Agreement pursuant to Section 13.2.7.

[THE REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK.]

39

IN WITNESS WHEREOF, the undersigned duly authorized officers of OraSure and Abbott, respectively, hereby execute this Agreement on the date first above written on behalf of OraSure and Abbott, respectively.

ORASURE TECHNOLOGIES, INC.
By:	/s/ Douglas A. Michels
Print Name:	Douglas A. Michels
Title:	President & CEO
ABBOTT LABORATORIES
By:	/s/ Joseph M. Nemmers, Jr.
Print Name:	Joseph M. Nemmers, Jr.
Title:	Sr. Vice President, Diagnostic Operations President, Diagnostics Division

40

Exhibits

No.	Title
1.53	Transfer Prices
14.13.1	Alternative Dispute Resolution

41

EXHIBIT 1.53

TRANSFER PRICE; PRICE ADJUSTMENTS

1. Transfer Price – OraQuick® ADVANCE^™ Device. Subject to Section 3, below, Abbott shall pay OraSure a Transfer Price of *** for each OraQuick® ADVANCE^™ Device purchased or supplied to Distributor under the Agreement.

2. Transfer Price – OraQuick® ADVANCE^™ Controls. Subject to Section 3, below, Abbott shall pay OraSure a Transfer Price for the OraQuick® ADVANCE^™ Controls of *** per kit, which shall contain one (1) negative control, one (1) HIV-1 positive control and one HIV-2 vial.

3. Price Adjustments. (a) OraSure may increase the Transfer Prices for the first Renewal Term (if any) and each subsequent Renewal Term (if any) by giving notice of the new Transfer Price thirty (30) days prior to the beginning of the applicable Renewal Term. The Transfer Price increase for the first Renewal Term shall not exceed the aggregate percentage increase in the Producer Price Index for Standard Industrial Code 2835, as reported by the Bureau of Labor Statistics of the United States Department of Labor (“PPI”), during the most recently completed thirty six (36) consecutive month period for which PPI data (final or preliminary) is available. The Transfer Price increase for each subsequent Renewal Term shall not exceed the aggregate percentage increase in the PPI during the most recently completed twelve (12) consecutive month period for which PPI data (final or preliminary) is available.

(b) If there has been a decrease in the PPI as provided below, Abbott may decrease the Transfer Prices for the first Renewal Term (if any) and each subsequent Renewal Term (if any) by giving notice of the new Transfer Price thirty (30) days prior to the beginning of the applicable Renewal Term. The Transfer Price decrease for the first Renewal Term shall not exceed the aggregate percentage decrease in the PPI during the most recently completed thirty six (36) consecutive month period for which PPI data (final or preliminary) is available. The Transfer Price decrease for each subsequent Renewal Term shall not exceed the aggregate percentage decrease in the PPI during the most recently completed twelve (12) consecutive month period for which PPI data (final or preliminary) is available.

42

EXHIBIT 14.13.1

ALTERNATE DISPUTE RESOLUTION (ADR)

The parties recognize that bona fide disputes as to certain matters may arise from time to time during the term of this Agreement which relate to either party’s rights and/or obligations. To have such a dispute resolved by this Alternative Dispute Resolution (“ADR”) provision, a party first must send written notice of the dispute to the other party for attempted resolution by good faith negotiations between their respective presidents (or their designees) of the affected subsidiaries, divisions, or business units within twenty-eight (28) days after such notice is received (all references to “days” in this ADR provision are to calendar days).

If the matter has not been resolved within twenty-eight (28) days of the notice of dispute, or if the parties fail to meet within such twenty-eight (28) days, either party may initiate an ADR proceeding as provided herein. The parties shall have the right to be represented by counsel in such a proceeding.

1. To begin an ADR proceeding, a party shall provide written notice to the other party of the issues to be resolved by ADR. Within fourteen (14) days after its receipt of such notice, the other party may, by written notice to the party initiating the ADR, add additional issues to be resolved within the same ADR.

2. Within twenty-one (21) days following receipt of the original ADR notice, the parties shall select a mutually acceptable neutral to preside in the resolution of any disputes in this ADR proceeding. If the parties are unable to agree on a mutually acceptable neutral within such period, either party may request the President of the CPR Institute for Dispute Resolution (“CPR”), 366 Madison Avenue, 14th Floor, New York, New York 10017, to select a neutral pursuant to the following procedures:

(a) The CPR shall submit to the parties a list of not less than five (5) candidates within fourteen (14) days after receipt of the request, along with a Curriculum Vitae for each candidate. No candidate shall be an employee, director, or shareholder of either party or any of their subsidiaries or affiliates.

(b) Such list shall include a statement of disclosure by each candidate of any circumstances likely to affect his or her impartiality.

(c) Each party shall number the candidates in order of preference (with the number one (1) signifying the greatest preference) and shall deliver the list to the CPR within seven (7) days following receipt of the list of candidates. If a party believes a conflict of interest exists regarding any of the candidates, that party shall provide a written explanation of the conflict to the CPR along with its list showing its order of preference for the candidates. Any party failing to return a list of preferences on time shall be deemed to have no order of preference.

(d) If the parties collectively have identified fewer than three (3) candidates deemed to have conflicts, the CPR immediately shall designate as the neutral the

43

candidate for whom the parties collectively have indicated the greatest preference. If a tie should result between two candidates, the CPR may designate either candidate. If the parties collectively have identified three (3) or more candidates deemed to have conflicts, the CPR shall review the explanations regarding conflicts and, in its sole discretion, may either (i) immediately designate as the neutral the candidate for whom the parties collectively have indicated the greatest preference, or (ii) issue a new list of not less than five (5) candidates, in which case the procedures set forth in subparagraphs 2(a) - 2(d) shall be repeated.

3. No earlier than twenty-eight (28) days or later than fifty-six (56) days after selection, the neutral shall hold a hearing to resolve each of the issues identified by the parties. The ADR proceeding shall take place at a location agreed upon by the parties. If the parties cannot agree, the neutral shall designate a location other than the principal place of business of either party or any of their subsidiaries or affiliates.

4. At least seven (7) days prior to the hearing, each party shall submit the following to the other party and the neutral:

(a) a copy of all exhibits on which such party intends to rely in any oral or written presentation to the neutral;

(b) a list of any witnesses such party intends to call at the hearing, and a short summary of the anticipated testimony of each witness;

(c) a proposed ruling on each issue to be resolved, together with a request for a specific damage award or other remedy for each issue. The proposed rulings and remedies shall not contain any recitation of the facts or any legal arguments and shall not exceed one (1) page per issue.

(d) a brief in support of such party’s proposed rulings and remedies, provided that the brief shall not exceed twenty (20) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding.

Except as expressly set forth in subparagraphs 4(a) - 4(d), no discovery shall be required or permitted by any means, including depositions, interrogatories, requests for admissions, or production of documents.

5. The hearing shall be conducted on two (2) consecutive days and shall be governed by the following rules:

(a) Each party shall be entitled to five (5) hours of hearing time to present its case. The neutral shall determine whether each party has had the five (5) hours to which it is entitled.

(b) Each party shall be entitled, but not required, to make an opening statement, to present regular and rebuttal testimony, documents or other evidence, to

44

cross-examine witnesses, and to make a closing argument. Cross-examination of witnesses shall occur immediately after their direct testimony, and cross-examination time shall be charged against the party conducting the cross-examination.

(c) The party initiating the ADR shall begin the hearing and, if it chooses to make an opening statement, shall address not only issues it raised but also any issues raised by the responding party. The responding party, if it chooses to make an opening statement, also shall address all issues raised in the ADR. Thereafter, the presentation of regular and rebuttal testimony and documents, other evidence, and closing arguments shall proceed in the same sequence.

(d) Except when testifying, witnesses shall be excluded from the hearing until closing arguments.

(e) Settlement negotiations, including any statements made therein, shall not be admissible under any circumstances. Affidavits prepared for purposes of the ADR hearing also shall not be admissible.

As to all other matters, the neutral shall have sole discretion regarding the admissibility of any evidence.

6. Within seven (7) days following completion of the hearing, each party may submit to the other party and the neutral a post-hearing brief in support of its proposed rulings and remedies, provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. This page limitation shall apply regardless of the number of issues raised in the ADR proceeding.

7. The neutral shall rule on each disputed issue within fourteen (14) days following completion of the hearing. Such ruling shall adopt in its entirety the proposed ruling and remedy of one of the parties on each disputed issue but may adopt one party’s proposed rulings and remedies on some issues and the other party’s proposed rulings and remedies on other issues. The neutral shall not issue any written opinion or otherwise explain the basis of the ruling.

8. The neutral shall be paid a reasonable fee plus expenses. These fees and expenses, along with the reasonable legal fees and expenses of the prevailing party (including all expert witness fees and expenses), the fees and expenses of a court reporter, and any expenses for a hearing room, shall be paid as follows:

(a) If the neutral rules in favor of one party on all disputed issues in the ADR, the losing party shall pay one hundred percent (100%) of such fees and expenses.

(b) If the neutral rules in favor of one party on some issues and the other party on other issues, the neutral shall issue with the rulings a written determination as to how such fees and expenses shall be allocated between the parties. The neutral shall

45

allocate fees and expenses in a way that bears a reasonable relationship to the outcome of the ADR, with the party prevailing on more issues, or on issues of greater value or gravity, recovering a relatively larger share of its legal fees and expenses.

9. The rulings of the neutral and the allocation of fees and expenses shall be binding, non-reviewable, and non-appealable, and may be entered as a final judgment in any court having jurisdiction.

10. Except as provided in paragraph 9 or as required by law (including applicable securities laws and regulations), the existence of the dispute, any settlement negotiations, the ADR hearing, any submissions (including exhibits, testimony, proposed rulings, and briefs), and the rulings shall be deemed Confidential Information. The neutral shall have the authority to impose sanctions for unauthorized disclosure of Confidential Information.

11. All disputes referred to ADR, the statute of limitations, and the remedies for any wrong that may be found, shall be governed by the laws of the State of Delaware.

12. The neutral may not award punitive damages or any other damages excluded by Section 14.5 (Limitation of Liability) of the Agreement. The parties hereby waive the right to punitive damages.

13. The hearings shall be conducted in the English language.

46

EX-10.30

Exhibit 10.30

Portions of this Exhibit were omitted and filed separately with the Secretary of the Commission pursuant to an application for confidential treatment filed with the Commission pursuant to Rule 406 under the Securities Act of 1933. Such omissions are designated as ***.

AMENDMENT NO. 1 TO SUPPLY AND DISTRIBUTION AGREEMENT

This Amendment No. 1 to Supply and Distribution Agreement (this “Amendment”), dated as of July 21, 2005, is between OraSure Technologies, Inc., a Delaware corporation (“OraSure”), and Abbott Laboratories, an Illinois corporation (“Abbott”).

BACKGROUND

OraSure and Abbott previously entered into that certain Supply and Distribution Agreement, dated as of February 11, 2005 (the “Prior Agreement”). The parties desire to amend the Prior Agreement as more specifically set forth in this Amendment.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing, and other mutual promises and covenants contained in this Amendment, OraSure and Abbott intending to be legally bound, hereby agree as follows:

1. Revenue-Based Amount for Hospitals. Section 8.2.2 of the Prior Agreement is hereby amended and restated in its entirety, as follows:

“8.2.2 Revenue-Based Amount for Hospitals. If an amount equal to *** of Abbott Net Sales in the Hospital Segment and U.S. Government Hospital Segment for a Quarterly Period (such amount being the “Hospital Adjustment Number”) exceeds the Hospital Baseline for such Quarterly Period, then Abbott shall pay OraSure a Revenue-Based Amount equal to the excess of the Hospital Adjustment Number over the product of (a) the total number of OraQuick® ADVANCE^™ Devices sold in the Hospital Segment and U.S. Government Hospital Segment during such Quarterly Period, multiplied by (b) the Transfer Price for such Products. If, however, the Hospital Adjustment Number for the Quarterly Period is less than the Hospital Baseline for the Quarterly Period, then OraSure shall pay Abbott, in the form of a credit against amounts due to OraSure under this Agreement, an amount equal to the difference of (x) the product of the Transfer Price for the OraQuick® ADVANCE^™ Device multiplied by the total number of OraQuick® ADVANCE^™ Devices sold in the Hospital Segment and U.S. Government Hospital Segment during the Quarterly Period minus (y) the Hospital Baseline for the Quarterly Period.”

2. Effect of Amendment. Except as amended hereby, the Prior Agreement shall remain in full force and effect. All references to the Prior Agreement shall be deemed to mean the Prior Agreement as amended by this Amendment.

3. Governing Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, excluding its conflict of law principles.

4. Counterparts. This Amendment may be executed by the parties in more than one counterpart, each of which, when executed and delivered, shall be deemed to be an original, and all such counterparts shall constitute a single instrument. A facsimile transmission of a signed original shall have the same effect as delivery of the signed original.

IN WITNESS WHEREOF, this Amendment has been executed by OraSure and Abbott as of the date first written above.

ORASURE TECHNOLOGIES, INC.
By:	/s/ Douglas A. Michels
	Douglas A. Michels
	President and Chief Executive Officer
ABBOTT LABORATORIES
By:	/s/ Joseph M. Nemmers, Jr.
	Joseph M. Nemmers, Jr.
	Senior Vice President, Diagnostic Operations
	President, Abbott Diagnostics

EX-23

Exhibit 23

Consent of Independent Registered Public Accounting Firm

The Board of Directors

OraSure Technologies, Inc.:

We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-118385, No. 333-102235, No. 333-50340, No. 333-48662 and No. 333-138814) of OraSure Technologies, Inc. of our reports dated March 16, 2007, with respect to the balance sheets of OraSure Technologies, Inc. as of December 31, 2006 and 2005, and the related statements of operations, stockholders’ equity and comprehensive income (loss) and cash flows for each of the years in the three-year period ended December 31, 2006, management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2006 and the effectiveness of internal control over financial reporting as of December 31, 2006, which reports appear in the December 31, 2006 annual report on Form 10-K of OraSure Technologies, Inc.

Our report dated March 16, 2007, on the financial statements refers to the adoption of the fair value method of accounting for stock-based compensation as required by Statement of Financial Accounting Standards No. 123(R), Share-Based Payment, effective January 1, 2006.

/s/ KPMG LLP

Philadelphia, Pennsylvania

March 16, 2007

EX-24

Exhibit 24

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Douglas A. Michels

Signature

Douglas A. Michels

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Michael Celano

Signature

Michael Celano

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Jack Goldstein, Ph.D.

Signature

Jack Goldstein, Ph.D.

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Ronny B. Lancaster

Signature

Ronny B. Lancaster

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Charles W. Patrick

Signature

Charles W. Patrick

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Roger L. Pringle

Signature

Roger L. Pringle

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Ronald H. Spair

Signature

Ronald H. Spair

Print Name

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that the undersigned constitutes and appoints Mark L. Kuna, and Jack E. Jerrett, and each of them, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for the undersigned and in the undersigned’s name, place, and stead, in any and all capacities, to sign the Annual Report on Form 10-K of OraSure Technologies, Inc., for the year ended December 31, 2006, and any and all amendments to such report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or each of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

IN WITNESS WHEREOF, this Power of Attorney has been signed by the undersigned effective as of February 20, 2007.

/s/ Douglas G. Watson

Signature

Douglas G. Watson

Print Name

EX-31.1

Exhibit 31.1

Certification

I, Douglas A. Michels, certify that:

1. I have reviewed this annual report on Form 10-K of OraSure Technologies, Inc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d –15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the entity, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 16, 2007

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2

Exhibit 31.2

Certification

I, Ronald H. Spair, certify that:

1. I have reviewed this annual report on Form 10-K of OraSure Technologies, Inc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d –15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within the entity, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors:

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 16, 2007

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

(Principal Financial Officer)

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of OraSure Technologies, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas A. Michels, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

March 16, 2007

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of OraSure Technologies, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald H. Spair, Chief Operating Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

March 16, 2007